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ABSTRACT 
 
Cardiovascular disease is the leading cause of death of both men and women in developed 
countries, killing more people than any form of cancer. In Australia, cardiovascular disease 
accounts for our greatest direct health care expenditure each year (11 %). Among those at 
greatest risk are those suffering from obesity and/or type 2 diabetes (T2D). These conditions 
put additional stress on the heart, in part, by altering normal cardiac energy metabolism. The 
heart produces a large amount of energy by metabolising substrates in the blood such as fatty 
acids and glucose. A healthy heart is able to adapt its substrate use depending on availability, 
however in obesity/T2D the ability for the heart to use glucose to produce energy is impaired 
and the heart instead predominately relies on fatty acids to produce energy and exhibits an 
uncoupling between glucose uptake and oxidation. These changes in substrate use are 
suggested to reduce cardiac efficiency and promote heart enlargement and dysfunction. Heart 
enlargement is referred to as hypertrophy and usually occurs first in the left ventricle, this is 
the chamber of the hearts that pumps blood out to the body. While having a larger heart may 
seem like a positive change to the heart, remodelling of the heart can only temporarily 
compensate for the stresses of obesity and T2D, overtime the continued presence of these 
stresses and prolonged cardiac hypertrophy/dysfunction may progress to heart failure.  
 
Echocardiography (an ultrasound of the heart) can be used to detect alterations in heart 
structure and function. However, despite professional knowledge of the risks associated with 
obesity and T2D in the development of cardiovascular disease, monitoring blood pressure 
remains the first line method when assessing risk in normotensive obese and/or T2D patients. 
With requests for obese and T2D patients to undergo echocardiography usually restricted to 
those with chronic hypertension (high blood pressure) or to those who have presented with 
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symptoms such as shortness of breath or chest pain. The concern of limiting the use of 
echocardiography under these conditions is that it presumes obesity and T2D are insufficient 
stresses to cause hypertrophy and dysfunction independent of hypertension and it may restrict 
detection of the disease until late in the disease progression. Another major obstacle we face in 
the field is that even if these alterations are identified early, most available drugs act by treating 
hypertension and do not target cardiac metabolism or specifically obesity and/or T2D induced 
heart failure. Furthermore, current anti-hypertensive drugs have been reported to have little 
effectiveness in treating heart failure specifically in obese and T2D patients. Highlighting our 
need for the identification of new therapeutic options to treat heart failure in obesity and T2D.  
 
This thesis addressed these issues from multiple directions; Firstly, by determining whether 
changes in cardiac structure and function can be detected via echocardiography in obese and/or 
T2D patients in the absence of hypertension. Previous studies had failed to clearly characterise 
cardiac structure and function in patients with the disease states obesity, T2D and hypertension 
clearly separated which prevented clarity on this issue. Secondly, investigating changes in 
cardiac structure and function and cardiac metabolism mouse models of obesity/T2D including; 
Sprague Dawley rat offspring exposed to a maternal high fat diet, diet induced obese C57BL6 
mice and the db/db mouse. This work allowed us to further explore the detrimental changes in 
cardiac energy metabolism in during different stages of obesity/T2D and to identify when our 
potential therapeutic target, protein kinase D (PKD) may be acting.  And finally, by 
determining whether modification of PKD activity may protect from obesity/T2D induced 
cardiac hypertrophy/dysfunction. This was done both in vitro and in vivo, by investigating PKD 
action in regulating cardiac energy metabolism in neonatal ventricular cardiomyocytes and by 
investigating the effects of high fat diet feeding in mice expressing a cardiac specific dominant 
negative PKD construct and by pharmacological inhibition of PKD using the PKD selective 
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inhibitor CID755673, in db/db mice. The major outcomes from this work are summarised 
below in order of chapter presentation in the thesis.  
 
Chapter 2: This cross sectional study comprised a total of 353 Caucasian patients, grouped 
based on diagnosis of obesity, T2D and hypertension, with normotensive obese patients further 
separated based on metabolic health. Basic metabolic parameters were collected and LV 
structure and function were assessed via transthoracic echocardiography. Multivariable logistic 
and linear regression analyses were used to identify predictors of LVH and diastolic 
dysfunction. Metabolically healthy normotensive obese patients exhibited relatively low risk 
of LVH. However, normotensive metabolically non-healthy obese, T2D and obese/T2D 
patients all presented with reduced normal LV geometry that coincided with increased LV 
concentric remodelling. Furthermore, normotensive patients presenting with both obesity and 
T2D had a higher incidence of concentric hypertrophy and grade 3 diastolic dysfunction than 
normotensive patients with either condition alone, indicating an additive effect of obesity and 
T2D. Alarmingly these alterations were at a comparable prevalence to that observed in 
hypertensive patients. Interestingly, assessment of LVPWd, a traditional index of LVH, 
underestimated the presence of LV concentric remodelling. The implications for which were 
demonstrated by concentric remodelling and concentric hypertrophy strongly associating with 
grade 1 and 3 diastolic dysfunction respectively, independent of sex, age and BMI. Finally, 
pulse pressure was identified as a strong predictor of LV remodelling within normotensive 
patients. 
 
Chapter 3: Female Sprague Dawley rats were fed either normal fat diet (12%) or high fat diet 
(43%) three weeks prior to mating, remaining on diets until study completion. Hearts of 
postnatal day 1 (PN1) and PN10 pups were collected. Bioenergetics and respiration analyses 
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were performed in neonatal ventricular cardiomyocytes (NVCM). In offspring exposed to 
mHFD, body weight was increased at PN10 accompanied by increased body fat percentage 
and blood glucose. Heart weight and heart weight to body weight ratio were increased at PN1 
and PN10, and were associated with elevated signalling through the AMPK-Class IIa HDAC-
MEF2 axis. The expression of the MEF2-regulated hypertrophic markers ANP and BNP were 
increased as were expression of genes involved in fatty acid oxidation. However this was only 
accompanied by an increased protein expression of fatty acid oxidation enzymes at PN10. 
NVCM isolated from these pups exhibited increased glycolysis and an impaired substrate 
flexibility. 
Chapter 4: Neonatal ventricular cardiomyocytes were used to assess PKD activation in 
conditions related to obesity and T2D and cellular bioenergetics and respiration analysis were 
used in NVCM expressing a constitutively active (CA) PKD construct (expressed via lenti-
virus infection), to determine whether PKD regulates cardiac energy metabolism. Mice 
expressing an inducible, cardiac specific dominant negative (DN) PKD transgene were 
developed. These mice were challenged with a high fat diet (HFD) for 18 weeks, two weeks 
after DN PKD induction at 12 weeks of age,  to determine whether DN PKD could protect 
from obesity/T2D cardiomyopathy. Angiotensin II, norepinephrine and glucose oxidase 
activated PKD in vitro. NVCM expressing CA PKD exhibited reduced rates of glycolysis and 
glucose oxidation, and  increased fatty acid oxidation vs contriol (GFP) NVCM. Mice fed HFD 
exhibited an obesity/pre-diabetes phenotype, for which cardiac specific DN PKD mice 
exhibited protection from developing LV hypertrophy and systolic dysfunction. 
 
Chapter 5: Chronic PKD inhibition via CID755673 administration to T2D db/db mice for two 
weeks reduced expression of the gene expression signature of PKD activation, enhanced 
indices of both diastolic and systolic left ventricular function and was associated with reduced 
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heart weight. These alterations in cardiac function were independent of changes in glucose 
homeostasis, insulin action and body composition. These findings suggest that PKD inhibition 
could be an effective strategy to enhance heart function in obese and diabetic patients and 
provide an impetus for further mechanistic investigations into the role of PKD in diabetic 
cardiomyopathy.  
In summary significant alterations in heart structure and function were observed in 
normotensive metabolically non-healthy obese and/or T2D patients similar to those in 
hypertensive patients. This thesis identified early alterations in cardiac energy metabolism and 
the presence of left ventricular hypertrophy in pups exposed to a maternal high fat diet. As 
obesity is often “inherited”, these findings assist in our understanding of why obesity and T2D 
are risk factors of cardiovascular disease. And finally, this thesis implicated PKD in controlling 
cardiac energy metabolism and identifying that reductions in PKD activity improve cardiac 
structure/function in two separate mouse models of obesity/T2D. This thesis is submitted in a 
thesis by publication format. With an introduction to the chapter followed by the chapter 
manuscript and finally summary of the chapter. Please note the publication status of the 
manuscripts at the end of each chapter introduction.  
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CHAPTER 1 
 
 
Protein Kinase D, a Potential Therapeutic Target to Treat 
Obesity/Type 2 Diabetes Cardiomyopathy 
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INTRODUCTION CHAPTER 1 
 
Heart failure is a debilitating disease that is a major killer of both men and women (1).  It places 
a huge economic burden on western society, and also has a substantial impact on quality of 
life, with millions of individuals having significant disabilities associated with heart failure (2).   
Heart failure presents primarily as two major types, heart failure with reduced ejection fraction 
(HFrEF) and heart failure with preserved ejection fraction (HFpEF). Both types of heart failure 
and their associated co-morbidities and mortalities have been reported at a comparable 
prevalence (3-5). The criteria to diagnose HFrEF is clearly defined, characterised by the 
presence of systolic dysfunction with an ejection fraction <45-50%, with or without the 
accompanying presence of diastolic dysfunction. The criteria to diagnose HFpEF is less clear, 
although it is generally accepted to be characterised by the presence of diastolic dysfunction 
and elevated LV filling pressure, without LV dilation and with preserved systolic function or 
mild systolic dysfunction (ejection fraction >50%) (6).  
 
Among the populations at greatest risk of heart failure include those suffering from 
hypertension, obesity and type 2 diabetes (T2D) as these diseases are suggested to promote 
heart enlargement (hypertrophy) and dysfunction (usually diastolic dysfunction), which if left 
untreated may progress to heart failure.  Chronic hypertension has long been considered a 
traditional cause of heart failure, while the ability for obesity and T2D to cause heart failure 
independent of hypertension has been controversial. This is in part due to the chronic nature of 
obesity and T2D. By the time heart failure has been detected it is likely the individual would 
have already developed hypertension or another cardiac disease such as coronary artery disease 
secondary to their obesity and T2D, making it difficult to distinguish the extent, if any, obesity 
and T2D have had in the development of heart failure. That being said, current option is largely 
that HFrEF is driven by hypertension for which the presence of obesity and T2D may worsen 
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the severity of the condition and that populations suffering from HFpEF exhibit a high 
prevalence of obesity and T2D. 
 
Current therapies to treat heart failure act primarily by reducing neurohormonal signalling or 
by improving hemodynamics. However, despite some successes, these treatments lack 
effectiveness in completely preventing mortalities associated with heart failure, with death 
rates at 20% and 50%, one and five years post diagnosis respectively (2). Furthermore, while 
existing therapeutics were initially developed to treat hypertension induced HFrEF, the 
increasing incidence of HFpEF and lack of HFpEF specific drugs has pushed their application 
into both forms of heart failure. However, studies report little effectiveness of these traditional 
heart failure drugs in improving HFpEF, particularly in obesity and T2D (7-14). Suggesting 
current therapeutics are insufficient to treat alterations in the heart when accompanied by 
metabolic disease and that new therapies are needed to treat heart failure in obesity and T2D. 
An increasing body of evidence supports targeting alterations in cardiac energy metabolism in 
the treatment of heart failure.  
 
In the following paper we have discussed the use of a potential therapeutic target, protein 
kinase D (PKD) in the obese and T2D heart. PKD has previously been implicated in pressure 
overload hypertrophy and in regulating cardiac energy metabolism. To understand the 
potential implications of PKD discussed in the review paper  see the below description of 
normal cardiac energy metabolism and how cardiac energy metabolism is altered in the obese 
and T2D heart and the attached publication in the appendix where I have reviewed these 
alterations in more detail.  
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Normal cardiac energy metabolism in the adult heart 
 
The heart functions to pump blood around the body and requires a large and constant supply 
of energy. The healthy adult heart is able to adapt is substrate use depending on availability. 
Typically, the heart obtains about 40% of its energy needs from the metabolism of glucose, 
lactate, ketones, and amino acids, and the remaining 60% from the metabolism of fatty acids. 
These substrates must be acquired continuously from the extracellular fluid due to a low ability 
for the heart to store energy substrates intracellularly. The majority of adenosine triphosphate 
(ATP) produced from these substrates (~95%) is a result of mitochondrial oxidative 
metabolism, ~70-90% of which is derived from fatty acid oxidation and the remaining from 
the metabolism of glucose, lactate, ketone bodies and amino acids. The remaining ~5% of ATP 
is produced from glycolysis.  
 
Fatty acid metabolism: Fatty acids circulate in the blood either as fatty acids bound to albumin, 
or as part of triacylglycerols (TGs) contained in chylomicrons and very low density lipoproteins 
(VLDL) (Figure 1a). These TGs need to be cleaved by lipoprotein lipase at the sarcolemma to 
allow their uptake into the cardiomyocyte (15). Once cleaved, fatty acid uptake is then 
facilitated by two mechanisms; fatty acid transporters (CD36, fatty acid transport protein-1 and 
cytoplasmic fatty acid binding protein) and/or via passive diffusion (16). Once inside the cell, 
fatty acids are esterified forming fatty acyl-CoA. Fatty acyl CoA molecules are converted to 
acyl-L-carnitine moieties by carnitine palmitoyltransferase 1 (CPT-1) (17) and transported into 
the mitochondria where they are converted back to fatty acyl CoA and undergo β-oxidation, 
producing acetyl CoA that can be used in the TCA cycle and flavin adenine dinucleotide 
(FADH2) and nicotinamide adenine dinucleotide (NADH) which can enter the electron 
transport chain (ETC) to generate ATP.  The TCA cycle also produces NADH and FADH2 that 
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feeds into the electron transport chain, which in the presence of oxygen results in the conversion 
of ADP to ATP (Figure 1a).  
Fatty acid oxidation can be regulated in multiple ways, including via: 1) fatty acid supply to 
the heart, 2) malonyl CoA induced CPT-1 inhibition (18) (malonyl CoA is produced via acetyl 
CoA carboxylase (19) and degraded by malonyl CoA decarboxylase (MCD)), 3) the ratios of 
FAD/FADH2 and NAD
+/NADH (which can influence enzymatic activity of acyl-CoA 
dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase, respectively), 4) the acetyl CoA/CoA 
ratio which can influence the activity of 3-ketoacyl-CoA thiolase, 5) post-translational 
acetylation of fatty acid oxidative enzymes, and 6) transcriptional  regulation of fatty acid 
oxidative enzyme expression (Figure 1a). This tight regulation of fatty acid oxidation is 
required to maintain the hearts ability to switch between available substrates. Metabolic 
flexibility is vital in the heart due in part, due to differences in substrate efficiency.  
 
Fatty acids produce the greatest ATP yield per 2 carbon out of all cardiac substrates, however 
they also have the highest oxygen requirement to produce this ATP. For the generation of ATP 
from a typical fatty acid, palmitate, the heart consumes 23 molecules of O2 per fatty acid 
molecule with an ATP yield of 105, P/O ratio 2.33, making fatty acids the least efficient (ATP 
produced/O2 consumed) of the myocardial energy substrates. Fatty acid efficiency is further 
reduced due to the requirement of the hydrolysis of two Pi molecules from ATP for the 
esterification of fatty acids to fatty acyl CoA. In addition, the cytoplasmic cycling of fatty acids 
between fatty acyl CoA and TG and back to fatty acids also requires 2 Pi molecules, a process 
further decreasing fatty acid efficiency (Figure 1a).  
 
Glucose metabolism: Glucose is taken up by the cardiomyocyte via GLUT1 and GLUT4 
transporters, with GLUT4 being primarily responsible for the insulin-dependent uptake of 
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glucose (Figure 1b). Once glucose is transported into the cell it is phosphorylated by 
hexokinase, generating glucose 6-phosphate (G6P). G6P can then be utilised in multiple 
pathways, which include the generation of pyruvate via glycolysis, the synthesis of glycogen, 
or being shuttled into the hexosamine biosynthetic or pentose phosphate pathways.  The 
pyruvate generated from glycolysis can either be converted to lactate or be transported into the 
mitochondria via the mitochondrial pyruvate carrier (MPC) and converted to acetyl-CoA by 
pyruvate dehydrogenase (PDH).  This acetyl CoA is then further metabolized in the TCA cycle. 
PDH is activated via dephosphorylation by PDH phosphatase and inhibited by PDH kinase 
(PDK), the latter of which is activated by increased acetyl CoA/CoA and NADH/NAD+ ratios.  
Alternatively, pyruvate can be carboxylated to oxaloacetate or malate by pyruvate carboxylase 
or malic enzyme respectively, replenishing the TCA cycle intermediates (a process called 
anaplerosis) (Figure 1b).  
 
When considering the amount of O2 consumed to produce ATP, glucose is the most efficient 
of the energy substrates, consuming 6 molecules of O2 per glucose molecule with an ATP yield 
of 31, P/O ratio of 2.58. Unlike fatty acid oxidation (which as mentioned consumes two Pi 
molecules in the initial cytoplasmic esterification of the fatty acids) glucose metabolism 
produces two Pi molecules in the cytoplasm during the glycolytic conversion of glucose to 
pyruvate. In the instance that glucose-6-phosphate is converted to glycogen, one high energy 
phosphate molecule is required (UTP to UDP). However the release of glucose from glycogen 
and eventual conversation back to glucose-6-phosphate does not require any high energy 
phosphate. There is, therefore, the net loss of one high energy phosphate in the cytoplasmic 
cycling of glucose-6-P to glycogen and back to glucose-6-P (Figure 1b). 
 
Altered cardiac energy metabolism in the obese and/or type 2 diabetic adult heart 
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The failing heart can exhibit 30-40% less ATP content than a healthy heart [15, 16], which is 
likely due to the presence of a reduced mitochondrial oxidative capacity in heart failure. In 
addition, in obesity and T2D the heart loses its metabolic flexibility.  Switching to rely almost 
entirely on fatty acids for oxidative metabolism even in the presence of glucose and insulin. 
Furthermore, the obese and T2D heart exhibits an uncoupling between glucose uptake and 
oxidation (Figure 1a – 1b).  
 
Fatty acid metabolism in the obese and T2D heart: Increases in plasma concentrations of 
fatty acids have been associated with increased risk of the development of HFpEF (20). With 
myocardial fatty acid oxidation increasing in response to conditions such as type 2 diabetes 
(T2D), obesity and insulin resistance. Obese women with left ventricular hypertrophy (LVH) 
and reduced cardiac efficiency show an increased myocardial fatty acid uptake and oxidation, 
with the severity of their insulin resistance correlating with the higher rates of fatty acid 
oxidation (21).  In addition, men with type 2 diabetes and T2D cardiomyopathy also exhibit 
increased fatty acid uptake and oxidation (22).  These findings are consistent with animal 
models of obesity and T2D, such as diet induced obese (DIO), db/db and ob/ob mice.   In these 
animals, the heart switches to a predominant reliance on fatty acid oxidation, while exhibiting 
LVH (23), diastolic dysfunction (24, 25) and in severe cases, systolic dysfunction (26-28). 
Furthermore, transgenic mice exhibiting increased fatty acid uptake (29, 30) or oxidation (31, 
32) also develop LVH and diastolic dysfunction. These data suggest that obesity and T2D are 
associated with increased fatty acid oxidation and that increased fatty acid oxidation may 
promote the development of heart failure. 
 
Glucose metabolism in the obese and T2D heart: Increases in plasma glucose levels have 
been correlated with the severity of heart failure and have been suggested to be a predictor of 
the future development of heart failure (33, 34). Rodent models of T2D and insulin resistance 
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(in which plasma glucose levels are increased and myocardial insulin resistance develops) 
exhibit LVH, diastolic dysfunction and systolic dysfunction and show increased susceptibility 
to pressure and volume overload induced heart failure (35, 36).  
 
Glucose oxidation rates are decreased in both HFrEF and HFpEF (37, 38), and specifically in 
obese and T2D mice that develop HFpEF (39-41).   In addition, angiotensin II (hormone 
increased in obesity and T2D) induced HFpEF has  been reported to decreased glucose 
oxidation (45%) and PHD activity and to increased PDK4 expression in mice (37). This finding 
is consistent with another study observing the same decreases in glucose oxidation in 
angiotensin II treatment mice, an effect that was blunted in response to PDK4 deletion (38).  In 
mice subjected to mild aortic artery constriction induced HFpEF, a decrease in myocardial 
glucose oxidation has been shown to precede the development of diastolic dysfunction (42). 
Furthermore, transgenic mice with a mutation preventing the oxidation of pyruvate also 
develop LVH, diastolic dysfunction (43) and systolic dysfunction (44).  These data suggest that 
decreases in glucose oxidation are present in obesity and T2D and that decreases in glucose 
oxidation may promote HF. Interestingly, despite these decreases in glucose oxidation in 
obesity and T2D and in HFpEF, cardiac glucose uptake is increased.  The significance of this 
is described below.  
 
Gary Lopaschuk, a world leader in cardiac energy metabolism, has suggested in an attempt to 
compensate for the decreases in mitochondrial oxidative metabolism and ATP production in 
the failing heart, glycolytic rates increase (since glycolysis is an alternate source of ATP 
production independent of mitochondrial oxidative metabolism) (Figure 1b) (45, 46). These 
increases in glycolysis are however insufficient to completely compensate for the energy deficit 
in heart failure or to restore cardiac function. This is in part due to glycolysis producing only 
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two ATP molecules per glucose molecule, compared to 31 ATP molecules that would have 
been produced if glucose was terminally oxidised. Furthermore, this increase in glycolysis is 
uncoupled to the oxidation of pyruvate and lactate and is accompanied by an accumulation of 
H+ in the cytoplasm, which may eventually lead to Ca2+ accumulation (discussed in more detail 
in the following paper). Therapeutic interventions, or the use of inducible cardiac specific 
mutations that result in increased glucose oxidation and better coupling of glucose uptake and 
oxidation in a setting of heart failure, have resulted in improved and in some cases restored 
cardiac structure and function. For example, in leptin resistant obese/T2D mice exposed to 
myocardial infarction, restoration of glucose oxidation by treatment with a STAT3 activator 
attenuated myocardial infarction induced reductions in ejection fraction and increases in end 
diastolic and systolic volumes (47).  In mice exposed to coronary artery ligation knockout of 
malonyl CoA decarboxylase improved coupling between glycolysis and glucose oxidation, 
decreased H+ production and improved total LV work (of note this was despite an increased 
hypertrophic response in these mice) (48).  Therefore, these data suggest that the obese and 
T2D heart exhibits an uncoupling between glucose uptake and oxidation and that this 
uncoupling promotes heart failure. 
 
In summary, the obese and T2D heart exhibits an impaired substrate flexibility, decreased 
mitochondrial oxidative function, decreased ATP production, increased fatty acid oxidation, 
decreased glucose oxidation and an uncoupling between glucose uptake and oxidation. 
Interventions that decrease fatty acid oxidation and/or restore  glucose oxidation can improve 
cardiac function.  
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Figure 1. Cardiac energy metabolism of A. fatty acids and B. glucose. Red arrows represent 
alterations in metabolism observed in obesity and T2D (49).  
  
22 
 
Protein Kinase D, a Potential Therapeutic Target to Treat Obesity/Type 2 Diabetes 
Cardiomyopathy 
 
 
Kirstie A. De Jong1 and Sean L. McGee1. 
 
1 Metabolic Reprogramming Laboratory, Metabolic Research Unit, School of Medicine, 
Deakin University, Waurn Ponds, Victoria, Australia.  
 
Paper status; yet to be submitted for per review as of 24.01.2018  
  
23 
 
INTRODUCTION 
 
Our heart is beating constantly, from an early stage of embryonic development, throughout our 
entire life time. This beating allows for the constant flow of blood needed to deliver nutrients 
and remove waste in the body and requires a large and constant supply of energy. When energy 
supply is impaired due to altered substrate availability and/or utilisation, a cardiomyopathy can 
develop. Cardiomyopathy is a type of heart disease in which the heart has become enlarged in 
response to stress (referred to as pathological hypertrophy) and has reduced ability function, 
leading to heart failure (HF). Obesity and type 2 diabetes (T2D) are major risk factors for the 
development of a cardiomyopathy, as they alter normal cardiac energy metabolism.  
 
A healthy heart is able to adapt its substrate use, depending on availability, but typically utilises 
40% glucose, lactate, ketones, and amino acids and 60% fatty acids (50). In the obese/T2D 
heart, substrate utilisation has switched to almost entirely FA oxidation (50). This shift to 
increased FA oxidation is contributed to by multiple factors (discussed in more detail later) 
including; increased levels of circulating FAs, increased ability for uptake of FAs, increased 
expression and activity of enzymes involved in FA oxidation and increased accumulation of 
FA oxidation intermediates. This increase in FA oxidation is suggested to cause the 
development of cardiomyopathy by promoting; cardiac insulin resistance (51), mitochondrial 
dysfunction (52), apoptosis (53, 54), altered calcium handling (55) and pro-hypertrophic 
signalling. In addition, obesity and T2D are associated with increased pro-hypertrophic 
neurohormonal signalling, particularly by the sympathetic nervous system and renin-
angiotensin-aldosterone pathways (56, 57). Combined, these changes in cardiac metabolism 
and neurohormonal signalling are suggested to promote the development of a cardiomyopathy 
independent of cardiac diseases; hypertension, myocardial infarction (MI), coronary artery 
disease (CAD) and cardiac ischemia (CI).  
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In the past cardiomyopathy research has predominately focused on hypertrophy and contractile 
dysfunction induced by the cardiac diseases listed above, which are known as pressure overload 
cardiac factors and are widely accepted causes of cardiomyopathy disease. The ability for 
obesity/T2D to cause a cardiomyopathy independent from cardiac disease is controversial. This 
is in part due to the chronic nature of obesity and T2D. By the time a cardiomyopathy is 
diagnosed, it is likely the individual has already developed a cardiac disease. Distinguishing in 
humans the extent to which obesity and T2D contribute to the development of cardiomyopathy 
independent of cardiac disease is difficult. However, as these cardiac diseases mentioned 
(hypertension, MI, CAD and CI) usually develop secondary to obesity and T2D, many people 
with a cardiomyopathy (regardless of the cause) are obese and/or T2D. In addition, hypertrophy 
and cardiac dysfunction have been reported in the hearts of obese/T2D young adults in the 
absence of cardiac disease (58). Altered cardiac metabolism is not restricted to obesity/T2D 
cardiomyopathy, with cardiac insulin resistance found to accompany pressure overload 
induced hypertrophy and to occur prior to the development of pressure overload induced 
contractile dysfunction (59). Focusing attention in research specifically during the stage of 
obesity and T2D can provide an opportunity to identify therapeutic targets that can be applied 
early in the disease progression, in a large percentage of the population at risk.  
 
In this paper we review the potential therapeutic role for protein kinase D (PKD) in the 
development of obesity/T2D cardiomyopathy. Focusing on evidence supporting the activation 
of PKD in the obese and T2D heart and how PKD may be implicated in development of cardiac 
hypertrophy and in the regulation of cardiac energy metabolism. 
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PKD expression and activity is increased in the failed human heart and in response to 
altered metabolic and neurohormonal signalling associated with obesity/T2D 
 
In humans, PKD expression and activity has been found to be increased in the failing heart 
(60). Left ventricular tissue from end stage dilated cardiomyopathy (n=13) and ischemic 
cardiomyopathy (n=9) showed increased PKD phosphorylation at a site indicative of PKD 
activity, by 263% and 67% respectively, in comparison to non-failing hearts (n=7) (60). It is 
unknown whether PKD expression and activity is increased in the obese/T2D human heart 
before end stage HF. However, in vitro/in vivo studies in rodents suggest that metabolic and 
neurohormonal abnormalities associated with obesity and T2D may act to increase PKD 
activity in the heart. For example, PKD phosphorylation is increased in cardiomyocytes co-
treated with high palmitate and high glucose and in the hearts of male Wistar rats exhibiting 
hyperglycaemia in response to acute (1 day) and chronic (7 day) streptozotocin (STZ) treatment 
(61). In addition, endothelin-1 (ET1) and norepinephrine (known promoters of cardiac 
hypertrophy that are elevated in obesity/T2D (62, 63)), have also been shown to activate PKD 
in vitro (64). These data suggest a role for PKD in obesity/T2D induced cardiomyopathy.  
PROTEIN KINASE D 
 
Protein kinase D (PKD) was previously thought to be a PKC isoform, known as PKCµ. 
However catalytic domain homology and substrate specificity has since distinguished PKD to 
be part of the calcium calmodulin-dependent kinase (CaMK) family (65, 66). PKD is a 
serine/threonine kinase with three known isoforms, PKD1 (65), PKD2 (67) and PKD3 (68). 
All PKD isoforms consists of an N-terminal regulatory domain, a pleckstrin homology (PH) 
domain and a catalytic domain.  
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PKD structure  
 
 The N-terminal regulatory domain, also known as the cysteine rich domain (CRD) consists of 
a tandem repeat of zinc finger like cysteine rich motifs, cys1 and cys2. It is unique in that is 
not does not contain a high lipid affinity. These cysteine rich motifs, in particular cys2 provide 
a site for phorbol esters (PE) and DAG (activators of PKD) to bind PKD (69) and is highly 
homologous to that of PKCs, which also bind phorbol esters and DAG (65, 70). The CRD also 
assists in the translocation of PKD to the plasma membrane and nucleus and has a role in 
repressing the catalytic activity of PKD when not bound to PE and DAG (71). The PH domain 
allows for binding of PKD to membrane lipids (72) and may also autoregulate PKD (73). As 
mutations within this PH domain render PKD constitutively active, with increased basal 
activity and reduced ability for further activation in response to phorbol ester stimulation (73). 
The catalytic domain contains the activation loop with phosphorylation sites Ser744 and Ser748 
(74), both of which need to be phosphorylated to allow subsequent PKD autophosphorylation 
at Ser916. It’s important to note, that PKD phosphorylation at Ser916 may not always represent 
the activated form of PKD. With phosphorylation at this site found to persist when PKD is in 
an inactive state and post pharmalogial PKD inhibition. . In addition  the catalytic domain 
contains a postsynaptic density-95/discs large/zonula occludens-1 (PDZ)-binding motif 
(however this is only observed in the PKD isoforms PKD1 and PKD2) (75). Phosphorylation 
of PKD at Ser744 and Ser748 within the activation loop is largely mediated by DAG activated 
PKCs. There are three classes of PKCs; conventional PKC isoforms; α, β1, β2 and γ, which are 
activated by DAG, phorbol esters and are Ca2+ dependent. Novel PKC isoforms; δ, ε, η and θ, 
for which activation is dependent on DAG and phorbol esters and independent of Ca2+ and the 
atypical PKC isoforms; λ and ζ, for which activation is independent of DAG, phorbol esters 
and Ca2+ (76). In the human heart, expression and phosphorylation of PKCs are increased in 
HF (77-79)..  
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PKD is activated by the pro-hypertrophic DAG-PKC pathway 
 
Lipid derived second messengers transduce one of the main signalling cascades required for 
PKC-dependent activation of PKD. The production of these second messengers is induced via 
the binding of an extracellular ligands (hormones, bioactive lipids, cytokines and growth 
hormones) to G protein coupled receptors (GPCRs) on the sarcolemma of the cardiomyocyte 
(80, 81). This ligand binding induces a conformational change allowing coupling of the GPCR 
with heterotrimeric guanine-nucleotide regulatory proteins (G-proteins) (80). The G-protein 
converts GTP to GDP upon GPCR coupling and there is a dissociation of the subunits within 
the G-protein, with the Gα subunit dissociating from the Gβγ subunit (80). Both Gα and Gβγ 
subunits then go on to mediate downstream signalling effects (80). In the heart, the downstream 
signalling effects of Gα are of most interest, as they have been identified to mediate 
hypertrophic responses. There are four main families of Gα subunits which the receptor can 
couple with (Gαs, Gαi, Gαq, Gα12/14) and it is at the point of dissociation from Gβγ subunits 
where their downstream signalling diverges (80). Figure 1 illustrates the main subunits that are 
discussed below.  
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Figure 1. GPCR couple to G protein subunits, which induce different downstream signalling 
events. The downstream signalling events that are induced upon binding of an extracellular 
ligand to GPRCs, depends on the type of G protein subunit the GPCR couples with. Gas 
signalling promotes contractility responses via the production of cAMP, Gai signalling inhibits 
contractile responses through inhibition of cAMP production and Gaq signalling promotes 
PKD activation via increasing DAG production and PKC activation. Activated PKD has been 
implicated in contraction and in promoting hypertrophy through the re-activation of the foetal 
gene program.  
 
The Gαs subunit couples with adenylyl cylase (AC), resulting in production of the secondary 
messenger cAMP and activation of cAMP dependent protein kinase (PKA) (82). PKA is an 
essential kinase in the regulation of contraction, influencing calcium influx and reuptake and 
has been shown to negatively influence PKD activity (83) (discussed later). Chronic activation 
of Gαs signalling in mice results in increased sensitivity to catecholamine stimulation, leading 
to the development of hypertrophy, fibrosis and HF (84). Gαi may act as a negative regulator 
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of Gαs signalling, thereby preventing chronic Gαs stimulation by competing with the GPCRs 
that Gαs couples to. This results in reduced production of cAMP and subsequent contractility 
responses (85, 86).  
 
The Gαi, Gαq and Gα12/14 subunits have all been implicated in PKD activation (87). However, 
it is Gαq which may have the predominant role in PKD activation as it couples with 
phospholipase C (PLC), stimulating the hydrolysis of phosphatidylinositol 4,5-bisphosphate 
into two lipid derived second messengers, inositol 1,4,5-P3 and diacylglycerol (DAG) (82). 
IP3 acts to increase intracellular Ca2+ levels (88) and DAG acts to activate PKD, both directly 
and indirectly via PKC; DAG production induces the translocation of PKD from the cytosol to 
the plasma membrane, where it binds PKD at the CRD (75). Increased DAG and Ca2+ levels 
simultaneously increase activity of PKC isoforms, which are recruited to the plasma membrane 
where they directly phosphorylate PKD at Ser744 and Ser748 within the activation loop (74, 89). 
This phosphorylation stabilises the active conformation of PKD and results in its translocation 
into the nucleus, where PKD can act on its substrate targets. Nuclear export of PKD back to 
the cytosol requires its PH domain and the CRM1-dependent nuclear export pathway (90). The 
action of PKD in the nucleus has been associated with promoting hypertrophy at the 
transcriptional level (discussed later).  
 
The obese/T2D heart exhibits increased DAG-PKC signalling 
 
In obesity and T2D, activity of the DAG-PKC pathway in the heart is increased in response to 
multiple factors; increased neurohormonal signalling, increased DAG production in response 
to impaired mitochondrial dysfunction and increased expression and activity of PKC isoforms 
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(Figure 2). It is unknown whether this increased DAG-PKC signalling in the obese/T2D heart 
is associated with a subsequent increase in PKD activation and activity.  
 
 
Figure 2. The obese/T2D heart favours PKD activation. The obese/T2D heart favours PKD 
activation via reduced expression of β-ARs and increased expression of α-ARs, elevated levels 
of catecholamines and via the accumulation of DAG and activated PKCs in response to 
increased FA influx and hyperglycemia. 
 
Catecholamines may increase PKD activity in the obese/T2D heart  
 
The up regulation of the sympathetic nervous system in obesity/T2D allows for the heart to 
meet increased contractility demands (91) and is mediated by the increased release of  
catecholamines; sympathetic hormones which act via adrenergic receptors to increase 
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contractility signalling in the heart (82). Adrenergic receptors are a type of GPCR that have 
been extensively studied in the development of hypertrophy. There are two classes of 
adrenergic receptors; the α-adrenergic receptors (αARs); α1A, α1B, α1D, α2A, α2B, α2C, and the 
β-adrenergic receptors (βARs); β1, β2 and β3 (82). βARs are the predominant adrenergic 
receptor in the healthy heart, with an approximately 10 fold greater expression than the αARs. 
αARs and βARs can bind the same catecholamines (82), however the adrenergic receptors 
differ in the G-protein subunit they couple with, allowing different intracellular signalling 
events to occur in response to binding of the same catecholamine (82). The effect of increased 
catecholamines in obesity and T2D in promoting hypertrophy, therefore depends on the type 
of the adrenergic receptor it binds to, influenced in part, by the expression level of that receptor 
and the G-protein subunit the activated receptor couples with.  
 
As mentioned above, PKD activation involves the coupling of a GPCR with the G protein 
subunit, Gαq. As Gαq signalling promotes both PKC activation and DAG production via 
coupling with PLC. It is the αARs which couple with Gαq (82). Endogenous agonists to the 
αARs in the heart include; angiotensin-II (Ang-II), endothelin-1 (ET-1), noradrenaline and 
adrenaline (82). All of which have been shown to cause hypertrophy in vivo in rodent studies 
and all of which are increased in the heart in obesity/T2D. In addition, Ang-II (92), 
norepinephrine (92), ET-1 (92-94) and phenylephrine (α-AR agonist) (92, 93) have all been 
shown to activate PKD in cardiomyocytes in vitro. Together these data support a role for AR 
signalling activation of PKD.   
 
The βARs share the endogenous ligands (noradrenaline and adrenaline) with the αARs (82). 
However βARs couple with the Gαs subunit (82). Therefore noradrenaline and adrenaline 
signalling via βARs promote cAMP accumulation and PKA activation, and may not promote 
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PKD activation. The stressed heart however, shows reduced β1AR signalling and an increased 
expression and activity of αARs in their place (82). Resulting in increased levels of 
catecholamines acting via Gαq coupled GPCRs, increasing DAG-PKC signalling, which may 
in turn increase PKD activation and activity.  
 
Reduced β1AR signalling in the stressed heart may be due to the down regulation or 
desensitisation of adrenergic receptors (82). As attenuation or desensitisation of the adrenergic 
receptors may occur following repeated stimuli or prolonged stimuli of the receptors by 
agonists (82). This results in the phosphorylation of the adrenergic receptor by secondary 
kinases, such as PKA, PKC and by G protein coupled receptor kinases. PKA and PKC are 
suggested to phosphorylate (and therefore down regulate) all adrenergic receptors, not just 
those bound by an agonist, while G protein coupled receptor kinases are suggested to only 
phosphorylate adrenergic receptors with a bound agonist (75, 95). Phosphorylation of the 
receptors results in their internalisation in an intracellular compartment and their recycling. 
Alternatively, there may be reduction in protein synthesis and degradation of the receptors, 
resulting in their down-regulation (96). Regardless of the mechanism of down-regulation of 
adrenergic receptors in response to repeated/prolonged stimulation, it is unknown whether the 
downstream effects of this will reduce PKD translocation and activity, by preventing repeated 
and/or prolonged PKC dependent PKD activation.  
 
Interestingly, while DAG levels at the plasma membrane are transient, lasting seconds to 
minutes (97). Prolonged association of activated PKD at the plasma membrane may occur via 
the binding of the cys2 motif to not only DAG but also to Gαq (97). Cys1 binding induces rapid 
PKD activation and nuclear import, whilst cys2 binding results in prolonged association of 
activated PKD with Gαq at the plasma membrane prior to nuclear import (97). The rate at which 
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PKD translocates to the nucleus in response to activation may therefore be influenced by the 
cys motif involved in binding at the plasma membrane. As desensitisation of the adrenergic 
receptors by internalisation requires their association with scaffolding proteins (82), it is 
possible that prolonged association of activated PKD with Gαq at the plasma membrane may 
prevent its down regulation, by inhibiting scaffold association.  
 
Hyperglycemia and high fat diets may increase PKD activity via the DAG-PKC pathway in 
the obese/T2D heart 
 
In addition to catecholamines, high fat diets and hyperglycaemia also increase DAG-PKC 
signalling in the obese/T2D heart by promoting DAG synthesis and PKC activation. C57/BL6 
mice fed a high fat diet (60% kcal fat) for 10 weeks, showed greater DAG accumulation in the 
heart compared to mice fed a low fat diet (4% kcal fat) (479±174 vs 266 ±29, p<0.05), 
associated with an increased translocation of PKC to the plasma membrane and decreased 
cytosolic PKC level (98). Increased cardiac DAG levels in response to high fat diets are 
suggested to be caused by a high influx of FAs into the cardiomyocyte which are exceeding 
mitochondrial oxidation capacity and/or energetic requirements, resulting in the re-
esterification of excess FAs to form triglyceride (TG) stores. (99) FAs are converted to the lipid 
intermediate glycerol-3-phosphate, which is converted to phosphatidic acid, then to DAG and 
then to TG (100). The obese/T2D heart exhibits high levels of stored TG compared to healthy 
hearts (101). It is suggested this increased TG storage is a protective mechanism of the heart, 
to reduce the action of toxic lipid intermediates such as DAG. 
 
Hyperglycaemia promotes DAG synthesis with the accumulation of the glycolytic 
intermediate, dihydroxyphosphate. Dihydroxyphosphate is reduced to glycerol-3-phosphate, 
which can then be utilised for DAG synthesis (102), as described in the process of TG storage. 
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It is suggested that as in the heart of obese, the heart of diabetic patients exhibits chronically 
elevated DAG levels and PKC activity (103). Sprague Dawley rats treated with STZ for 2 
weeks show a 72% increase in DAG levels in the heart, with an associated 21% increase in 
membrane bound PKC activity compared to control rats (with no significant difference in 
cytosolic PKC concentration between STZ treated and controls) (104). These increases reduced 
to normal levels only when hyperglycaemia was reversed (with the use of cell islet 
transplantation) (104). In addition, in rats with diabetic cardiomyopathy, blood glucose 
concentrations are positively correlated with DAG levels in the heart. With their hearts 
exhibiting an increased presence of membrane-bound PKC and PKC activity, that unlike STZ 
treated Sprague Dawley rats, is also associated with a decreased cytosolic PKC concentration, 
compared to control hearts. In fact, an associated decrease in cytosolic PKC concentrations 
with increased DAG and membrane-bound PKC is a common finding in the heart in many 
rodent models of diabetes. This suggests that increased PKC activity in response to cardiac 
hyperglycaemia, may be caused by the accumulation of DAG in the heart (which as mentioned 
promotes translocation of PKC from the cytosol to the plasma membrane). However PKC 
activity may also be increased in the diabetic heart in response to hyperglycaemic-induced 
production of reactive oxygen species, which have also been shown to activate PKC (105).  
 
In summary, while it is unknown whether PKD activity is increased in the obese/T2D heart, 
the decreased presence of βARs and increased presence of αARs, combined with elevated 
catecholamines, increased FA influx and hyperglycaemia increase DAG-PKC signalling via 
promoting Gαq signalling, DAG synthesis and PKC activation. Which may in turn promote a 
subsequent increase in PKD activity in the obese/T2D heart.  
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PKD is not only activated by the DAG-PKC pathway 
 
It is important to note however, that PKD may not only be activated in a PKC dependent 
manner. Other PKC- independent methods of PKD activation could include contraction 
(discussed later) and Gβγ subunit binding to the PH domain of PKD (106).  An extensive study 
by Jamora et al 1999 (106) determined PKD activation by Gβγ is required for normal golgi 
formation and protein trafficking, and that this is independent of PKC isoforms and PKA. This 
was based on observations inhibitors of PKC; calphostin C (does not inhibit all PKC isoforms) 
and of PKA; KT5710 and PKI (PKA specific inhibitors) were unable to block the effects of 
Gβγ in golgi formation. While calphostin C acts to inhibit PKC isoforms by competing with 
their DAG/PE binding sites at the CRD, which PKD also contains, the concentration required 
for PKC inhibition has been shown to have no effect on PKD activity (70). How Gβγ directly 
activates PKD is still unclear. PKD is not located in the cytosol, instead remaining bound to 
the golgi membrane where the Gβγ subunit also remains after dissociation from Gα (106). The 
use of pure PH domains of PKD (inhibiting activation of membrane bound PKD, by acting as 
a competitive binding target to Gβγ) and blocking of the PH domain with an antibody, 
prevented Gβγ mediated golgi formation (106), suggesting that Gβγ directly interacts with the 
PH domain of PKD in its activation. It is possible that this binding to the PH domain relieves 
the auto-inhibitory activity of the PH domain. The implications of possible PKC-independent 
PKD activation in the heart are still being elucidated. The downstream events of PKD in 
response to GPCR-DAG-PKC signalling have however in part been elucidated, with PKD 
found to promote the re-activation of the foetal gene program and to alter Ca2+ handling.  
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RE-ACTIVATION OF THE FOETAL GENE PROGRAM 
 
Hypertrophy can be promoted by many types of stress stimuli that may act via the same and/or 
different signalling pathways. These pathways converge at the transcriptional level, where the 
re-activation of the foetal gene program (a set of genes involved in calcium handling, 
contraction and cardiac metabolism) both initiates and accompanies the development of cardiac 
hypertrophy and dysfunction. Inhibiting the re-activation of the foetal gene program has been 
found to protect from hypertrophy in rodents (107).  
 
PKD directly phosphorylates class IIa HDACs, promoting the re-activation of the foetal 
gene program  
 
The repression or transcription of the foetal gene program in the heart is mediated by chromatin 
modifying enzymes; class IIa histone deactylases (HDACs) and histone acetylases (HATS) 
(108). HDACs deacetylase histone tails of chromatin resulting in condensation and 
transcriptional repression (109). Class IIa HDACs known to be expressed in the heart include; 
HDAC 4, 5, 7 and 9 (110). The actions of HDACs are opposed by HATs which acetylate 
histone tails, relaxing chromatin structure and promoting transcriptional activity (109). In a 
healthy heart class IIa HDACs act to repress the transcription of the foetal gene program 
through their association with pro-hypertrophic transcription factors in the nucleus such as the 
myocyte enhancer factor-2 (MEF2) (111, 112). MEF2 activity is up regulated in the human 
failing heart (113, 114). In rodent studies, the over expression (115) or knockout (116) of MEF2 
increases and attenuates hypertrophic responses respectively. Class IIa HDAC repression of 
MEF2 is released via stress-induced HDAC phosphorylation. Known HDAC kinases include 
the calcium calmodulin dependent kinase II (CaMKII) (111, 117, 118) and the recently 
identified HDAC kinase, PKD (Figure 3).  
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Figure 3. PKD directly phosphorylates class IIa HDACs. GPCR activated CaMKII and PKD 
are translocated to the nucleus where they directly phosphorylate class IIa HDACs at the 14-
3-3 chaperon binding sites. Inducing; HDAC nuclear export, de-repression of MEF2 and the 
reactivation of the foetal gene program.  
 
In cultured cardiomyocytes, PKD has been found to phosphorylate all class IIa HDACs; 4, 5, 
7 and 9 in vitro (119, 120). Ligand binding to GPCRs induce the main signalling cascades 
involved in the activation and nuclear import of CaMKII and PKD (as described in earlier), 
where they both directly phosphorylate HDACs at 2 serine-containing motifs at the N terminal 
extension  (118). This phosphorylation creates docking sites for the chaperon family 14-3-3 to 
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bind (121), inducing HDAC dissociation from MEF2 and HDAC nuclear export to the 
cytoplasm (111). This frees MEF2 in the nucleus to associate with HATs such as p300 (122, 
123) and promotes the transcription and re-activation of the foetal gene program (124). The 
foetal genes used in many studies as markers of hypertrophy at the transcriptional level include; 
the natriuretic peptides, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) 
and the beta-myosin heavy chain (β-MHC). 
 
The critical role for class IIa HDACs in preventing hypertrophy via repression of MEF2 has 
been illustrated in numerous studies. Mice with a null mutation of the most prominent class IIa 
HDAC in the heart, HDAC9 (with no compensatory increase in expression of the other HDACs 
4, 5 and 7) show an increased sensitivity to the hypertrophic stimuli thoracic aortic banding 
(pressure overload) and calcineurin signalling (neurohormonal signalling), leading to the over 
activation of MEF2 in the heart and a 46% increase in heart weight/body weight ratio compared 
to WT mice at 8 months of age (125). Over expression of class IIa HDACs 4, 5 or 9 in cultured 
cardiomyocytes, reduces MEF2 activity and agonist-dependent (GPCR ligand) hypertrophic 
responses (119, 125, 126). In the stressed human heart, MEF2 activity is suggested to not be 
increased in response to a reduction in the expression of class IIa HDACs, but instead due to 
an increase in phosphorylation of class IIa HDACs, resulting in reduced HDAC-mediated 
repression of MEF2. This increased HDAC phosphorylation in the stressed human heart has 
been associated with increased expression and activity of PKD (60).  
 
Left ventricular tissue from subjects with dilated cardiomyopathy (n=13) and ischemic 
cardiomyopathy (n=9) with increased PKD expression and activity, showed a 120% and 58% 
increase in HDAC5 phosphorylation respectively, compared to that in non-failing hearts (n=7) 
(P<0.05) (60). There was no change in the overall HDAC5 expression between any of the heart 
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groups, indicating a higher cytosol to nuclear ration of HDAC5 in the failing heart tissue. It is 
important to note that CaMKII expression and activity were also increased in the failing heart 
tissue. The extent to which PKD contributed to HDAC5 phosphorylation cannot be determined 
from this data alone.  
 
The same group continued in exploring the role of PKD in mediating HDAC5 nuclear export 
with the use of cardiomyocytes from rabbits with HF (60). As seen in the human tissue, rabbit 
HF cardiomyocytes showed increased PKD activity and HDAC5 phosphorylation. 
Immunostaining and expression of GFP-tagged HDAC5 allowed the authors to determine that 
this increased HDAC5 phosphorylation (in response to endothelin-1 treatment) was associated 
with a decreased nuclear to cytosol ratio of HDAC5. Furthermore, it was elucidated that PKD 
and CaMKII contributed equally to HDAC5 nuclear export, as inhibition of either CaMKII 
(using KN-93) or PKD (using G06976) in HF cardiomyocytes was able to partially increase 
the nuclear to cytosol ratio of HDAC5, however inhibition of both CaMKII and PKD was 
needed to restore nuclear to cytosol ratio of HDAC5 to that of control cardiomyocytes. Further 
supporting a role for PKD in HDAC5 nuclear export in HF, over expression (using adenovirus) 
of PKD in control rabbit cardiomyocytes resulted in increased nuclear export of HDAC5 and 
increased MEF2 driven transcription, as seen in HF cardiomyocytes. These data suggest PKD 
has a role in mediating HDAC5 nuclear export independent of CaMKII, supporting the role of 
PKD in promoting the development of hypertrophy at the transcriptional level.  
 
The ability of PKD to phosphorylate HDACs at the same sites as CaMKII, may not only 
increase the range of stress stimuli able to induce HDAC phosphorylation and subsequent 
MEF2 repression, but also suggests that PKD-mediated HDAC phosphorylation has a greater 
functional significance during different stages of development and/or disease progression. For 
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example, as mentioned above in adult rabbit HF cardiomyocytes, PKD was found to contribute 
equally with CaMKII in mediating HDAC5 phosphorylation and nuclear export in response to 
ET-1 (60). Contrary to this, HDAC5 phosphorylation and nuclear export in response to ET-1 
treatment was found to be mediated predominantly by PKD in rat neonatal cardiomyocytes 
(119). As the adult heart undergoes a foetal shift in gene expression, it is possible that PKD 
may again take over as the predominant HDAC kinase in the stressed heart.  
 
PKD promotes pressure overload induced hypertrophy 
 
Eric Olsen’s lab originally identified PKD as a HDAC kinase and further elucidated the role of 
PKD in the development of hypertrophy in vivo (127), by generating a mouse with conditional 
PKD1 knockout in cardiomyocytes (PKD1 cKO). It was then determined whether PKD1 
knockout could protect from the development of hypertrophy induced by the different stress 
stimuli including pressure overload (thoracic aortic constriction), chronic angiotensin-II 
stimulation (known PKD activator in vitro) and isoprotereol (ISO) (β-adrenergic agonist 
known to not activate PKD in vitro). There was no change in PKD2 or PKD3 expression in 
hearts in response to PKD1 knockout, despite reports of redundancy between the PKD 
isoforms. After 21 days of TAC, structural changes to hearts were more pronounced in WT 
mice than that in PKD cKO, with a greater level of thickening of the LV wall, fibrosis and heart 
weight/tibia length (HW/TL) ratio (47% in WT and 23% in PKD cKO). Functional changes 
were also more pronounced in WT hearts compared with PKD cKO hearts, showing a greater 
reduction in heart rate and in cardiac contractility. The reduced structural and functional 
changes in PKD1 cKO hearts compared with WT were accompanied with reduced re-activation 
of the foetal gene program. With PKD1 cKO mice expressing lower mRNA levels of ANF, 
BNP, β-MHC (markers hypertrophy) and Col1a2 (marker fibrosis) compared with WT 
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(baseline expression of these genes was unaltered in PKD cKO hearts). These results suggest 
that PKD acts as a HDAC kinase in response to pressure overload in vivo, promoting the 
reactivation of the foetal gene program, hypertrophy and cardiac dysfunction. Ang-II treatment 
for 14 days showed similar results as TAC. However the dose of Ang-II used in this study is 
known to cause hypertension, therefore it is difficult to determine whether PKD1 cKO reduced 
AngII-induced hypertrophy or Ang-II-stimulated hypertension-induced hypertrophy. 
Unexpectedly chronic isoproterenol treatment (7 days) resulted in WT mice again showing 
more pronounced structural changes and re-activation of foetal gene program than PKD cKO 
hearts (HW/TL 37% WT and 21% PKD cKO). PKD activation requires the coupling of the 
GPCR with the G protein Gαq, which isoproterenol does not initiate. Isoproterenol is a non-
selective βAR agonist. Activation of βARs by isoproterenol will induce the coupling of βARs 
to the G protein Gαs and subsequent production of the secondary messenger cAMP and PKA 
activation. The ability of PKD cKO to protect from isoproterenol-induced hypertrophy 
suggests a greater complexity between signalling cascades and the duration of stress stimuli in 
PKD activation than what is currently understood. 
 
Re-activation of the foetal gene program in obesity and T2D 
 
Interestingly obese individuals (without HF) show decreased plasma levels of the natriuretic 
peptides; ANF and BNP (128). Reductions in these natruiretic peptides are suggested to 
promote hypertension and pressure overload-induced cardiomyopathies. Decreased levels of 
natriuretic peptides have also been detected in rodent models of obesity (129, 130). With db/db 
and ob/ob mice (with cardiac dysfunction), exhibiting decreased levels of ANP and BNP 
compared to their lean littermates (130). These decreased ANP and BNP levels are also seen 
in C57BL/6 mice fed a HFD (130). However these HFD C57BL/6 mice showed no significant 
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cardiac dysfunction. This suggests that in obesity, the re-activation of the foetal gene program 
may not be involved in the early stages of cardiac dysfunction and that altered cardiac FA 
utilisation may be associated with decreased ANP and BNP levels.  
This raises the question as to whether the decreased levels of natriuretic peptides in obesity 
may reflect decreased activity of the class IIa HDAC kinases, CaMKII and PKD. Recently 
hyperglycaemia has been shown to promote formation of a constitutively active form of 
CaMKII and CaMKII induced Ca2+ release from the sarcoplasmic reticulum, which may 
promote contractile dysfunction (131). PKD has also been shown to be activated in 
hyperglycaemic conditions, however only when accompanied by elevated levels of saturated 
FAs (61). While it is unknown whether obesity alone increases the activity of CaMKII and 
PKD in the heart, these data suggest that increased activity of these HDAC kinases may develop 
with the onset of T2D.  
 
In contrast, increased expression of foetal genes has been reported in rodent models of diabetes. 
Male wister rats 2.5 weeks after treatment with STZ (60 mg/kg) (132) showed increased cardiac 
mRNA expression of ANP, with no changes in heart structure. At 7 weeks post STZ treatment, 
rats showed increased LV to body weight ratio, LV hypertrophy and further increased 
expression of ANP. The addition of Ang-II treatment further increased cardiac ANP levels and 
also resulted in increased BNP mRNA expression level (Ang-II as mentioned promotes 
hypertension). In this study at 7 weeks post treatment, Ang-II failed to induce hypertension, 
but did worsen the cardiac phenotype. This suggests that the increased circulating Ang-II levels 
seen in obesity may promote the re-activation of the foetal gene program and cardiac 
remodelling, prior to Ang-II induced hypertension. While Ang-II is a known PKD activator in 
vitro, this study unfortunately did not look at PKD activity levels in the STZ and Ang-II treated 
rats. This would have been interesting to determine, as STZ treatment alone (55 mg/kg) in male 
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wister rats has been shown to increase phosphorylation of cardiac PKD at Ser916  by >50%. 
This increase was detected one day post STZ treatment, are remained similarly elevated one 
week post treatment coinciding with the development of hyperglycaemia. With glucose levels 
at 18.7 ± 1.1 mM one day post STZ treatment and 19.6 ± 2 mM one week post STZ treatment. 
(61).  
 
It is well established that pressure overload cardiac stresses such as hypertension, promote the 
re-activation of the foetal gene program in rodents and subsequent cardiac remodelling and 
dysfunction. Recently several studies have looked at the effects of hypertension coupled with 
either diabetes or a high fat diet, in the re-activation of the foetal gene program. With the 
hypothesis that hypertension and diabetes or a high fat diet, would accelerate/worsen disease 
progression compared to hypertension alone.  
 
The spontaneously hypertensive rat (SHR) is thought to be a good model for chronic HF, as 
they develop early hypertension and LV hypertrophy with a slow progression to HF (133). A 
recent study aimed to look at the effect of STZ treatment in the development of cardiomyopathy 
in these rats (134). 18 month old SHR were treated with STZ at 40 mg/kg (dose is lower than 
that used in other studies to induce diabetes with STZ) SHR treated with STZ showed blood 
glucose of 487±29 mg/dL vs 89.21±21 mg/dL in non STZ treated SHR. Nine weeks after STZ 
treatment, echocardiography was used to determine cardiac structure and function phenotypes 
in STZ treated and non STZ treated SHR. STZ treated rats showed greater LV systolic and 
diastolic dysfunction, LV and left atrial dilation (with reduced LV wall thickness) and an 
associated increased expression of ANP and β-MHC. This suggests that diabetes further 
promotes the reactivation of the foetal gene program than of hypertension alone. Another study 
used the same SHR animal model, but looked at the effects of a high fat diet (HFD) on cardiac 
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phenotype. Unfortunately they did not assess mRNA expression of foetal genes, but did find 
the HFD to further increase diastolic dysfunction and cardiac remodelling (135). Rats treated 
with Ang-II and fed either standard, high oil or high fat diets, showed a greater increase in 
expression of ANP and BNP in high oil fed rats (136). This suggests that the fat composition, 
and not simply a HFD, may have an effect on re-activation of the foetal genes. There is still 
little known of the effects of a HFD alone and coupled with pressure overload cardiac stresses 
in the re-activation of the foetal gene program.  
 
CONTRACTILE DYSFUNCTION 
 
In obesity and T2D, LV hypertrophy is initially able to restore cardiac function. However, the 
continued presence of stress and prolonged LV hypertrophy lead to diastolic dysfunction. 
During ventricular diastole, the ventricles relax and fill with blood to around 70% capacity. 
Diastolic dysfunction impairs ventricular relaxation and chamber filling, however usually 
develops with preserved ejection fraction (as atria systole is able to pump blood into the 
ventricle at the start of the cardiac cycle, compensating for the reduced end diastolic volume). 
However, progression of disease to include systolic dysfunction may impair atria systole, 
leading to a reduced end diastolic volume and therefore reduced ejection fraction. This results 
in insufficient blood being ejected from the ventricles to the body, leading to HF.  
 
Altered Ca2+ handling promotes cardiac dysfunction. As mentioned earlier, PKA is a main 
kinase involved in Ca2+ handing and contractile signalling. PKA is activated by agonists that 
induce the Gαs subunit to couple with adenylyl cylase (AC) (which is usually co localised with 
β1ARs in the heart), allowing for the production of the second messenger cAMP. PKA targets 
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involved in Ca2+ handling and contraction include the voltage gated L type Ca2+ channel, RyR, 
phospholamban and cardiac troponin I (cTnI).  
 
PKD phosphorylates cardiac troponin I (cTnI) at the same sites as PKA 
 
A yeast 2-hybrid screen was used to find PKD substrates in a human cardiac library (137). A 
catalytic mutated form of PKD was used in this screen, to allow for prolonged association of 
PKD with its substrate targets. PKD was found to interact with multiple proteins involved in 
calcium handling; cTnI, cMyBP-C, telethonin and myomesin. PKD was found to 
phosphorylate cTnI at the same sites as PKA; Ser22 and Ser23 (altered cTnI phosphorylation is 
associated with contractile dysfunction).  Importantly, PKD was found to phosphorylate cTnI 
at a similar rate/level as PKA and showed a comparable enhancement of cTnI phosphorylation 
in the presence of Ca2+. The authors of this study went on to show that PKD mediated cTnI 
phosphorylation reduced myofilament Ca2+ sensitivity, as seen in PKA mediated cTnI 
phosphorylation. This same group went on to further elucidate the effects of PKD mediated 
cTnI phosphorylation in adult rat ventricular myocytes (ARVMs) (138), by infecting them with 
an adenovirus vector expressing a full length mouse PKD and enhanced green fluorescent 
protein (AdV:PKDwt/EGFP). Endothelin-1 (ET1) treatment (5 nmol/L, 10 minutes) in these 
ARMVs markedly increased PKD phosphorylation within the activation loop and at the auto-
phosphorylation site compared to that in ARMVs infected with an adenovirus containing only 
the enhanced green fluorescent protein (AdV:EGFP). The increased PKD activity in response 
to ET1 treatment was associated with increased cTnI phosphorylation at Ser22 and Ser23 that 
was not seen in AdV:EGFP infected ARMVs. Treatment of ISO (10 nmol/L, 10 minutes), 
increased cTnI phosphorylation at Ser22 and Ser23 in AdV:EGFP infected ARVMs at a 
comparable level to that in AdV:PKDwt/EGFP infected ARVMs, suggesting PKD does not act 
46 
 
via the βARs in cTnI phosphorylation (as mentioned earlier, ISO the selective βAR agonist 
does not activate PKD but is a known activator of PKA). Therefore PKD may take over as the 
predominant kinase mediating contractile dysfunction via cTnI phosphorylation in the stressed 
heart, which shows attenuated PKA signalling in response to desensitisation of β-ARs.  
 
However, Dirkx et al 2012 (139) have suggested that PKD increases myofilament Ca2+ 
sensitivity by phosphorylating the previously identified target, cMyBP-C (137). This finding, 
which was seen in healthy cardiomyocytes (not those with hypertrophy), is not supported by 
other studies examining the role of PKD in mediating contractile dysfunction (137, 140, 141). 
However, these studies highlight that the role of PKD in Ca2+ handling and in promoting 
contractile dysfunction is complex and requires further understanding before determining 
whether PKD inhibition will be beneficial in the obese/T2D in preventing/improving 
contractile dysfunction.  
 
CARDIAC METABOLISM 
 
Lipid accumulation in the heart is often thought of as a physical obstruction (blocked arteries 
and/or lipid deposition on chamber walls) that impairs blood flow. This document will however 
focus on intramyocardial lipid accumulation, which is of particular interest in cardiomyopathy 
disease, as it can alter not only cardiac hemodynamics (55) (through altered Ca2+ handling) but 
also cardiac metabolism and hypertrophic signalling. 
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PKD facilitates FA uptake 
 
As mentioned the obese/T2D heart has an increased reliance on FAs to meet cardiac energy 
requirements, exhibiting both an increased FA uptake and oxidation. Obesity and T2D are 
associated with increased levels of circulating FAs, which provide an increased cardiac FA 
supply (142). However an increased presence of FAs is not sufficient to result in a subsequent 
increase in FA uptake. FAs circulate in chylomicrons and very low density lipoproteins 
(VLDP) in the form of TGs. These TGs need to be cleaved by lipoprotein lipase (LPL) at the 
sarcolemma to allow their uptake into the cardiomyocyte (61, 143). Once cleaved, FA uptake 
is then facilitated by two mechanisms; FA transporters (FA transport protein-1 or CD36) and/or 
via passive diffusion (144). Over expression of FA transport protein-1 (29) in the heart result 
in a 4 fold increase in TG uptake and 2 fold increase in accumulation and cardiac specific 
mutation of CD36 results in a significant decrease in cardiac FA uptake (145), suggesting FAs 
transporters are the main route of cardiac FA uptake. The increased FA uptake in the obese/T2D 
heart therefore requires not only increased levels of circulating FAs, but also an increased 
presence of LPL and increased expression of FA transporters at the sarcolemma.  
 
CD36 and GLUT4 transporters are stored in internal compartments within the cardiomyocyte. 
Insulin and contraction promote the translocation of both GLUT4 and CD36 from internal 
stores to the sarcolemma (while insulin promotes CD36 sarcolemma translocation, it also 
inhibits FA oxidation (146) and promotes glycolysis). During a fasted state GLUT4 is 
internalised and there is an increased translocation of CD36, allowing the heart to adapt to the 
low glucose and high FA availability. In the obese/T2D heart, the ability to adapt to available 
substrates is impaired, with a permanent increase in CD36 and decrease in GLUT4 at the 
sarcolemma (147, 148). This change in transporter localisation is in part contributed to by the 
development of cardiac insulin resistance and prevents available glucose from being 
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transported into the cardiomyocyte. In vitro rodent studies have found this increased presence 
of CD36 cannot be reversed in the presence of insulin, suggesting a permanent presence of FA 
transporters at the sarcolemma and internalisation of GLUT4 in both the fed and fasted state in 
the obese/T2D heart (149).  
 
PKD has been implicated in contraction induced GLUT4 translocation but not CD36 
translocation (150). Contraction has been shown to increase autophosphorylation of PKD at 
Ser916 with an associated increase in phosphorylation of PKD substrates, suggesting contraction 
increases PKD activity. Contraction induced translocation of GLUT4 and CD36 to the 
sarcolemma of cardiomyocytes is largely mediated by the AMP-activated protein kinase 
(AMPK). Recently Luiken et al (2012) (150) suggested a role for contraction activated PKD in 
mediating GLUT4 translocation to the sarcolemma, independent of AMPK. In their study, they 
used siRNA against PKD or AMPK in the HL-1 cell line (producing a 40-50% knockdown of 
each protein) and oligomycin treatment to simulate the energetic demands of contraction. 
Oligomycin is an inhibitor of mitochondrial F1F0-ATPase and activates both PKD and AMPK. 
siRNA knockdown of PKD (which had no effect on oligomycin-induced AMPK activation) 
resulted in reduced oligomycin and electrofield stimulated (EFS) translocation of GLUT4 to 
the sarcolemma and reduced oligomycin induced glucose uptake, with no effect of CD36 
translocation and FA uptake.  This suggests that in the HL-1 cell line, PKD has a role in 
oligomycin and EFS induced GLUT4 translocation and glucose uptake. As expected, siRNA 
knockdown of AMPK reduced oligomycin and EFS GLUT4 and CD36 translocation, along 
with glucose and FA uptake. They were able to support this data with the use of isolated 
cardiomyocytes from cardiac specific PKD1 knockout (PKD1 KO) and AMPKα knockout 
(AMPKα KO) mice, which again showed reduced GLUT4 translocation and glucose uptake in 
EFS PKD1 KO cardiomyocytes and reduced both GLUT4 and CD36 translocation along with 
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glucose and FA uptake in AMPKα KO cardiomyocytes. It would be interesting to assess the 
effect of constitutively active PKD1 in the cardiomyocytes, to determine whether basal glucose 
uptake as well as contraction induced glucose uptake are increased.  
 
In addition to the increased presence of CD36 at the sarcolemma promoting FA uptake in the 
obese/T2D heart, LPL activity is also increased. The heart produces more LPL than any other 
organ in the body (151). This is not surprising considering its high energy demands, with the 
heart needing to acquire enough nutrients to produce 20 times its own weight in ATP each day. 
Kim, Wang (61) determined that the increased LPL activity post diabetes/obesity is 
independent of increased expression of the LPL gene and the number of LPL binding sites at 
the coronary lumen (HSPG binding sites on the cardiomyocyte cell surface), but instead due to 
an increased presence of functional LPL at the coronary lumen. This suggests that in obesity 
and T2D a mechanism must increase the translocation of LPL to the lumen where it can cleave 
available FAs.  
 
PKD has been identified to have a functional role in increasing LPL activity, by assisting in 
translocation of LPL to the coronary lumen (61). High palmitate/glucose treatment in vitro in 
cardiomyocytes activated PKD in a DAG-PKCδ manner (61). This activated PKD was found 
to assist in the formation of the transgolgi vesicle that contained LPL and in the movement of 
this vesicle to the sarcolemma. LPL at the sarcolemma is later transported to the coronary 
vascular lumen where it acts to cleave TGs. Inhibition of PKD or PKCδ resulted in reduced 
LPL activity at the coronary vascular lumen in the presence of high palmitate/glucose. The 
action of PKD in the heart under high lipid/glucose conditions may therefore increase the 
translocation of LPL to the sarcolemma, assisting in increasing LPL activity and FA uptake. 
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In summary increased FA uptake in the obese/T2D heart is facilitated by increased 
translocation of CD36 to the sarcolemma and increased activity of LPL. PKD is suggested to 
have no role in CD36 translocation, but is thought to increase FA uptake by facilitating 
translocation of LPL to the sarcolemma.  
 
Increased cardiac FA uptake promotes lipotoxicity  
 
The increased FA uptake in the obese/T2D heart results in lipotoxicity, mitochondrial stress 
and the accumulation of TG stores and toxic lipid intermediates. Once inside the cell, FAs are 
conjugated with CoA to form Fatty acyl-CoA. Fatty acyl-Co-A is then transported to the 
mitochondria and undergoes β-oxidation to generate ATP for cellular energy. Fatty-acyl CoA 
in excess not needed for ATP production can be re-esterified to form TG, to provide FA storage. 
In obesity and T2D where there is a greater influx of FAs than mitochondrial oxidative 
capacity, there is a greater level of TG storage in the heart.  
 
Cardiac TG accumulation has been detected in humans with end stage HF. Taegmeyer et al 
(2010) determined the level of accumulated lipid in the left ventricle in patients with HF 
(n=18), obtained during heart transplantation in diabetic, obese and non-obese/non-diabetic 
patients. Heart samples from non-failing hearts were also used (obtained from donors not 
suitable to be used in heart transplant). Hearts of diabetic and obese patients were found to have 
significantly higher level of lipid accumulation than non-failing hearts. Furthermore hearts of 
non-obese and non-diabetic patients with HF were found to have no lipid accumulation at all. 
This highlights that while lipid accumulation is greater in the failed obese/T2D heart compared 
to non-failing hearts, lipid accumulation is not essential for the development of HF. 
Importantly, these increases in lipid accumulation in obese/T2D hearts were associated with  
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increased expression of PPARα, β-MHC and TNF-α. PPARα is thought to promote 
cardiomyopathy by inducing the transcription of fatty acid transport protein-1, CD36, acetyl 
CoA synthase, carnitine palmitoyl transferase I (CPT I) (involved in FA uptake into 
mitochondria), medium, long and very long chain fatty acyl-CoA dehydrogenase (involved in 
mitochondrial FA β-oxidation) and Acyl-CoA synthase (involved in peroxisomal FA β-
oxidation) (152). As the heart samples analysed in this study were from end stage HF, it cannot 
be determined whether TG accumulation contributed to the development of HF or occurred as 
a result of HF. 
 
Rodent models of obesity and T2D have however shown that shown TG accumulation occurs 
prior to the development of a cardiomyopathy and that increased cardiac TG accumulation is 
associated with cardiac dysfunction (the associated cardiac dysfunction varies between animal 
models). The Zucker diabetic rat exhibits a 2 fold greater level of cardiac TG accumulation 
compared to controls, with associated systolic dysfunction. In the obese ob/ob animal model, 
these mice show increased TG accumulation compared to lean ob/+ littermates (6.8 +/- 0.4 vs. 
2.3 +/- 0.4 µg/mg) with an associated diastolic dysfunction (no systolic dysfunction) (24). 
However, as these rodent models are also obese, it is difficult to distinguish the contribution 
that TG accumulation has in the development of hypertrophy and contractile dysfunction, 
independent of other cardiac disease risk factors present in the animal models (increased 
nuerohormonal signalling, hypertension, increased cardiac output demands etc). Transgenic 
animal models expressing cardiac specific mutations that increase cardiac TG accumulation in 
the absence of systemic metabolic abnormalities (impaired glucose tolerance or obesity) have 
assisted in elucidating the extent to which TG accumulation contributes to cardiomyopathy 
disease. For example, mice over expressing aceyl-CoA synthase develop TG accumulation and 
associated diastolic dysfunction and LV hypertrophy at 4 weeks of age, with no change in body 
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weight (153).  Mice with over expression of FA transport protein-1 develop TG accumulation 
in the heart that is 4 fold greater at 3 months of age compared to their WT littermates, is 
associated with the development diastolic dysfunction (29). These data suggest that TG 
accumulation has a role in promoting cardiomyopathy.  
 
Today the use of the non-invasive 1H-Magnetic Resonance Spectroscopy (1H-MRS) has 
allowed for the assessment of TG accumulation in the human heart prior to end stage HF (154). 
A greater level of TG accumulation is found in the hearts of obese individuals, without LV 
systolic dysfunction, impaired glucose tolerance or T2D (101). After adjusting for BMI, age 
and circulating TG levels, lipid accumulation remained greater in the hearts of individuals with 
impaired glucose tolerance and T2D, compared to that in lean individuals (101). This suggests 
that hyperglycaemia associated with T2D promotes lipid accumulation, which precedes the 
development of cardiac dysfunction and HF in humans.  
 
Little is known about PKD and toxic lipid intermediates, other than DAG 
 
In addition to DAG, other toxic lipid intermediates accumulate in the heart when there is an 
imbalance between FA uptake and mitochondrial FA oxidative capacity and/or energetic 
requirements. Toxic lipid intermediates such as ceramide promote apoptosis in the heart and as 
discussed with DAG, may also promote PKD activity. Gαq signalling in particular was 
discussed to mediate the increased DAG-PKC signalling in the obese/T2D heart, however 
increased PKD signalling in response to the accumulation of toxic lipid intermediates in 
obesity/T2D may not be restricted to Gαq signalling. Indeed, lysophosphatidic acid (LPA) (a 
FA intermediate involved in TG synthesis) activates PKD in vitro, not only via Gαq, but also 
by Gαi and Gα12/14 signalling (87). LPA levels are increased in the human obese heart and 48 
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hour treatment of LPA 1-10 µM in mouse NVCM has been shown to induce hypertrophy, 
determined by an increased cell size and staining of ANF (155). Treatment with specific 
inhibitors of PLC and PKC had no effect on LPA induced hypertrophy, suggesting LPA was 
not acting via Gαq to induce hypertrophy (155). LPA can however act via Gαq signalling, and 
in fact did so in this study as well, increasing hydrolysis of IP at a level of around 30% to that 
seen by endothelin-1 (another  Gαq agonist) (155). Treatment with pertussis toxin (an inhibitor 
of Gαi and to which Gαq is insensitive to) inhibited LPA induced increases in cell size and ANF 
staining, while having no effect on LPA induced IP hydrolysis (155). This suggests that LPA-
induced hydrolysis of IP via Gαq was not sufficient to induce the hypertrophic response and 
that LPA was instead acting via Gαi to induce hypertrophy. As LPA has been shown to activate 
PKD in vitro via Gαi, it is possible that PKD mediates hypertrophic responses induced by LPA. 
There is still much to know about the relationship between PKD and not only LPA, but other 
toxic lipid intermediates in the development of cardiomyopathy.  
 
Not all HFDs are bad 
 
Not all high fat diets are bad for the heart. Diets rich in polyunsaturated FAs such as omega-3s 
have been shown to be beneficial to heart structure and function. In rodents omega-3 FAs 
protect from pressure overload-induced hypertrophy (156) (aortic band constriction) and 
reversed hypertrophy and LV dysfunction induced by a genetic carnitine deficiency (157). 
Carnitine is required for FA uptake into the mitochondria. Systemic deficiency of carnitine in 
mice leads to decreased FA β-oxidation, cardiac steatosis, hypertrophy, contractile dysfunction 
and increased DAG and PKC levels (consistent with previous discussions in this document, 
linking increased FA uptake to accumulation of DAG and increased PKC expression and 
activity). Diets rich in fish oil and polyunsaturated omega-3 FAs, decreased PKC activity, 
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cardiac hypertrophy and contractile dysfunction in the mice with carnitine deficiency (157). 
This improvement was suggested to be due to increased levels of a molecular species of DAG, 
containing a fatty acid composition that does not support PKC activation. In vitro studies have 
suggested the acyl chain of DAG distinguishes which DAG molecular species are capable of 
activating PKC and which cannot (158). With cardiac molecular species of DAG found to be 
influenced by the type of FAs in the diet. It is unknown whether diets rich in omega-3 FAs may 
reduce cardiac PKD activity. Consistent with this idea, others have shown omega-3 FAs reduce 
PKC activity (159, 160). Therefore it would be interesting to see whether PKD translocation 
to the sarcolemma and activation is reduced in mice fed a diet rich in omega-3 FAs.  
 
In addition to the composition of fat, the total calories consumed in a HFD may also influence 
the development of cardiac dysfunction. As mice fed an isolcaloric diet do not develop 
hypertrophy and contractile dysfunction, likely due to the maintenance of insulin sensitivity 
and normal cardiac glucose utilisation (161). This suggests that the detrimental effect HFDs 
have on the heart, is mediated by the development of cardiac insulin resistance and 
mitochondrial dysfunction.  
 
High fat diet-induced mitochondrial dysfunction  
 
Reducing FA oxidation and increasing glucose oxidation has been shown to improve both 
cardiac structure and function. db/db mice have been reported to oxidise glucose at a level of 
48% to that of their lean db/+ littermates (162). This decrease in glucose oxidation and 
subsequent increase in FA oxidation is suggested to be the main driver in cardiac dysfunction, 
as the over expression of GLUT4 increases glycolysis to levels of that seen in db/+ mice and 
is able to restore cardiac function (162, 163). One proposed mechanism by which increased FA 
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oxidation contributes to cardiac dysfunction is by promoting mitochondrial dysfunction. The 
increased FA oxidation in the obese/T2D heart, increases myocardial oxygen consumption 
(MVO2) (164) and is actually associated with a decreased ATP production (165-167), which is 
suggested in part to be caused by an increased mitochondrial uncoupling in the obese/T2D 
heart (168).  
 
Obesity-induced mitochondrial uncoupling in the heart 
 
ATP production is dependent on the maintenance of the proton gradient at the inner 
mitochondrial membrane, a reduction in this proton gradient impairs ATP production (169). 
The ratio of the influx to efflux of protons (protons are generated from the citric acid cycle) 
determines the mitochondrial membrane potential that is required for ATP production (169). 
Uncoupling proteins allow protons to re-enter the mitochondrial matrix, thus reducing the 
proton gradient and therefore reducing ATP production (169).  In humans a positive correlation 
has been found between plasma levels of free FAs and the presence of cardiac uncoupling 
proteins (170).  It is unknown whether PKD may contribute to increased mitochondrial 
uncoupling in the obese/T2D heart, however the ability of PKD to alter Ca2+ handling may 
implicate PKD as a promoter of reduced mitochondrial efficiency. PKD has been identified to 
act with p38 MAPK in reducing mitochondrial Ca2+ uptake in a hepatic cell line (171). H295R 
cells were treated for 10 minutes with 20 ng/ml of TNF-α to induce p38 MAPK activation and 
50 nM PMA to induce PKC isoform activation (the authors were specifically interested in novel 
PKC activation, as PMA also activates conventional PKC isoforms, they co-treated with the 
conventional PKC inhibitor G06976 at 5mM) and then stimulated with 15mM of K+ to induce 
depolarisation. TNF-α, PMA and G06976 treated cells showed reduced Ca2+ uptake into the 
mitochondria compared to control cells treated with an inactive form of PMA and G06976, 
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suggesting a novel PKC kinase is involved in reducing mitochondrial Ca2+ uptake. To further 
elucidate the kinases involved in controlling mitochondrial Ca2+ uptake, siRNA technology 
was used. Cells were infected with either an siRNA against PKD or a scrambled RNA for 
control cells, with the addition of Ang-II (previously shown to increase cytosolic Ca2+ and to 
activate PKD and p38 MAPK in H295R cells). Cells containing the siRNA against PKD 
showed a 50% increase in mitochondrial Ca2+ uptake compared to control cells. This suggests 
that the decrease in mitochondrial Ca2+ uptake in response to activation of novel PKC isoforms 
is mediated by PKD.  
 
It is unknown whether PKD has the same role in attenuating mitochondrial Ca2+ uptake in the 
heart. If PKD is found to do this, normal PKD signalling may provide a beneficial role in the 
obese/T2D heart. As cardiac hyperglycaemia is suggested to induce increased mitochondrial 
Ca2+ influx, promoting apoptosis via increased production of reactive oxygen species (172). 
However, normal Ca2+ uptake into the mitochondria is still needed to assist in ATP production, 
by promoting the synthesis of NADPH (173), with the level of Ca2+ influx correlated to the 
level of ATP production (this ATP production is of course dependent on availability of 
mitochondrial substrates, not just Ca2+ influx) (174). The over activation of PKD signalling in 
a stressed heart, may impair cardiac bioenergetics, by further reducing mitochondrial Ca2+ 
uptake, resulting in reduced ATP production.   
 
SUMMARY 
 
In summary, PKD activity may be increased in the obese/T2D heart in response to increased 
signalling via the DAG-PKC pathway, due to reduced expression of βARs, increased 
expression of αARs, elevated catecholamines, FAs and hyperglycaemia. Activated PKD may 
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promote the development of obesity/T2D cardiomyopathy at the transcriptional level by 
directly phosphorylating class IIa HDACs and may promote contractile dysfunction by 
phosphorylating contractile proteins such as cTnI and by altering normal Ca2+ handling. PKD 
may also act to increase FA uptake (by facilitating LPL vesicle formation and translocation), 
promoting obesity/T2D cardiomyopathy.  
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SUMMARY CHAPTER 1 
 
There are many unanswered questions in elucidating if PKD is a valid therapeutic target in the 
prevention/treatment of obesity/T2D cardiomyopathy. Firstly, while as mentioned, a study 
suggested cardiac PKD is activated by hyperglycaemia in vivo and by co treatment of high 
palmitate/glucose in vitro (61), it is unknown if this PKD activation promoted cardiac 
hypertrophy. In addition, the ability for hyperglycaemia to activate PKD may have little 
biological significance in the obese/T2D heart after the development of cardiac insulin 
resistance, where glucose uptake is reduced and FA uptake increased. Determining in more 
detail which factors/if any associated with obesity/T2D activate PKD is required, and whether 
this PKD activation is associated with hypertrophy. These questions have been investigated in 
chapters 5 and 6.  
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CHAPTER 2 
 
 
Obesity and Type 2 Diabetes have Additive Effects on Left 
Ventricular Remodelling in Normotensive Patients – A 
Cross Sectional Study   
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CHAPTER 2 INTRODUCTION 
 
There are many types of LVH and ways in which LVH can be assessed. Clinically, 
transthoracic echocardiography is used to assess the LV structural dimensions; internal 
ventricular septum diameter, left ventricular internal diameter and left ventricular posterior 
wall thickness. These measurements are obtained via M-Mode imaging and can be used to 
calculate estimated left ventricular mass. All of these M-Mode derived measurements have 
normal reference ranges and it is these measurements which are routinely assessed in clinical 
settings to determine the presence of LVH. In addition to M-Mode measurements obtained via 
echocardiography, electrocardiograms can also be used to assess the presence of LVH. While 
electrocardiography is easily accessible and more cost effective than echocardiography, it’s 
important to note that previous studies have reported electrocardiography to give false positive 
and negative readings in the detection of LVH (doi:  10.1016/j.amjcard.2014.11.037). 
Furthermore, for the purpose of assessing the presence of LVH both the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging recommend 
echocardiography and not the use of electrocardiography (doi: 10.1016/j.echo.2014.10.003). 
Therefore, echocardiography is the preferable method to assess LVH.  
In research settings an additional measure commonly used is the assessment of LV geometric 
patterns. For which there are four types; normal geometry, eccentric hypertrophy (increased 
LV mass), concentric remodelling (increased relative wall thickness (RWT) of the LVPW) and 
concentric hypertrophy (increased LV mass and RWT) (Figure 2.1). An advantage of assessing 
LV geometric patterns is that is takes into account the relative size of the individuals LV and 
does not entirely rely on normal reference ranges, which vary depending on age, sex and 
ethnicity. In addition, previous studies have reported a prognostic advantage to the 
characterisation of LV geometric patterns.  
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Figure 2.1. LV geometric patterns 
As mentioned, a major controversy in the field is whether LVH develops independently of 
hypertension in patients suffering from obesity and T2D. This controversy it not surprising 
considering the inconsistencies and limitations in the previous literature for which researchers 
and clinicians are challenged to decipher. For example, a PubMed search for relevant articles 
using the following terms: “normotensive”, “obesity”, “type 2 diabetes”, “left ventricular 
hypertrophy” and “LV geometry” and excluding those articles restricted to subjects with 
hypertension, history of cardiovascular disease, systemic disease, children or adolescence and 
animal models, resulted in 29 articles. The majority of these articles relied on LV mass/height 
(g/m2.7) to define LVH (25 articles, 86.2%) without assessing LV geometry, of which the 
collective findings were highly variable; two articles detected no increases in LV mass/height 
(g/m2.7) in normotensive obese subjects compared to lean subjects, while nine articles detected 
increases ranging 15-42%. Six articles detected no increases in LV mass/height (g/m2.7) in 
normotensive T2D subjects compared to non-T2D subjects, while two articles detected 
increases of 17% and 37%. Six articles combined obesity, T2D and hypertension within a 
single group, 33% of which identified BMI to associate with LV mass/height (g/m2.7) 
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independent of hypertension. The remaining four articles assessed LV geometric patterns in 
normotensive obese T2D subjects, the findings were again highly variable. The difficulty in 
summarizing these studies as a whole however are attributed to varying criteria in which LV 
geometry were characterized, the co-existence of T2D in obese subjects at varying prevalence 
and differing ethnicities observed. Therefore in summary, the previous literature provides 
inconsistencies in methodology and findings, resulting in a lack of strong evidence supporting 
the ability for obesity and T2D to cause LVH independently. In the following paper, we have 
provided clarity on this issue by carefully separating patient cohorts based disease and 
hypertension status and by rigorously analysing patient left ventricular structure beyond the 
basic clinical measures currently used.  
 
Hypothesis: LVH and diastolic dysfunction are present in normotensive obese and/or T2D 
patients and detectable via transthoracic echocardiography. 
 
Significance: We know that obese and T2D individuals have an increased risk of heart failure 
and that this is promoted by the development of LVH and dysfunction. While much of the 
disease progression of heart failure is asymptomatic, there are some additional risk factors that 
develop such as hypertension and the presentation of symptoms, and it’s during this later stage 
in which most attention and referrals for echocardiography are focused. In the following paper 
we are interested in looking at these changes in the heart much earlier, in the absence of 
hypertension, during the stage of obesity and/or T2D alone (Figure 2.2). With the hope that 
this will allow us to target the heart before too much damage has occurred.   
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Figure 2.2.  Simplified schematic of the typical assumed progression of heart failure in 
obesity and type 2 diabetes.  
 
Aims 
1.  To assess LVH via clinical indices and via LV geometric patterns in normotensive 
obese, T2D and obese/T2D patients.  
2. To assess LV diastolic function in normotensive obese, T2D and obese/T2D patients 
and associations between diastolic dysfunction and LVH.  
3. To determine which normotensive obese, T2D and obese/T2D patients are at greatest 
risk for LVH and diastolic dysfunction.  
 
Paper status is published, reference; De Jong KA, Czeczor JK, Sithara S, McEwen K, 
Lopaschuk GD, Appelbe A, Cukier K, Kotowicz M, McGee SL: Obesity and type 2 diabetes 
have additive effects on left ventricular remodelling in normotensive patients-a cross sectional 
study. Cardiovascular Diabetology 2017, 16:21. 
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ABSTRACT 
Background: It is unclear whether obesity and type 2 diabetes (T2D), either alone or in 
combination, induce left ventricular hypertrophy (LVH) independent of hypertension. In the 
current study, we provide clarity on this issue by rigorously analysing patient left ventricular 
(LV) structure via clinical indices and via LV geometric patterns (more commonly used in 
research settings). Importantly, our sample consisted of hypertensive patients that are routinely 
screened for LVH via echocardiography and normotensive patients that would normally be 
deemed low risk with no further action required.  
Methods: This cross sectional study comprised a total of 353 Caucasian patients, grouped based 
on diagnosis of obesity, T2D and hypertension, with normotensive obese patients further 
separated based on metabolic health. Basic metabolic parameters were collected and LV 
structure and function were assessed via transthoracic echocardiography. Multivariable logistic 
and linear regression analyses were used to identify predictors of LVH and diastolic 
dysfunction.   
Results: Metabolically healthy normotensive obese patients exhibited relatively low risk of 
LVH. However, normotensive metabolically non-healthy obese, T2D and obese/T2D patients 
all presented with reduced normal LV geometry that coincided with increased LV concentric 
remodelling. Furthermore, normotensive patients presenting with both obesity and T2D had a 
higher incidence of concentric hypertrophy and grade 3 diastolic dysfunction than 
normotensive patients with either condition alone, indicating an additive effect of obesity and 
T2D. Alarmingly these alterations were at a comparable prevalence to that observed in 
hypertensive patients. Interestingly, assessment of LVPWd, a traditional index of LVH, 
underestimated the presence of LV concentric remodelling. The implications for which were 
demonstrated by concentric remodelling and concentric hypertrophy strongly associating with 
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grade 1 and 3 diastolic dysfunction respectively, independent of sex, age and BMI. Finally, 
pulse pressure was identified as a strong predictor of LV remodelling within normotensive 
patients.  
Conclusions: These findings show that metabolically non-healthy obese, T2D and obese/T2D 
patients may develop LVH independent of hypertension. Furthermore, that LVPWd may 
underestimate LV remodelling in these patient groups and that pulse pressure can be used as 
convenient predictor of hypertrophy status. 
INTRODUCTION 
Obesity and T2D are well-accepted risk factors for the development of left ventricular 
hypertrophy (LVH)1, 2. However, it remains unclear as to whether these stresses are sufficient 
to cause LVH, independent of hypertension and other cardiac disease. This is largely due to 
the asymptomatic nature of LVH and the way in which risk is monitored in normotensive obese 
and/or T2D patients.  
LVH is traditionally characterised by increased thickness of the LV posterior wall diameter 
(LVPWd) and/or increased LV mass3. There are three LV geometric patterns that can identify 
the type of LVH present, eccentric hypertrophy (increased LV mass), concentric remodelling 
(increased relative wall thickness (RWT) of the LVPWd, normal LV mass) and concentric 
hypertrophy (increased LV mass and increased RWT). These changes in cardiac structure are 
often accompanied by diastolic dysfunction (DD, impaired LV relaxation) and can be detected 
in obese patients via transthoracic echocardiography (TTE)3. However, requests for patients to 
undergo TTE are often restricted to those with chronic hypertension, or to those who have 
returned an abnormal electrocardiogram result after presenting with symptoms such as 
arrhythmia, shortness of breath or chest pain. Monitoring risk in obese and/or T2D patients this 
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way presumes that without hypertension, obesity and T2D are insufficient stresses to induce 
LVH.  
Major limitations of past studies are that obesity and T2D have often been considered one 
disease state, and the individual contributions of these diseases to LVH in the absence of 
hypertension have remained obscured. Furthermore, in studies that have appropriately 
distinguished obesity4, 5 and T2D6-8, there has been a propensity to use LV mass alone as an 
independent variable to detect LVH, without assessing the RWT of the LV posterior wall. This 
restricts the type of LVH that can be detected to eccentric hypertrophy and prevents the 
detection of concentric remodelling and concentric hypertrophy. Previous studies suggest there 
is prognostic value in assessment of LV geometric patterns, with increased LV mass and 
concentric hypertrophy in particular9, 10 found to associate with increased risk of adverse 
cardiovascular events. Whether this prognostic value applies to normotensive patients with 
obesity and T2D remains unresolved. 
The current study aimed to determine whether patients presenting with obesity and type 2 
diabetes, either alone or in combination, exhibit LVH in the absence of hypertension. Both 
traditional indices of LVH and LV geometric patterns were used to identify LVH. Furthermore, 
we sought to determine whether LV geometry predicted the presence of diastolic dysfunction 
and whether routine metabolic parameters can be used to predict LVH in these patients. 
METHODS 
Study approval  
This cross sectional study comprised a total of 353 Caucasian patients, from the University 
Hospital Geelong and the Geelong Endocrinology and Diabetes Centre. The study was 
conducted in accordance with National Health and Medical Research Council (NHMRC) 
guidelines and was approved by the Human Research Ethics Committee (HREC) via the 
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Barwon Health Research and Integrity Unit, in accordance to guidelines outlined in Section 5 
of the National Statement on Ethical Conduct in Human Research. 
Participant groups 
Based on the diagnosis of obesity, T2D and hypertension, patients were designated into one of 
the following groups; normotensive obese (N.Obese) n=58, normotensive T2D (N.T2D) n=41, 
normotensive obese/T2D (N.Obese/T2D) n=42, hypertensive obese (H.Obese) n=71, 
hypertensive T2D (H.T2D) n=74 and hypertensive obese/T2D (H.Obese/T2D) n=67. For the 
diagnosis of obesity, T2D and hypertension, basic clinical and metabolic data were collected 
for each participant consisting of age, sex, height, weight, blood pressure, HbA1c %, fasting 
glucose, LDL-C, HLD-C, cholesterol and triglyceride levels (after overnight, 8 hour minimum 
fast), any history of anti-hyperglycaemic or anti-hypertensive medication, and any history of 
cardiovascular and/or systemic disease.  
Characterisation of and inclusion/exclusion criteria for participant groups 
Obesity was characterised as a BMI ≥ 30 kg/m2. Patients with a history of anti-hyperglycaemic 
medication were permitted within the obese group, due to the increasingly common use of 
biguanides in pre-diabetic/obese patients. T2D was characterised as having three or more 
elevated fasting glucose levels within a 12-month period, of ≥ 7 mmol/l, with or without a 
history of anti-hyperglycaemic medication.  Hypertension was characterised as having both 
elevated diastolic and systolic blood pressure of ≥ 140/90 mmHg, with or without a history of 
anti-hypertensive medication. Those patients with controlled hypertension (i.e. history of 
hypertension or use of anti-hypertensive medication, with a blood pressure < 140/90) were 
excluded from the study. Additional exclusion criteria for patients of all groups included 
history of cardiac disease or systemic disease, age < 18 years, or the collection of 
accompanying clinical and metabolic medical records within a time period > 6 months before 
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or after TTE procedure. For a more detailed description of the study design see supplementary 
data.  
Blood pressure measurements 
Blood pressure (BP) was recorded as per the American Heart Association guidelines, with the 
use of OMRON Intelli sense HEM-907 or HBF-1300 and cuff bladder at least 80% of the 
patient’s arm circumference. In the incidence of an elevated BP reading (≥ 140/90 mmHg), the 
measurement was repeated up to three times. With the lowest BP measurement recorded. Pulse 
pressure mmHg was calculated by subtracting diastolic BP from systolic BP (systolic BP 
mmHg - diastolic BP mmHg). 
Metabolically healthy vs metabolically non-healthy patients 
To separate normotensive obese patients based on metabolic health. We adhered to Karelis 
criteria. With metabolically healthy patients determined as; fasting glucose ≤ 5.5 mmol/l, HDL-
C ≥ 1.4 mmol/l, LDL-C ≤ 2.6 mmol/l, Cholesterol ≤ 5.5 mmol/l and triglycerides ≤ 1.8 mmol/l. 
Patients were categorised as being metabolically unhealthy if they exhibited > 1 more 
parameter outside these normal ranges.   
Transthoracic echocardiography  
Sonographers were qualified with a Diploma of Medial Ultrasonography or equivalent. Both 
the sonographers that performed the echocardiography and cardiologists that analysed the 
results were blinded to the study groups, due to this being a retrospective study. All 
echocardiograms were performed using the Phillips Ie33 with a S5-1 transducer. A 
combination of two dimensional, M-mode, pulsed wave and continuous wave Doppler and 
tissue Doppler were used. Left ventricular diameter and wall thicknesses were measured in the 
parasternal long axis view using two-dimensional or M-mode measurements (left ventricular 
internal diastolic dimension (LVIDd), left ventricular internal systolic dimension (LVISd), 
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interventricular septum dimension (IVSd), left ventricular posterior wall dimension 
(LVPWd)). Of note, while M-mode was used to measure the LV wall thickness whenever 
possible, in cases where the M-mode was not able to be properly aligned (orthogonal) two 
dimensional echocardiography was used. Mitral inflow velocities (E’ velocity, Peak E-wave, 
Peak A-Wave) and deceleration times (DT) were measured using pulsed wave Doppler in the 
apical 4 chamber view. Echocardiographic data was analysed using proprietary software.  
Characterisation of diastolic dysfunction 
Diastolic dysfunction (DD) was characterised according to the American Society of 
Echocardiography (ASE) guidelines11. Patients were graded with either normal diastolic 
function (E’ ≥ 10cm/s) or DD, characterised as Grade 1 (impaired relaxation) E’ < 10cm/s, E/A 
< 0.8, E/E’ ≤ 8; Grade 2 (pseudonormal) E’ < 10cm/s, E/A 0.8-1.5, E/E’ 9-14; or Grade 3 
(restrictive) E’ < 10cm/s, E/A ≥ 2, E/E’ > 14.  
Left ventricular geometry 
LV mass was estimated according to ASE guidelines12, in which LV mass (grams) = (0.8 ∙ 
[1.04 ∙ (LVEDd + IVSd + LVPWd)3 - (LVEDd)3]) + 0.6). LV mass was then indexed to body 
surface area (BSA, g/m2) and to height (g/m2.7). RWT was calculated using the formula, RWT 
= ((IVSd+LVPWd)/LVEDd) and via ((2 ∙ LVPWd)/LVEDd). LV geometry was characterised 
using the following criteria; Normal LV geometry, RWT ≤ 42, LVMI (g/m2.7) ≤ 51; eccentric 
hypertrophy (EH), RWT ≤ 42, LVMI (g/m2.7) > 51; concentric remodelling (CR), RWT > 42, 
LVMI (g/m2.7) ≤ 51 and concentric hypertrophy (CH), RWT > 42, LVMI (g/m2.7) > 51.  
Statistical analysis  
Continuous variables were represented as means ± 1 standard deviation (S.D), unless otherwise 
stated. Means of continuous variables were analyzed via ANOVA assessed with Bonferroni, 
and associations were determined by performing linear regression analysis, assessed with 
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Pearson’s correlation coefficient. Categorical variables were expressed as percentages or 
prevalence and analyzed via chi-square tests, using fisher’s exact test. To determine 
independent predictors of categorical variables, multivariable logistic regression analysis was 
performed. p<0.05 was considered significant. All statistical analysis were performed using 
SPSS version 23.  
 
RESULTS 
Basic Clinical Data 
Basic clinical data are presented in Table 1 and Supplementary Table 1. Of note, normotensive 
and hypertensive patients within the same group were of similar age and gender percentage 
(Table 1). Between groups, age was lower in both T2D and Obese/T2D groups compared to 
obese groups (p<0.001).  
The Co-existence of Obesity and T2D in Normotensive Patients had Additive Effects on 
the Prevalence of LVH 
The presence of LVH was determined by assessing the clinical hypertrophy indices LVPWd 
and LV mass, which were derived from M-Mode measurements (Table 2). Additional M-Mode 
measures are shown in Supplementary Table 1. 
We first confirmed that our patient population exhibited normal associations between age and 
BMI with indices of LVH (Supplementary Table 2). Age independently correlated with 
LVPWd (r2=0.35, p<0.001), LV mass (r2=0.24, p<0.01), LV mass/BSA (g/m2) (r2=0.34, 
p<0.001), LV mass/height (g/m2.7) (r2=0.26, p<0.01) and RWT (r2=0.38, p<0.001) in both 
normotensive and hypertensive subjects. BMI independently correlated with LVPWd (r2=0.15, 
p<0.05), LV mass (r2=0.16, p<0.05) and LV mass/height (g/m2.7; r2=0.39, p<0.001). The same 
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was true for hypertensive patients with the addition of a correlation between BMI and LV 
mass/BSA (g/m2; r2=-0.25, p=001, Supplementary Table 2).  
TABLE 1. Participant characteristics.  
GROUP OBESE T2D OBESE/T2D 
Condition Norm. Hyper. Norm. Hyper. Norm. Hyper. 
Basic Clinical Data 
n 58 71 41 74 42 67 
Age (years) 48 ± 2.0 54 ± 1.6 68 ± 1.9 ǂ ǂ ǂ 68 ± 1.0 ǂ ǂ ǂ 60 ± 1.9 ǂ ǂ ǂ 65 ± 1.2 ǂ ǂ ǂ 
Female % 59 52 40 43 53 48 
BMI (kg/m
2
) 34 ± .77 37 ± .74 26 ± .40 ǂ ǂ ǂ 26 ± .47 ǂ ǂ ǂ 36 ± .71××× 36 ± .74××× 
Height (cm) 166 ± 1.4 167 ± 1.1 171 ± 1.7 170 ± 1.2 166 ± 1.9 170 ± 1.4 
Heart Rate (bpm) 74 ± 1.7 73 ± 1.7 71 ± 2.4 71 ± 2.0 76 ± 2.6 72 ± 1.8 
Systolic BP (mmHg) 127 ± 1.6 159 ± 3.0 *** 128 ± 1.6 164 ± 2.0 *** 128 ± 1.6 161 ± 2.0 *** 
Diastolic BP (mmHg) 78 ± 1.1 93 ± .77 *** 75 ± 1.2 95 ± .52 *** 76 ± 1.5 94 ± 1.5 *** 
PP (mmHg) 49 ± 1.4 66 ± 2.8 *** 52 ± 1.7 69 ± 1.9 *** 53 ± 2.5 68 ± 2.2 *** 
Glucose (mmol/l) 5.2 ± .10 5.2 ± .14 8.4 ± .49 ǂ ǂ ǂ 8.5 ± .51 ǂ ǂ ǂ 11 ± .72 ǂ ǂ ǂ 9.1 ± .43 ǂ ǂ ǂ 
Cholesterol (mmol/l) 5.1 ± .24 4.7 ± .24 4.1 ± 0.3 4.0 ± .16 4.1 ± .22 3.9 ± .11 
HDL-C (mmol/l) 1.3 ± .07 1.5 ± .13 1.2 ± .09 1.2 ± .04 1.2 ± .12 1.2 ± .05 
LDL-C (mmol/l) 3.1 ± .23 2.6 ± .28 2.2 ± .21 ǂ 1.9 ± .11 ǂ 1.9 ± .16 ǂ 1.8 ± .10 ǂ 
Triglycerides (mmol/l) 1.9 ± 1.3 1.6 ± .13 2.0 ± .34 1.9 ± .16 2.4 ± .33 2.4 ± .20 
History anti-hyperglycaemic and anti-hypertensive medication 
Biguanides % 8.62 % 1.41 % 26.83 % ǂ ǂ 47.30 % ǂ ǂ 47.30 % ǂ ǂ ǂ 50.72 % ǂ ǂ 
DPP-4 inhibitors % 0 % 0 % 4.88% ǂ ǂ 6.76 % ǂ ǂ 0 % 7.46 % ǂ ǂ 
Sulphonylureas % 0% 0 % 17.07 % ǂ ǂ 41.89 % ǂ ǂ 33.33 % ǂ ǂ 41.79 % ǂ ǂ 
Insulin % 0 % 0 % 24.39 % ǂ ǂ 16.22 % ǂ ǂ 40.48 % ǂ ǂ 25.37 % ǂ ǂ  
ACE inhibitors % 0 % 16.90 % *** 0 % 33.78 % *** 0 % 46.27 % *** 
Ang II antagonists % 0 % 15.14 % *** 0 % 20.27 % *** 0 % 19.40 % *** 
Beta-Blockers % 0 % 18.31 % *** 0 % 49.32 % *** 0 % 58.21 % *** 
Ca2+ channel blockers  0 % 11.27 % *** 0 % 14.86 % *** 0 % 11.94 % *** 
***p<0.001 vs same group, different condition, ǂ p<0.05, ǂ ǂ p<0.01, ǂ ǂ ǂ p<0.001 vs obese 
group, same condition, ××× p<0.001 vs T2D group, same condition. 
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LVPWd was increased in H.Obese and N.Obese/T2D groups vs N.Obese (1.1 ± .03 and 1.1 ± 
.03, vs 0.9 ± 02, p<0.05 and p<0.001 respectively) and in H.Obese/T2D patients vs all other 
groups (1.2 ± .02, p<0.001, Table 2). The prevalence of patients within each group exhibiting 
LVPWd above recommended ASE guidelines (0.9 cm females, 1.0 cm males) were increase 
between N.Obese vs H.Obese (35.71% vs 64.71%, p<0.05), N.T2D vs H.T2D (39.39% vs 
63.89%, p<0.05), N.Obese/T2D vs H.Obese/T2D (64.10% vs 92.54%, p<0.05) and in both 
normotensive and hypertensive Obese/T2D groups in comparison to Obese and T2D groups 
alone (p<0.05). This shows that in the absence of hypertension, LVPWd measures that are 
indicative of LVH are present in obese and T2D patients (albeit at a lower prevalence than in 
hypertensive patients), and that the co-existence of these stresses had an additive effect on the 
prevalence of LVPWd above ASE guidelines.  
Estimated LV mass (grams) was increased between N.Obese vs H.Obese (159 ± 5.7 vs 191 ± 
8.2, p<0.01), N.Obese/T2D vs H.Obese/T2D (191 ± 8.2 vs 233 ± 6.2, p<0.001) and in both 
H.Obese and H.T2D groups vs H.Obese/T2D (191 ± 8.2 and 187 ± 5.1 vs 233 ± 6.2, both 
p<0.001). When indexed to BSA (g/m2), LV mass remained increased between only H.Obese 
vs H.Obese/T2D (88 ± 3.5 vs 106 ± 4.0, p<0.01, Table 2). However, as indexation of LV mass 
to BSA in obese patients has been suggested to be inaccurate13, we also indexed to height^2.7. 
Using this method, LV mass/height (g/m2.7) was increased in H.Obese vs N.Obese (47 ± 1.8 vs 
40 ± 1.5, p<0.01), N.Obese/T2D vs N.Obese (48 ± 2.4 vs 40 ± 1.5, p<0.05) and between 
H.Obese/T2D vs both H.Obese and H.T2D (55 ± 1.8 vs 47 ± 1.8 and 43 ± 1.4, p<0.01 and 
p<0.001 respectively) (Figure 1A). Alarmingly, LV mass/height was comparable between 
normotensive vs hypertensive T2D and Obese/T2D groups (p=1.0 and p=0.178, respectively, 
by ANOVA). When considering normotensive vs hypertensive Obese/T2D groups 
independently via a student’s t-test, a significant difference in LV mass/height was observed 
(p=0.023, Figure 1A).  
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TABLE 2. M-Mode echocardiographic images. 
GROUP OBESE T2D OBESE/T2D 
Condition Norm. Hyper. Norm. Hyper. Norm. Hyper. 
M-Mode Measurements 
IVSd (cm) 1.0 ± .03 1.1 ± .02 ** 1.1 ± .03 1.1 ± .02 1.1 ± .03 
1.3 ± .02 ǂ ǂ ǂ 
××× 
LVIDd (cm) 4.9 ± .08 4.8 ± .08 4.7 ± .11 4.6 ± .08 4.6 ± .10 4.8 ± .05 
LVPWd (cm) 0.9 ± 02 1.1 ± .03 1.0 ± .03 ǂ  1.1 ± .03 1.1 ± .03 ǂ ǂ ǂ 
1.2 ± .02 ***     
ǂ ǂ ǂ ××× 
LV mass (g) 159 ± 5.7 191 ± 8.2 ** 172 ± 8.0 187 ± 5.1 191 ± 8.2 
233 ± 6.2 ***    
ǂ ǂ ǂ ××× 
LV mass/BSA 76 ± 2.4 88 ± 3.5 90 ± 3.9 103 ± 4.3 90 ± 4.3 106 ± 4.0 ǂ ǂ 
**p<0.01, ***p<0.001, vs same group, different condition; ǂ p<0.05, ǂ ǂ p<0.01, ǂ ǂ ǂ p<0.001, 
vs obese group, same condition; ××× p<0.001 vs T2D group, same condition. 
 
No difference in the Prevalence of Concentric Remodelling and Concentric Hypertrophy 
was Observed between Normotensive and Hypertensive Obese/T2D Patients  
To determine whether the observed increases in LVPWd and LV mass were associated with 
alterations in LV geometry, RWT was calculated and used with LV mass/height to identify 
normal LV geometry, EH, CR or CH12. Hypertension increased RWT in obese patients 
(p<0.01), while the coexistence of obesity and T2D increased RWT compared with obesity 
alone in both normotensive and hypertensive patients (p<0.01, Figure 1B). Calculated LV 
geometry patterns are shown in Figure 1C and Supplementary Figure 1. The percentage of 
patients with normal LV geometry decreased between N.Obese vs H.Obese (71% vs 28%, 
p<0.001), N.T2D vs H.T2D (52% vs 29%, p<0.05), N.Obese/T2D vs H.Obese/T2D (20% vs 
4%, p<0.05), N.Obese vs N.Obese/T2D (p<0.001) and H.Obese vs H.Obese/T2D (p<0.01). 
The percentage of patients with EH increased between N.Obese vs H.Obese (6.5% vs 19%, 
p<0.05) and decreased between H.Obese vs both H.T2D and H.Obese/T2D (19% vs 4.8% and 
4% respectively, p<0.05). The percentage of patients with CR increased between N.Obese vs 
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N.T2D (15% vs 44%, p<0.01). The percentage of patients with CH increased between N.Obese 
vs H.Obese (6% vs 24%, p<0.01), N.T2D vs H.T2D (4% vs 27%, p<0.01), both N.Obese and 
N.T2D vs N.Obese/T2D (6% and 4% vs 37%, p<0.001) and both H.Obese and H.T2D vs 
H.Obese/T2D (24% and 27% vs 55%, p<0.001). As with LV mass/height, the prevalence of 
CR and CH were comparable between normotensive vs hypertensive Obese/T2D groups 
(p=0.629 and p=0.164 respectively). This suggests that, in the absence of hypertension, obesity 
and T2D have an additive effect on the development of CH. 
 
FIGURE 1. A LV mass/height (g/m2.7), B RWT, Error bars represented as mean ± SD. C 
Percentage of subjects with Normal LV geometry, eccentric hypertrophy, concentric 
remodelling or concentric hypertrophy. **p<0.01, vs same group, different condition; ǂǂ 
p<0.01, vs obese group, same condition; ×× p<0.01, vs T2D group, same condition. 
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Assessment of Unadjusted LVPWd Alone Underestimates LV Remodelling in 
Normotensive Obese and T2D Patients 
Due to discrepancies in past studies that have assessed LVH in normotensive patients with 
metabolic syndrome14, we determined whether different outcomes in assessment of LVH 
would be obtained using unadjusted LVPWd, which is commonly used in clinical practice, 
versus RWT. Interestingly, in those patients across all groups characterised with CR, 44% of 
normotensive patients and 25% hypertensive patients (p<0.05) exhibited LVPWd within 
normal ASE ranges. This analysis was determined using the preferred formula 
((IVSd+LVPWd)/LVID) to derive RWT, as this formula assumes asymmetric LV remodelling 
by taking into account both septal and posterior aspects of the LV chamber. When using an 
alternative formula that does not include IVSd ((2xLVPWd)/LVIDd) similar results were 
obtained (data not shown). These findings are further supported by the observed differences in 
LVPWd between LV geometric patterns, with patients characterised with EH and CR 
exhibiting comparable LVPWd (1.07 ± 0.01 vs 1.07 ± 0.01), greater than that detected in 
patients with normal LV geometry (0.83 ± 0.01, p<0.001) and lower than that detected in 
patients with CH (1.25 ± 0.02, p<0.001, Figure 2A). As expected due to LV geometric 
characterisation criteria, RWT was comparable between patients with normal LV geometry and 
EH (0.35 ± 0.01 vs 0.39 ± 0.01), increased in those exhibiting CR (0.49 ± 0.01, p<0.001 vs 
normal and EH) and interestingly was further increased in those with CH (0.53 ± 0.02, p<0.001 
vs normal and EH, p<0.05 vs CR, Figure 2B). These results suggest that in obese and/or T2D 
patients, assessment of unadjusted LVPWd alone may underestimate the presence of LV 
remodelling and as such, the additional use of RWT may provide a more sensitive measure in 
these patients.  
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FIGURE 2. Normotensive and hypertensive patients grouped based on characterisation of 
normal LV geometry, eccentric hypertrophy, concentric remodelling and concentric 
hypertrophy. A LVPWd (cm), B RWT. Data represented as means ± SEM. ǂǂǂ p<0.001 vs 
normal geometry, ××× p<0.001 vs eccentric hypertrophy, + p<0.05 vs concentric remodelling. 
 
LV Geometric Patterns Associate with Differing Grades of Diastolic Dysfunction  
To assess the prognostic value of characterising LV remodelling in normotensive obese and/or 
T2D patients, multivariable logistic regression analysis was used to determine whether LV 
geometric patterns predicted diastolic dysfunction. 
Again we first confirmed that our patient population exhibited normal associations, in this case 
between age and indices of diastolic function (Supplementary Table 2). In normotensive 
patients, age correlated with E/A ratio (r=-0.25, p<0.001), E/E’ (r=0.23, p<0.01), DT (r=0.11, 
p<0.05) and LAVi (r=0.28, p<0.001). The same was true for hypertensive patients, with the 
exception of LAVi. Associations between BMI and indices of diastolic function were also 
assessed, as previous studies have yielded conflicting results in this area15, 16. However, no 
associations between BMI with indices of diastolic function were observed (Supplementary 
Table 2). 
89 
 
CR was a predictor of both grade 1 DD (odds ratio (OR) 3.487, p=0.038) and grade 3 DD (OR 
2.157, p=0.029) when including sex and BMI as covariates. With the addition of age as a 
covariate, the association with grade 1 DD remained (OR 3.474, p=0.045), and was lost with 
grade 3 DD (OR 1.9, p=0.071). CH proved to be a stronger predictor of grade 3 DD (OR 3.7, 
p<0.001) with the inclusion of sex and BMI as covariates. This association was only slightly 
attenuated with the addition of age as a covariate (OR 3.2, p<0.005). Supporting these findings, 
RWT and LV mass/height were identified as predictors of grade 3 DD (OR 30.28, p<0.001 and 
OR 1.051, p<0.001 respectively) when including sex and BMI as covariates. With the addition 
of age as covariate, the association between LV mass/height with grade 3 DD was lost (OR 
1.011, p=0.337) and was moderately attenuated in relation to RWT (OR 19.245, p=0.012; 
Table 3). These data suggest, that the presence of CR is a predictor of grade 1 DD and CH and 
RWT are predictors of grade 3 DD, independent of sex, age and BMI in obese and/or T2D 
patients.  
TABLE 3. Associations between diastolic dysfunction and LV remodelling 
LVH TYPE/ 
INDICES 
GRADE 1 DD GRADE 2 DD GRADE 3 DD 
 OR (95% C.I) p value OR (95% C.I) p value OR (95% C.I) p value 
Covariates: LVH type/indices, sex and BMI  
EH 3.1 (0.2-55.7) N/S 2.5 (0.7-8.6) N/S 0.6 (0.2-2.1) N/S 
CR 3.5 (0.1-11.3) 0.038 1.1 (0.5-2.1) N/S 2.2 (1.1-4.3) 0.029 
CH 0.5 (0.1-3.0) N/S 0.7 (0.3-1.4) N/S 3.7 (1.7-8.0) 0.000 
RWT 11.1 (0.2-562) N/S 0.2 (0.02-2.6) N/S 30.1 (3.2-286) 0.000 
LV mass/height 1.1 (1.0-1.1) N/S 1.0 (0.9-1.0) N/S 1.1 (1.0-1.1) 0.000 
Covariates: LVH type/indices, sex, BMI and age 
EH 2.4 (0.1-46.1) N/S 2.8 (0.8-10.2) N/S 0.8 (0.2-3.2) N/S 
CR 3.5 (1.1-11.7) 0.045 1.2 (0.6-2.4) N/S 1.9 (0.9-3.9) 0.071 
CH 0.7 (0.-4.8) N/S 0.8 (0.4-1.7) N/S 3.2 (1.4-7.2) 0.003 
RWT 1.0 (0.9-1.0) N/S 1.0 (0.9-1.0) N/S 19.2 (1.9-193) 0.012 
LV mass/height 1.1 (1.0-1.1) N/S 1.0 (0.9-1.1) N/S 1.0 (1.0-1.0)  0.337 
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The Co-existence of Obesity and T2D in Normotensive Patients had an Additive Effect 
on the Prevalence of Grade 3 Diastolic Dysfunction 
The prevalence of DD in normotensive vs hypertensive obese and/or T2D groups irrespective 
of LV geometric type was determined (Figure 3A-D). Accounting for sex and age, normal 
diastolic function decreased between N.Obese vs H.Obese (50% vs 32.4%, p<0.05) and N.T2D 
vs H.T2D (48.8% vs 24.3%, p<0.05) groups, grade 1 DD increased between N.Obese vs 
H.Obese (5% vs 17%, p<0.05) and grade 3 DD increased between N.Obese vs H.Obese (13.8% 
vs 39.2%, p<0.05), N.T2D vs H.T2D (19.5% vs 47.8%, p<0.05) and N.Obese/T2D vs 
H.Obese/T2D (34.1% vs 47.8, p<0.05) groups. The prevalence of Grade 3 DD in both 
normotensive and hypertensive Obese/T2D patients was greater than that detected in obese 
(p<0.01) and T2D (p<0.05) groups alone. These results suggest that there is an additive effect 
on diastolic decline when obesity and T2D co-exist, compared to when these stresses present 
individually. 
Systolic function was also assessed, however, all groups exhibited indices within the range of 
normal, as per ASE guidelines (Supplementary Table 1). 
 
Pulse Pressure is an Independent Predictor of Increased RWT in Normotensive Patients 
In order to determine which normotensive obese and T2D patients were at greatest risk of 
developing LVH, linear regression analysis was used to determine whether routinely measured 
metabolic parameters (Table 1) associated with RWT. RWT was chosen as the independent 
variable to detect risk of LVH, as RWT provided the most sensitive measure to detect LVH in 
our normotensive patients. In addition, concentric remodelling and concentric hypertrophy 
were the most prevalent types of LV geometry detected, for which both have the common 
requirement for increased RWT.  
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Pulse pressure (Figure 3E) and fasting glucose (Supplementary Figure 3A) were associated 
with RWT (r2=0.28, p<0.001 and r2=0.33, p<0.001, respectively). Specifically, pulse pressure 
≥ 54 mmHg and fasting glucose ≥ 7.7 mmol/l were associated with a RWT > 42, a value 
characteristic of concentric remodelling and also concentric hypertrophy when accompanied 
by an increase in LV mass. When accounting for sex, age and BMI, the correlations between 
pulse pressure (r2=0.33, p<0.001), fasting glucose (r2=0.35, p<0.001) and RWT were slightly 
strengthened. This suggests that these parameters can be used to predict risk in normotensive 
obese and/or T2D patients, independent of age and BMI.  The same associations were not 
detected in hypertensive obese and/or T2D patients (Supplementary Figure 3B-C). Presumably 
due to the stronger influences of hypertension on cardiac structure in comparison to obesity 
and T2D. 
 
FIGURE 3. Percentage of normotensive and hypertensive obese, T2D and obese/T2D groups 
with A Normal diastolic function, B Grade 1 DD, C Grade 2 DD and D Grade 3 DD. E Linear 
regression analysis between RWT and Pulse Pressure (mmHg) in normotensive obese and/or 
T2D patients, ***p<0.001 via linear regression analysis. Accounting for sex and age; *p<0.05 
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vs same group, different condition, ǂ p<0.05, ǂ ǂ p<0.01, ǂ ǂ ǂ p<0.001 vs obese group, same 
condition, ××× p<0.001 vs T2D group, same condition. 
 
Normotensive Metabolically Non-Healthy Obese Patients Exhibited Increased 
Prevalence of Concentric Remodelling and Diastolic Dysfunction  
As BMI did not associate with RWT or indices of DD in our patients (Supplementary Table 2 
& 3), we aimed to determine what factors in normotensive obese patients were associated with 
the observed alterations in LV geometry and DD (Figure 1C & 3B-D). To do this, N.Obese 
patients were stratified into metabolically healthy and metabolically non-healthy N.Obese 
groups (see methods). In doing so, we determined that metabolically healthy N.Obese patients 
have a relatively low risk of concentric remodelling and concentric hypertrophy compared with 
metabolically non-healthy N.Obese, exhibiting normal LV geometry at a prevalence of 84.8% 
vs 35% (p<0.001), concentric remodelling at 5% vs 47% (p<0.001) and concentric hypertrophy 
at 5% vs 12% (p<0.05, Figure 4A). The prevalence of eccentric remodelling remained low in 
both metabolically healthy and non-healthy N.Obese patients (5.2% vs 6%, Figure 4A). In 
addition, the prevalence of concentric remodelling and concentric hypertrophy in normotensive 
metabolically non-health obese patients was comparable to H.Obese patients (47% and 12% 
vs 47% and 25%, p=1.0 and p=0.13 respectively), suggesting that in obese patients, metabolic 
abnormalities have effects similar to hypertension on LV remodelling. The prevalence of 
normal diastolic function declined between metabolically healthy N.Obese vs metabolically 
non-healthy N.Obese (61% vs 42%, p<0.05, Figure 4B), while grade 3 DD increased (5.5% vs 
20%, p<0.05, Figure 4E). There were no differences in grade 1 and 2 DD between groups 
(Figures 4C and D).  
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FIGURE 4. Percentage of metabolically healthy (MH) and metabolically non-healthy (MNH) 
normotensive with A Normal LV geometry, eccentric hypertrophy, concentric remodelling and 
concentric hypertrophy, B Normal diastolic function, C Grade 1 DD, D Grade 2 DD, and E 
Grade 3 DD. Accounting for sex and age; *p<0.05 vs MH. 
 
DISCUSSION 
Despite professional knowledge of the risks associated with obesity and T2D in the 
development of cardiovascular disease, monitoring blood pressure remains the first line method 
when assessing risk in normotensive obese and/or T2D patients. While this practice allows for 
the early detection of hypertension, it may not be sufficient to allow for the early detection of 
LVH and DD. Indeed, results from this current study suggest that in the absence of 
hypertension, LVH and DD may be present and detectable via TTE in normotensive obese 
and/or T2D patients. The major findings from this study are that; 1. Significant alterations in 
LV remodelling indicative of LVH were detected in normotensive metabolically non-healthy 
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obese, T2D and obese/T2D patients. 2. Assessment of LVPWd via recommended ASE 
guidelines underestimated the presence of LV remodelling. 3. Concentric remodelling was a 
predictor of grade 1 DD and concentric hypertrophy and RWT predictors of grade 3 DD, 
independent of sex, age and BMI. 4. Normotensive patients with an increased risk of a RWT > 
42 with those exhibiting pulse pressure ≥ 54 mmHg.   
Considering obese patients first, metabolically healthy N.Obese patients exhibited a relatively 
low prevalence of LV remodelling, with > 80% of these patients exhibiting normal LV 
geometry. It was only in those N.Obese patients characterised with “poor” metabolic health 
that significant alterations in LV geometry were detected. This was particularly true for 
concentric remodelling (47%), which was 9.4 times higher than that in metabolically healthy 
N.Obese patients and 1.6 times higher than that in H.Obese patients. This suggests that obesity 
per se, as defined by a BMI ≥ 30 (kg/m
2
), does not promote the development of concentric 
remodelling, but rather it is the metabolic health status of the patient with a BMI ≥ 30 (kg/m
2
) 
that has the greatest influence on increases in RWT. Supporting this claim, our study showed 
that BMI had no association with RWT or diagnosis of concentric remodelling. Therefore, 
these results suggest additional risk assessment should be performed in normotensive obese 
patients with more than one of the following metabolic parameters; fasting glucose > 5.5 
mmol/l, HDL-C < 1.4 mmol/l, LDL-C > 2.6 mmol/l, Cholesterol > 5.5 mmol/l and triglycerides 
> 1.8 mmol.   
H.Obese patients on the other hand exhibited not only concentric remodelling (28%) but also 
concentric hypertrophy (25%), at a prevalence 4.8 and 2 times higher than that in metabolically 
healthy and non-healthy N.Obese patients respectively. This is consistent with previous studies 
in which autopsy results identified hypertensive obese patients to exhibit both concentric 
remodelling and concentric hypertrophy and for normotensive obese patients to present with 
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mainly concentric remodelling17. N.T2D patients exhibited similar alterations in LV geometry 
as metabolically non-healthy obese, showing a comparable prevalence of concentric 
remodelling (44%) and a low prevalence of concentric hypertrophy (4%), 6.75 times lower 
than that in H.T2D patients. Interestingly, it was only in those N.Obese/T2D patients in which 
the predominant LV geometric patterns detected included both concentric remodelling (30%) 
and concentric hypertrophy (36%), which was comparable to that in H.Obese patients. These 
results suggests that the co-existence of obesity and T2D in normotensive patients had an effect 
on the development of CH which was similar to the negative influence hypertension had when 
coupled with obesity or T2D alone. 
To our knowledge, this is the first study reporting that the use of unadjusted LVPWd vs RWT 
underestimated the presence of LV remodelling in obese and T2D patients. This had particular 
relevance in normotensive patients, with 45% of those characterised with concentric 
remodelling exhibiting LVPWd within the ranges of normal ASE guidelines. This result was 
unchanged regardless of how RWT was derived. However, consideration of septal wall 
thickening was preferred due to the presence of asymmetric LV remodelling in some patients, 
with IVSd showing similar patterns of enlargement as LVPWd within our groups 
(Supplementary Table 1). Of note, this increase in septal thickening was accompanied by aortic 
stenosis, with a thinning of the proximal ascending aorta correlating with increased IVSd 
(r=0.24 p=0.001, data not shown), a correlation that has previously been identified in subjects 
with asymmetric remodelling18. These data suggest that in normotensive obese and/or T2D 
patients assessment of unadjusted LVPWd alone may underestimate the presence of LV 
remodelling (both symmetric and asymmetric) and, as such, the additional use of RWT may 
provide a more sensitive measure in these patients.  
The implications of underestimating LV remodelling are evident in this study with the use of 
multivariable logistic regression analysis identifying an association between concentric 
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remodelling with diagnosis of grade 1 DD and concentric hypertrophy and RWT with grade 3 
DD (independent of sex, age and BMI). This suggests that reliance on unadjusted LVPWd in 
normotensive obese and T2D patients underestimates not only LV remodelling, but also 
associated cardiovascular risk. While previous studies have identified associations between LV 
geometry with adverse cardiac function and cardiovascular risk19-24, these studies have 
predominately focused on hypertensive patients or have not had access to subject data 
regarding hypertension. The data from this study provides insight into the prognostic value of 
LV geometry, specifically in normotensive obese and T2D patients.  
While subject numbers in the present study were low, the identification that pulse pressure and 
fasting glucose to be associated with RWT may assist health practitioners in narrowing down 
the otherwise large patient pool of at risk individuals to which this study relates, with pulse 
pressure ≥ 54 mmHg and fasting glucose ≥ 7.7 mmol predictors of RWT > 42. RWT was 
chosen as an independent variable to detect risk of LVH due to concentric remodelling and 
concentric hypertrophy being the predominant LV geometric patterns detected for which both 
have the common requirement for increased RWT. In addition, RWT provided a more sensitive 
measure to detected LV remodelling in our patients and increases in RWT have previously 
been associated with adverse cardiovascular events9, 25, 26. In healthy subjects normal pulse 
pressure levels have been detected at 40 mmHg. The recorded pulse pressure measurements in 
the current study were increased, averaging > 50 mmHg in normotensive and > 60 mmHg in 
hypertensive patients. Similar increases in pulse pressure have previously been recorded in 
subjects with metabolic syndrome27, 28. To our knowledge, this is the first study identifying the 
use of pulse pressure as a predictor of increased RWT that can be applied to all normotensive 
obese, T2D and obese/T2D patients. In a dataset from the HyperGEN study29 normotensive 
subjects with a higher pulse pressure (> 60 mmHg) were associated with an increased 
prevalence of thickening of the LVPWd and increased RWT. This pulse pressure quartile 
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however contained a lower average BMI (27.06 kg/m2) and percentage of T2D subjects 
(3.97%) compared to current study.   
Fasting glucose, has been associated with indices of LVH in the past30. Furthermore, patients 
with impaired fasting glucose or T2D have previously been reported to exhibit a 9% and 11% 
respectively increase in the prevalence in concentric remodelling than that in euglycemic 
patients (of note, 46% of patients were hypertensive)31. The identification of the association 
with fasting glucose with RWT in the current study was strengthened when accounting for age 
and BMI. When comparing the use of fasting glucose vs pulse pressure as a predictor of 
increased RWT via multivariable stepwise regression analysis, fasting glucose was a stronger 
predictor of RWT (data not shown). In regards to the practicality of using pulse pressure and 
fasting glucose as markers of increased risk, these parameters are already routinely collected 
in normotensive obese and T2D patients, therefore their use will not result in an additional 
burden in either cost or time. However, it should be noted that although the presence of elevated 
pulse pressure and fasting glucose were associated with LV remodelling, this study is not 
suggesting that these are a requirement and, as such should not provide a means to exclude 
patients at risk. 
There are some limitations that need to be considered when interpreting the findings from this 
study. In regards to diastolic function, the reader is reminded that these measurements were 
obtained from an assessment at one time point and that diastolic function may vary between 
examinations. Furthermore, the size of the research groups were limited and restricted to 
patients to one ethnic group.  
CONCLUSION 
In summary, the data from this current study suggest that in the absence of hypertension, 
metabolically non-healthy obese, T2D and obese/T2D patients are at risk of LVH and LV 
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remodelling and that this risk is increased when accompanied by increased pulse pressure or 
fasting glucose. The identification of LVPWd vs RWT to underestimate LV remodelling in 
normotensive obese and/or T2D patients suggests that the use of RWT may provide a more 
sensitive measure in future studies and in risk assessment in these patient groups. 
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SUPPLEMENTARY DATA 
 
Additional study design information 
 
The study was conducted using pre-recorded endocrinology and echocardiography data from 
two separate databases. The first database searched contained basic patient clinical 
characteristics obtained from the Endocrinology department of the Geelong hospital and the 
Geelong Endocrinology and Diabetes practice. This database was used to obtain a list of 
patients at each clinic who were either obese and non-T2D, T2D and non-obese or obese and 
T2D. Obesity was characterised by a BMI > 30 and T2D as having three or more elevated 
fasting glucose level readings (>7 mmol/l) within a 12 month period. After this search 2397 
patients met the selection criteria (1158 obese only, 572 T2D only, 667 obese and T2D). 
Additional data collected for each patient from this database included; age, sex, height, weight, 
blood pressure, fasting glucose, HbA1c %, LDL-C, HLD-C, total cholesterol and triglycerides, 
history of anti-hyperglycaemic medication, history of anti-hypertensive medication and history 
of cardiovascular or systemic disease.  
 
These 2397 patients were then cross referenced with the second separate cardiovascular 
database to determine whether the patients had undergone an echocardiography within 6 
months of collection of the basic clinical data above. For which 503 patients were matched. 
The patient data collected from the cardiology database was; age, sex, height, weight, reason 
for referral for echocardiography and echocardiography results. Patients with an unclear 
echocardiography due to technical reasons (largely caused by presence of obesity), age < 18 
years, history of systemic or cardiovascular disease and those with systolic only or diastolic 
only hypertension or well controlled hypertension were excluded from the study. After this 
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point, 353 patients were left that met the selection criteria (129 obese only, 115 T2D only and 
109 obese and T2D). These patients were then further separated into normotensive and 
hypertensive groups. With hypertension characterised as having both elevated diastolic and 
systolic blood pressure of ≥ 140/90 mmHg, with or without a history of anti-hypertensive 
medication. Final groups numbers were; normotensive obese, 58; normotensive T2D, n=41; 
normotensive obese/T2D, n=42, hypertensive obese, n=71; hypertensive T2D, n=74; and 
hypertensive obese/T2D, n=67. 
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Table S1. 
GROUP OBESE T2D OBESE/T2D 
Condition  Norm. Hyper. Norm. Hyper. Norm. Hyper. 
Glucose Homeostasis 
Hba1c  - - 7.1 ± 0.3 7.6 ± 0.5 8.0 ± 0.3 7.7 ± 0.2 
M-Mode Measurements  
Aortic Root (cm) 0.3 ± .06 3.2 ± .05 3.5 ± .08 ǂǂǂ 3.4 ± .05 ǂ 3.3 ± .06 3.6 ± .05 ǂǂǂ 
Ascending Aorta 
(cm) 
3.7 ± .14 3.9 ± .10 3.8 ± .13 4.0 ± .10 3.8 ± .14 4.1 ± .11 
LA Volume index 29 ± 1.5 31 ± 1.2 32 ± 2.1 33 ± 1.5 28 ± 1.9 31 ± 1.8 
IVSd (cm) 1.0 ± .03 1.1 ± .02 1.1 ± .03 ǂǂǂ 1.1 ± .02 1.1 ± .03 ǂǂǂ 
1.3 ± .02 ǂǂǂ 
××× 
LVIDd (cm) 4.9 ± .08 4.8 ± .08 4.7 ± .11 4.6 ± .08 4.6 ± .10 4.8 ± .05 
LVIDs (cm) 3.1 ± .12 3.1 ± .10 3.1 ± .12 3.1 ± .11 3.0 ± .11 3.1 ± .08 
Peak E-Wave 0.8 ± .02 0.8 ± .03 0.8 ± .04 0.8 ± .03 0.9 ± 05 0.9 ± .05 
Peak A-Wave 0.7 ± .03 0.8 ± .04 08 ± .04 0.9 ± .03 0.8 ± .04 0.9 ± .04 
E/A Ratio 1.3 ± .07 1.1 ± .06 1.1 ± .08 1.2 ± .06 1.1 ± .07 1.1 ± .07 
E’ 8.4 ± .43 7.6 ± .31 6.6 ± .38 5.8 ± .22 7.1 ± .31 6.0 ± .31 
E/E’ 11 ± .46 12 ± .8 12 ± 1.3 14 ± .60 14 ± 1.1 16 ± .98 ǂǂǂ 
DT 225 ± 10 223 ± 6.9 221 ± 11 227 ± 8.9 202 ± 7.4 230 ± 11 
Systolic Indices Derived from M-Mode Measurements 
Stroke Volume 72.6 ± 3.6 71.3 ± 2.8 67.3 ± 4.1 64.9 ± 3.0 70.4 ± 2.9 67.0 ± 2.6 
Cardiac Output 5386 ± 267 5094 ± 214 4308 ± 273 4500 ± 212 5269 ± 289 4727 ± 208 
EF% 61.9 ± 2.1 65.0 ± 1.6 62.7 ± 2.2 63.3 ± 2.04 67.8 ± 2.0 62.7 ± 1.9 
FS% 34.0 ± 1.4  36.3 ± 1.2 34.7 ± 1.6 35.7 ± 1.5 39.4 ± 2.2 35.0 ± 1.3 
ǂ ǂ ǂ p<0.001 vs obese group, same condition, ××× p<0.001 vs T2D group, same condition 
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Table S2.  
VARIABLE AGE BMI 
Condition Norm. Hyper. Norm. Hyper. 
 p value r2 p value r2 p value r2 p value r2 
Association with indices of Left Ventricular Hypertrophy 
LVPWd 0.000 0.35 N/S 0.07 0.050 0.15 0.005 0.18 
LV mass  0.003 0.24 0.063 0.11 0.035 0.16 0.001 0.21 
LV mass/BSA 0.000 0.36 0.001 0.25 N/S -0.07 0.001 -0.25 
LV mass/ height^2.7 0.004 0.26 N/S 0.06 0.000 0.39 0.000 0.38 
RWT 0.000 0.38 N/S 0.09 N/S 0.04 N/S 0.07 
Association with indices of Diastolic Dysfunction 
E/A ratio 0.000 -0.25 0.04 -0.09 N/S 0.03 N/S -0.03 
E/E’ 0.011 0.23 0.001 0.16 N/S 0.05 N/S 0.29 
DT 0.035 0.11 0.026 0.14 N/S -0.02 N/S -0.07 
LAVi 0.003 0.28 N/S 0.03 N/S -0.09 N/S -0.08 
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Figure S1. Percentage of normotensive and hypertensive obese, T2D and obese/T2D groups 
with A Normal LV geometry, B Eccentric hypertrophy, C Concentric remodelling and D 
Concentric hypertrophy. * p<0.05, **p<0.01, ***p<0.001 vs same group, different condition, 
ǂ p<0.05, ǂ ǂ p<0.01, ǂ ǂ ǂ p<0.001 vs obese group, same condition, ××× p<0.001 vs T2D group, 
same condition. 
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Figure S2. Percentage of patients characterised with normal LV geometry, eccentric 
hypertrophy, concentric remodelling and concentric hypertrophy with A Normal diastolic 
function, B Grade 1 DD, C Grade 2 DD and D Grade 3 DD. Accounting for sex and age; ǂ 
p<0.05, ǂ ǂ p<0.01vs normal geometry, × p<0.05, ×× p<0.001 vs  eccentric hypertrophy,+ 
p<0.05 vs concentric remodelling. 
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Figure S3. Linear regression analysis between RWT and fasting glucose (mmol/l) in obese 
and/or T2D; A normotensive patients and B hypertensive patients and C linear regression 
analysis between RWT with pulse Pressure (mmHg) in hypertensive obese and/or T2D 
patients. 
 
 
  
  
p=0.278 
p=0.606 
r2=0.35 
p<0.001 
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CHAPTER 2 SUMMARY 
 
In summary our data supported our hypothesis and met the aims of the study. Our findings 
have a number of important clinical implications for cardiologists, endocrinologists and general 
practitioners. They show that monitoring patient risk through blood pressure measurement may 
be insufficient to identify at risk obese and/or T2D patients. Furthermore, that traditional 
measures of LV hypertrophy may underestimate patient risk. Our findings reveal that 
transthoracic echocardiography is justified in metabolically non-healthy patients, particularly 
in the presence of elevated pulse pressure and fasting glucose.  
 
Limitations of the study  
1. Blood pressure was measured within a 6 month time frame of the echocardiography 
and there was no use of ambulatory blood pressure.  
2. Fasting plasma insulin data was not available. This would have been interesting to 
assess, as plasma insulin has previously been shown to associate with LVH and 
cardiovascular risk.     
3. The study was restricted to one ethnicity (however, due to the small sample sizes this 
was preferable for the current study). 
 
Strengths of the study 
1. The stresses hypertension, obesity and T2D were clearly separated and combined 
allowing us to investigate the associations of the disease states separately and in 
combination with the presence of LVH and dysfunction. 
2. The further separation of normotensive obese subjects based on metabolic health 
allowed us to shed light on some of the discrepancies of past studies. Finding obesity 
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per se, as defined by a BMI ≥ 30 (kg/m
2
), did not promote the development of 
concentric remodelling, but rather the metabolic health status of the patient with a BMI 
≥ 30 (kg/m
2
) had the greatest influence on increases in RWT.  
3. We confirmed that our sample exhibited normal associations between age and diastolic 
decline and with indices of LVH, providing added confidence that the dataset was 
representative of general obese and/or T2D populations.  
4. LVH was assessed in great detail, via both clinical indices and via assessment of LV 
geometric patterns.  
5. Diastolic dysfunction was graded as per clinical guidelines. Allowing ease for clinicians 
to interpret the findings in a relevant manner.  
6. We were able to narrow down the patient pool of “at risk” individuals, increasing the 
application potential of the study.  
 
As detailed in Chapter 1, this thesis is centred around the hypothesis that alterations in cardiac 
structure and function in obesity and T2D, as observed in this current chapter, are driven in 
part, by alterations in normal cardiac energy metabolism. In the following Chapter 3 we explore 
this hypothesis further by investigating the effects of a maternal high fat diet on cardiac energy 
metabolism and LVH.  
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CHAPTER 3 
 
  
Maternal High Fat Diet Induces Early Cardiac Hypertrophy and Alters Cardiac 
Metabolism in Sprague Dawley Rat Offspring   
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CHAPTER 3 INTRODUCTION 
 
One of the most interesting factors associated with researching obesity and T2D induced heart 
failure are the complexity of these conditions and their development. While it is clear that 
obesity and type 2 diabetes are predominately driven by poor life style choices, an increasing 
body of evidence suggests that some individuals show a predisposition to developing obesity, 
T2D and associated cardiovascular disease. This is driven by multiple factors including a 
genetic predisposition (which is beyond our control) and by an adverse maternal environments 
such as maternal obesity and maternal high fat diets (which are largely within our control).  
 
As will be discussed in the following paper, maternal obesity and maternal high fat diets 
(mHFD) are associated with increased cardiovascular risk in adult offspring. The underlying 
mechniams however remain unclear. As alterations in cardiac energy metabolism are suggested 
to precede the development of LVH and dysfunction we aimed to assess the influence of a 
mHFD on offspring cardiac energy metabolism. This work was particularly focused on Class 
IIa HDAC-MEF2 axis signalling as my laboratory has previously shown that the Class IIa 
HDAC-MEF2 axis is involved in regulating fatty acid oxidation in striated muscle and, as 
detailed in Chapter 1, this axis is also one of the main signalling pathways involved in 
development of cardiac hypertrophy for which PKD is suggested to signal via. We therefore 
hypothesised that a mHFD would be associated with activation of signalling controlling class 
IIa HDAC activity and subsequent downstream activation of genes involved in fatty acid 
oxidation and cardiac hypertrophy in offspring. Please note, in regards to the methodology 
chosen, the mHFD persisted not only through gestation but also lactation. This allowed us to 
“recreate” the typical mHFD environment observed in humans. In which the stress continues 
via the mother’s breast milk post birth. Additional analyses performed in isolated neonatal 
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ventricular cardiomyocytes allowed for us to gain some insight into the intrinsic adaptations in 
cardiac energy metabolism induced via the mHFD specifically during gestation.  
 
Hypothesis: a mHFD predisposes to cardiovascular risk in part by altering cardiac energy 
metabolism similar to what is observed in the obese/T2D adult heart and induces cardiac 
hypertrophy. And finally, that these alterations are mediated, at least in part, by the Class IIa 
HDAC-MEF2 axis.  
 
Significance: Determining whether a mHFD alters cardiac energy metabolism in offspring can 
assist us in understanding why offspring exposed a maternal obesity and HFD exhibit an 
increased risk for cardiovascular disease in adult life.  
 
Aims 
4. To investigate Class IIa HDAC-MEF2 axis signaling in mHFD exposed pups. 
5. To investigate cardiac hypertrophy in mHFD exposed pups. 
6. To investigate cardiac energy metabolism in mHFD exposed pups. 
 
 
Paper status is published, reference; Kirstie A. De Jong, Sanna Barrand, Ryan J. Wood-
Bradley, Douglas L. De Almeida, Juliane K. Czeczor, Gary D. Lopaschuk, James A. Armitage 
and Sean L. McGee, 2018, Maternal high fat diet induces early cardiac hypertrophy and alters 
cardiac metabolism in Sprague Dawley rat offspring. Nutrition, Metabolism and 
Cardiovascular Diseases. 2018;28:600-609.
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ABSTRACT 
 
Background: Maternal high fat diets (mHFD) have been associated with an increased 
offspring cardiovascular risk. Recently we found that the class IIa HDAC-MEF2 pathway 
regulates gene programs controlling fatty acid oxidation in striated muscle. This same pathway 
controls hypertrophic responses in the heart. We hypothesized that mHFD is associated with 
activation of signal controlling class II a HDAC activity and activation of genes involved in 
fatty acid oxidation and cardiac hypertrophy in offspring.   
 
Methods: Female Sprague Dawley rats were fed either normal fat diet (12%) or high fat diet 
(43%) three weeks prior to mating, remaining on diets until study completion. Hearts of 
postnatal day 1 (PN1) and PN10 pups were collected. Bioenergetics and respiration analyses 
were performed in neonatal ventricular cardiomyocytes (NVCM). 
 
Results: In offspring exposed to mHFD, body weight was increased at PN10 accompanied by 
increased body fat percentage and blood glucose. Heart weight and heart weight to body weight 
ratio were increased at PN1 and PN10, and were associated with elevated signalling through 
the AMPK-Class IIa HDAC-MEF2 axis. The expression of the MEF2-regulated hypertrophic 
markers ANP and BNP were increased as were expression of genes involved in fatty acid 
oxidation. However this was only accompanied by an increased protein expression of fatty acid 
oxidation enzymes at PN10. NVCM isolated from these pups exhibited increased glycolysis 
and an impaired substrate flexibility.  
 
Conclusion: Combined, these results suggest that mHFD induces signalling and transcriptional 
events indicative of reprogrammed cardiac metabolism and of cardiac hypertrophy in Sprague 
Dawley rat offspring.  
  
KEY WORDS 
Maternal high fat diet, cardiovascular risk, cardiac hypertrophy and cardiac metabolism. 
 
 
  
116 
 
INTRODUCTION 
 
Maternal obesity and excessive weight gain during gestation are of increasingly common 
occurrence, currently affecting ~30-40% of infants born each year [1]. This adverse maternal 
environment is associated with an increased cardiovascular disease risk later in life [2-8].  The 
underlying mechanisms however remain poorly understood. A number of studies have 
demonstrated altered cadiovascular structure and function in adult offspring exposed to a HDF 
early in life, however, co-mobrbinidites such as hypertension, renovascular disease and 
aberrant autonomic function in these models has made it difficult to determine whether a 
primary cardiac phenotype exists, and which signalling pathways may underly any aetiology 
[9-12].  As alterations in cardiac energy metabolism are major contributors to cardiovascular 
risk we aimed to investigate the impact of a maternal high fat diet (mHFD) on signalling and 
transcriptional responses controlling cardiac energy metabolism and hypertrophy in Sprague 
Dawley rat offspring. Hypothesising that a mHFD would be associated with activation of 
signalling controlling class IIa HDAC activity and subsequent downstream activation of genes 
involved in fatty acid oxidation and cardiac hypertrophy in offspring. 
 
 
The healthy heart exhibits a high degree metabolic flexibility, adapting its substrate use 
depending on availability. Typically the adult heart utilizes ~40% glucose, lactate, ketones and 
amino acids and ~60% fatty acids [13]. Impairments in cardiac metabolic flexibility, such as 
those observed in obesity and type 2 diabetes (T2D) in which the heart has switched to rely 
predominately on fatty acids, promotes the development of cardiac hypertrophy and 
dysfunction [13-15]. Animal studies suggest this is in part due to a subsequent decrease in 
glucose oxidation, compensatory glycolysis and decreased adenosine triphosphate (ATP) 
production [13]. 
 
We have recently found that the class IIa histone deacetylase – myocyte enhancing factor 2 
(HDAC-MEF2) pathway regulates gene programs controlling fatty acid oxidation in striated 
muscle [16]. This same pathway controls hypertrophic responses in the stressed heart [17]. In 
a healthy heart class IIa HDACs act to repress transcription of genes involved in hypertrophy 
and cardiac metabolism through their association with transcription factors in the nucleus such 
as the myocyte enhancer factor-2 (MEF2). The class IIa HDACs, which include isoforms 4, 5, 
7 and 9, are catalytically inactive against acetyl-lysine due to a single amino acid substitution 
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within their active site [18]. They are thought to exert their transcriptional repressive influence 
through recruitment of a corepressor complex containing HDAC3, which can deacetylate 
histones and other regulators of gene transcription [19]. The function of this repressive complex 
is disrupted by phosphorylation of the class IIa HDACs, which results in their nucelar export 
and the expression of MEF2-depedent genes [20]. Known HDAC kinases include the calcium 
calmodulin dependent kinase II (CaMKII) [21], 5' AMP-activated protein kinase (AMPK) [22] 
and protein kinase D (PKD) [23]. Cardiac CaMKII and PKD have been shown to be activated 
by neurohormonal signalling and hyperlipidemic conditions [24] and AMPK is activated 
during times of cardiac metabolic stress to increase energy production, resulting in increased 
fatty acid oxidation along with increased glucose uptake and glycolysis [25]. Combined, these 
data from our previous work and past literature support the hypothesis of our current study.  
 
MATERIALS AND METHODS 
 
Experimental Animals/Study Design 
 
The study was carried out in accordance with guidelines of the National Health and Medical 
Research Council (NHMRC) of Australia and was approved by the Deakin University Animal 
Ethics Committee. Four to six week old male and female Sprague Dawley rats were obtained 
from the Animal Resource Centre (Perth, Western Australia). The animals were housed in pairs 
under constant temperature and humidity control with 12 hour light-dark cycles. All males were 
kept on a normal chow diet three weeks before mating (). All females rats were given either a 
normal fat diet (NFD, 12% total calculated digestible energy from lipids, SF04-001) or high 
fat diet (HFD, 43%  total calculated digestible energy from lipids, SF04-001, Speciality Feeds, 
Glen Forrest, WA, Australia) three weeks prior to mating. The females stayed on their allocated 
diets until the study completion. Please refer to supplementary Figure 1 and supplementary 
Tables 1A and 1B for details on diet durations in the study design and the diet composition. 
For mating, one male rat was housed with two female rats for one week, during this time the 
males consumed the same diet as the females they were housed with. After one week the 
females were then separated and housed individually. All subsequent litters were normalised 
on postnatal day 1 (PN1) to 10-12 pups. Male hearts were collected for analysis at PN1 (n=2 
pups per litter/6 litters per diet) and PN10 (n=2 pups per litter/8 litters per diet), for which the 
atria were removed and the ventricular tissue weighed and snap frozen in liquid nitrogen and 
stored at -80C for later analysis. In the case of neonatal ventricular cardiomyocyte (NVCM) 
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isolation, heart tissue was used immediately (detailed below). PN10 pups underwent a blood 
glucose test (Accu Chek performa, Roche North Ryde, NSW, Australia ) via cardiac puncture 
and body composition analysis via Echo-MRITM (EchoMRI Corporation Pte Ltd, Singapore ) 
on the day of dissection. These measures could not be taken at PN1 due to the insufficient 
amount of blood that can be obtained from PN1 pups without clotting and due to risk of 
hyperthermia during body composition analysis. 
 
Neonatal ventricular cardiomyocyte cell isolation  
 
PN1 hearts (n=2-3 hearts per litter/3 litters per diet) were collected and immediately transferred 
to Hanks balanced and salt solution (HBSS, Gibco, Life Tech, 14175-095) under sterile 
conditions. The atria were removed and the ventricular tissue incubated overnight in 
HBSS/trypsin (Gibco, Invitrogen, 27250-018) solution at 4°C. The following day, ventricular 
tissue were transferred to HBSS/collagenase type 2 (Worthington Biochemical Corporation, 
LS004176) and gently agitated at 37°C.  Collected cells were spun down and pellets 
resuspended in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Life Tech, 11885-084), 
foetal bovine serum (FBS, HyClone, In Vitro, 15-010.02) and ampicillin (Sigma, A9393).  The 
cell suspensions were then plated onto 10 cm petri dish and incubated at 37°C to allow for 
separation of the fibroblasts from the cardiomyocytes. The cell suspensions containing 
predominantly cardiomyocytes were plated into a 24-well XF24 cell culture microplate at a 
cell density of 1.5x104 cells/well in DMEM, FBS, ampicillin and 5-bromo-2-deoxyuridin to 
prevent proliferation of any remaining fibroblasts (Thermo Fisher and Scientific, B23151). The 
NVCM were left for 48 hours to recover after which time they were used for bioenergetics and 
respiration analysis.  
 
Bioenergetics and respiration analysis 
 
The cellular bioenergetics profile of NVCM were assessed using the Seahorse XF24 Flux 
Analyzer (Seahorse Bioscience, Bellerica, USA). Two different assays were performed; a 
glucose oxidation assay and a fatty acid oxidation assay. For the glucose oxidation assay the 
cells were washed and incubated in a non-CO2 incubator for 1 hour in DMEM containing 25 
mM of glucose (pH 7.4). Three basal extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) measurements were performed. These measurements were repeated 
following injection of each of the following compounds; 1 mM oligomycin (ATP synthase 
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inhibitor) and 1 mM rotenone and antimycin (complex I and III inhibitors). For the fatty acid 
oxidation assay the cells were washed and incubated in a non-CO2 incubator for 1 hour in 
DMEM containing 0.25 mM of BSA conjugated palmitate and 50 mM carnitine (pH 7.4). Six 
basal ECAR and OCR measurements were performed, after which 100 nM insulin and 25 mM 
glucose were injected into the media of each well and the measurements were repeated. 
Calculations of respiratory parameters of mitochondrial function were performed as previously 
described [26] and included subtraction of non-mitochondrial respiration from all 
mitochondrial respiration parameters. Following completion of the assays, ECAR and OCR 
were normalized to total protein as assessed via BCA assay.  
 
Western blotting  
 
Heart ventricles (PN1 n=2 pups per litter/6 litters per diet and PN10 n=2 pups per litter/8 litters 
per diet) were homogenised in ice-cold lysis buffer (50mM Tris pH7.5, 1mM EDTA, 1mM 
EGTA, 10% glycerol, 1% triton X-100, 50mM NaF, 5mM Na4P2O7, 1mM Na3VO4, 1mM DTT, 
protease inhibitor cocktail) and protein content was determined using the BCA method. 20µg 
of protein was separated by SDS-PAGE and transferred onto PVDF membrane using standard 
protocols. Blocked membranes were exposed to primary antibodies towards ACC pS79, 
AMPK, AMPK pT172, CaMKII, CaMKII pT172, CPT1, HDAC4/5, HDAC4/5 pS256, 
MEF2A, PGC1a, PKD, PKD pS916, PPARa (Cell Signalling Technology, Danvers, USA) and 
normalised to α-tubulin (Sigma-Aldrich, St. Louis, USA). Membranes were visualised using 
the ChemiDoc™ XRS+ with Image Lab™ software. 
 
Real time RT-PCR  
 
Heart ventricles (PN1 n=2 pups per litter/6 litters per diet and PN10 n=2 pups per litter/8 litters 
per diet) were homogenised in trizol and RNA was isolated using RNAeasy columns (Qiagen, 
Doncaster, Australia). RNA was reverse transcribed using Superscript III chemistry (Life 
Technologies, Mulgrave, Australia) and cDNA was quantified using Oligreen (Life 
Technologies, Mulgrave, Australia). Real time RT-PCR was performed using primers specific 
for β-MHC, ANP, BNP, Col1a1, Col1a2, Col3a1, Cox7a, CPT-1b, GLUT1, GLUT4, MCD, 
PGC-1α and PPARα (sequences available upon request). Gene expression was quantified using 
the 2ΔCT method and normalised to Oligreen and expressed relative to PN1 mNFD pups. 
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Statistical analysis 
 
All data represented as mean ± SEM unless otherwise stated. All data were analysed via one 
way ANOVA or students t-test where appropriate using SPSS version 23. p<0.05 was 
considered significant.  
 
RESULTS 
Considering the maternal phenotype first, after three weeks on the diet HFD damns consumed 
a higher average megajoule (MJ) than NFD damns, this remained throughout gestation 
(Supplementary Figure 1). However the damns showed no differences in % changes in body 
weight or changes in blood glucose throughout the study (Supplementary Figure 1). Comparing 
offspring born from NFD and HFD damns, body weight (g) was unchanged at PN1 (6.33 ± 
0.16g vs 6.37 ± 0.28g) but was higher at PN10 (23.07 ± 0.62g vs 26.19 ± 0.45g, p<0.001), this 
was accompanied by an increased fat mass (%) when unadjusted (1.54 ± 0.16 vs 2.27 ± 0.16, 
p<0.001) and when normalised to lean mass (6.94 ± 0.29 vs 9.84 ± 0.31, p<0.001) and an 
increase in  plasma glucose (7.5 ± 0.15 vs 8.36 ± 0.22 mmol/l, p<0.001) (Table 1).  
 
mHFD PN1 and PN10 pups exhibited increased signalling through the Class IIa HDAC-MEF2 
axis 
 
Hearts from offspring at PN1 and PN10 were collected to investigate the putative role of the 
class IIa HDAC-MEF2 axis in controlling cardiac metabolism and developmental hypertrophic 
responses. mHFD pups exhibited an increased Class IIa HDAC5 phosphorylation, 
corresponding to S246, S259 and S155 of HDAC4, 5 and 7 respectively, at both PN1 and PN10 
(2.7 and 2.8 fold respectively, p<0.001, Figure 1.A) and of MEF2 at PN1 (2.9 fold, p<0.001) 
and to a lesser degree at PN10 (1.3 fold, p<0.05, Figure 1.B), suggesting that signalling via the 
class IIa HDAC-MEF2 axis was increased in response to the mHFD. To elucidate the upstream 
pathway/s involved in phosphorylating the class IIa HDAC, we examined the phosphorylation 
status of the class IIa HDAC kinases AMPK, PKD and CaMKII, which is reflective of their 
activation. Phosphorylation of the AMPK subunit at T172 was increased at both PN1 and PN10 
(1.8 fold and 3.3 fold, p<0.001, Figure 1.C), PKD phosphorylation at its autophosphorylation 
site, S916 was unchanged between diets, but increased at the later time point of PN10 in both 
mNFD and mHFD (1.9 and 1.7 fold, p<0.001, Figure 1.D). In contrast to this, phosphorylation 
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of CaMKII decreased at the later time point of PN10 in the mNFD hearts, interestingly this 
was not observed in the mHFD PN10 hearts (2.3 fold increase vs mNFD PN10p<0.001, Figure 
1.E). These data suggest that the mHFD induced signalling through the Class IIa HDAC-MEF2 
axis via AMPK.  
 
Table 1. 
AGE PN1 PN10 
DIET mNFD mHFD mNFD mHFD 
Body weight (g) 6.33 ± 0.16 6.37 ± 0.28 23.07 ± 0.62 26.19 ± 0.45*** 
Heart weight (mg)  34.99 ± 1.65 42.60 ± 2.09*** 124.24 ± 4.37 155.03 ± 5.22*** 
HW/BW (mg/g) 5.55 ± 0.29 6.69 ± 0.13*** 5.48 ± 0.08 6.04 ± 0.14*** 
Plasma glucose (mmol/l) - - 7.50 ± 0.15 8.36 ± 0.22** 
Lean mass (%) - - 21.61 ± 0.31 22.78 ± 0.25†  
Fat mass (%) - - 1.54 ± 0.16 2.27 ± 0.16*** 
Fat/lean mass (%)  - - 6.94 ± 0.29 9.84 ± 0.31*** 
 
Body weight (BW), Heart weight (HW). **p<0.01, ***p<0.001 and †p=0.06 vs PN10 mNFD. 
 
 
Figure 1.  Expression of proteins involved in hypertrophy signalling normalised to α-tubulin 
in PN1 and PN10 pups exposed to either the mNFD or mHFD. A. HDAC5 S259, B. MEF2A, 
C. AMPK T172, D. PKD S916, E. CaMKII T286, F. Representative western blots. *p<0.05, 
**p<0.01, ***p<0.001 vs same age mNFD, ×p<0.05, ×××p<0.001 vs same diet PN1. 
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mHFD PN1 and PN10 pups exhibited cardiac hypertrophy 
 
We next examined downstream hypertrophic signalling of the class IIa HDAC-MEF2 axis. 
Heart weight (mg) and height weight to body weight (mg/g) ratio were increased at both PN1 
(34.99 ± 1.65 vs 42.60 ± 2.09mg and 5.55 ± 0.29 vs 6.69 ± 0.13mg/g, p<0.001) and PN10 
(124.24 ± 4.37 vs 155.03mg ± 5.22 and 5.48 ± 0.08 vs 6.04 ± 0.14mg/g, p<0.001) despite the 
increased body weight observed at PN10 (Table 1). These increases in heart weight were 
accompanied by an increased expression of the foetal gene program, with mRNA expression 
of the MEF2-regulated genes ANP and BNP increased at PN1 (6.8 and 3.6 fold respectively, 
p<0.001) and to a lesser degree at PN10 (2.1 fold and 1.6 fold respectively, p<0.05, Figure 2.A-
B). β-MHC expression however, was unchanged between diets, but increased at the later time 
point in both mNFD and mHFD (18 and 2.2 fold respectively, p<0.05, Figure 2.C). In addition, 
markers of fibrosis were increased in mHFD hearts (Figure 1.D-E) with Col1a1 and Col1a2 
expression increased at PN1 (3.5 and 3.1 fold respectively, p<0.05) and PN10 (1.7 and 1.9 fold 
respectively, p<0.05, Figure 2.D-E). Interestingly, Col3a1 expression was unchanged (Figure 
2.F) suggesting not all isoforms are involved in accommodating the increased collagen demand 
observed in hypertrophy at this stage.  
 
Figure 2. mRNA expression of hypertrophic markers in PN1 and PN10 pups exposed to either 
the mNFD or mHFD. A. ANP, B. BNP, C. B-MHC, D. Col1a1, E. Col1a2, F. Col3a1. *p<0.05, 
**p<0.01, ***p<0.001 vs same age mNFD, ×p<0.05, ××p<0.01, ×××p<0.001 vs same diet 
PN1. 
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mHFD hearts exhibited transcriptional reprogramming of substrate metabolism  
 
We have recently found that the class IIa HDAC-MEF2 axis regulates gene programs 
controlling fatty acid oxidation in striated muscle, with increased MEF2 activity corresponding 
to an increased capacity for fatty acid oxidation [16]. We investigated these reprogramming 
events in the current model. Of note, as expected due to the increased reliance on fatty acids 
post birth, the fatty acid oxidation profile of mNFD pups was increased at PN10 compared to 
that at PN1 (Figures 3.A-E and 4.A-D). In hearts obtained at PN1 and PN10, mHFD increased 
the expression of genes involved in fatty acid oxidation, including CD36 (1.7 fold, p<0.05 and 
9 fold, p<0.001), MCD (1.7 and 4.3 fold, p<0.05), PGC1a (4.8 fold, p<0.01 and 1.6 fold, 
p<0.05), PPARa (5.6 and 1.7 fold, p<0.01) and CPT1b (7.9 and 2.2 fold, p<0.05) (Figure 3.A-
E). This was accompanied by an increase in the protein expression of enzymes involved in fatty 
acid oxidation at PN10 only (Figure 4.A-D) with PGC1a (1.6 fold, p<0.01), CPT1b (1.9 fold, 
p<0.001) and PPARa (2 fold, p<0.001) increased. In addition, ACC S79, a key post-
translational modification controlling fatty acid oxidation, that is phosphorylated by AMPK, 
was also increased (2.2 fold, p<0.05).  Interestingly, increased mRNA expression of GLUT1 
(5.3 fold, p<0.001) a transporter that mediates the uptake of glucose in an insulin-independent 
manner and of GLUT4 (4.6 fold, p<0.01) were detected in mHFD PN1 hearts (Figure 3.F-G). 
These data suggest transcriptional reprogramming of cardiac metabolism at both PN1 and 
PN10, with increased expression of genes involved in both glucose and lipid metabolism at 
PN1 and increased expression of genes and proteins involved in lipid metabolism at PN10.   
 
124 
 
 
Figure 3. mRNA expression of genes involved in fatty acid oxidation in PN1 and PN10 pups 
exposed to either the mNFD or mHFD. A. CD36, B. MCD, C. CPT1b, D. PGC1a, E. PPARa. 
F. GLUT1, G. GLUT4. *p<0.05, **p<0.01, ***p<0.001 vs mNFD. ×p<0.05, ××p<0.01, 
×××p<0.001 vs same diet PN1. 
 
Figure 4. Expression of proteins involved in fatty acid oxidation normalised to a-tubulin in 
PN1 and PN10 pups exposed to either the mNFD or mHFD. A. ACC S79, B. CPT1b, C. 
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PGC1a, D. PPARa, E. Representative western blots. *p<0.05, **p<0.01, ***p<0.001 vs 
mNFD. ×p<0.05, ××p<0.01, ×××p<0.001 vs same diet PN1. 
 
mHFD NVCM exhibited increased glycolysis and an impaired substrate flexibility 
 
To further explore the metabolic reprogramming events in these hearts cellular bioenergetics 
and respiration were investigated in NVCM isolated from pups at PN1. As analysis of NVCM 
occurred three days post isolation we reasoned that any phenotypic differences in metabolism 
would represent intrinsic metabolic reprogramming. NVCM obtained from pups from both 
diets were subjected to glucose and fatty acid oxidation assays.  In the glucose oxidation assay, 
in which the exogenous substrate provided was restricted to glucose, mHFD NVCM exhibited 
increased basal and peak (induced by inhibition of ATP synthase) ECAR, a proxy measure of 
glycolytic rate, with no change in the OCR. This increased ECAR/OCR suggests glycolysis, 
but not glucose oxidation was increased. (Figure 5.A). Of note, there were no differences in 
uncoupled respiration or non-mitochondrial respiration upon inhibition of complex I and III 
between the groups (data not shown). During the fatty acid oxidation assay in which the 
exogenous substrate provided was initially restricted to palmitate, OCR was unchanged 
between NVCM from both diets, indicating no change in fatty acid oxidation (Figure 5.E). 
Interestingly, with the addition of insulin and glucose into the media the delta change in OCR 
was lower in mHFD NVCM (27%, p<0.01, Figure 5.B) suggesting an impaired substrate 
flexibility when switching from fatty acid to glucose oxidation. As the assays were performed 
3 days post NVCM isolation, in the absence of the mHFD environment, these alterations in 
cellular bioenergetics and respiration are indicative of intrinsic adaptations in response to the 
mHFD.  
 
126 
 
 
Figure 5. Bioenergetics and respiration analysis of NVCM from PN1 pups exposed to either 
the mNFD (open symbol) or mHFD (closed symbol). A. Basal and maximum ECAR/OCR. B. 
OCR during substrate flexibility assay. *p<0.05 vs mNFD, ǂǂp<0.01 vs mNFD for delta change 
in the ECAR and OCR post insulin and glucose injection.  
 
DISCUSSION 
 
While maternal obesity and excessive weight gain during gestation have been associated with 
increased risk of cardiovascular disease risk later in life, the underlying mechanisms remain 
unclear. In the current study we have provided insight into early metabolic adaptations that 
occur in the heart in response to a mHFD in Sprague Dawley rat offspring.  The major findings 
from the study were that mHFD induced early offspring cardiac hypertrophy, elevated cardiac 
AMPK-Class IIa HDAC-MEF2 signalling, induced transcriptional reprogramming of cardiac 
metabolism and impaired metabolic substrate flexibility.  
 
The HFD contained 43% digestible energy from lipids. Higher than the recommended fat 
intake of 25-30% during pregnancy [27]. In humans maternal diets with a fat intake of more 
than 35% total energy have previously been associated with increased body weight and 
adipocity at birth [28, 29] and with an adverse cardiometabolic profile (increased plasma 
glucose, insulin and lipids) during childhood and adulthood. Indeed in the current study both 
body weight and blood glucose were increased in the offspring exposed to the mHFD at PN10. 
While the glucose levels were still within acceptable ranges [30] the increases in body weight 
were accompanied by a 41% increase in fat mass. These observations are not only inline with 
the above studies assessing a maternal diet of >35% fat but also with what has been reported 
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in children exposed to maternal hyperlipidemia or born from obese mothers, where increases 
in BMI, waist circumference and body fat percentage have been detected. Increases in BMI, 
fat mass and plasma glucose are well established cardiovascular risk factors [13]. Indeed, we 
have previously shown BMI and plasma glucose associate with indices of LV hypertrophy 
including LV mass, left ventricular posterior wall diameter and relative wall thickness and for 
increases in plasma glucose to associate with diastolic decline in obese and/or T2D adult 
patients [31]. It is thought that these factors increase risks in part, due to alterations in normal 
cardiac energy metabolism.  
 
As mentioned, a healthy heart is able to adapt its substrate use, typically utilising ~40% glucose, 
lactate, ketones and amino acids and ~60% fatty acids [13]. With the majority of ATP (~95%) 
produced via oxidative metabolism (~70% from the oxidative metabolism of fatty acids) and 
the remaining ATP (~5%) produced from glycolysis and lactate [13]. However, in response to 
chronic hyperlipidemia, such as in obesity, the heart switches to rely predominately on fatty 
acids for oxidative metabolism and there is an uncoupling between glucose uptake and 
oxidation. These alterations have been reviewed in detail previously [13, 32, 33]. Breifly, these 
changes in cardiac energy metabolism are thought to be maladaptive to the heart as fatty acids 
are less efficient cardiac substrate than glucose, consuming more O2 per ATP yeild and 
requiring the use of ATP throughout various stages of metabolism. In addition, an uncoupling 
between glucose uptake and oxidation, results in lactate accumulation and a decreased ATP 
yield per glucose molecule, with just 2 ATP produced via glycolysis per glucose molecule 
compared to 31 ATP molecules per oxidised glucose molecule. Combined, these factors 
decrease cardiac effeciciency and the overall ATP production in the heart. Alarmingly, in 
response to the mHFD we detected alterations in cardiac energy metabolism that are reflective 
of these maladaptive alterations observed in the obese heart.  
 
The transcriptional fatty acid oxidation profile was increased as at PN1 and PN10. This was 
only accompanied by an increased protein expression of key enzymes involved in fatty acid 
oxidation at PN10. This suggests that while the transcriptional regulations of fatty acid 
oxidation genes were increased at PN1, it would be unlikely to be accompanied by an increase 
in fatty acid oxidation at this time. This is supported by experiments performed in the mHFD 
NVCM islotaed from PN1 pups for which basal and maximum OCR in the presence of 
palmitate were unchanged between mNFD and mHFD NVCM. Furthermore, this early change 
in fatty acid oxidation at the transcriptional level but not protein level has been reported during 
128 
 
the stage of compensated hypertrophy in rodent models of obesity and T2D, with changes in 
enzymatic activity often reported during the later stages of the disease progression when 
cardiac hypertrophy is accompanied by diastolic dysfunction (reference). Importantly, we also 
observed normal physiological changes in fatty acid oxidation in the hearts. The heart switches 
from a predominate reliance on glucose to fatty acid oxidation post birth [34, 35]. Evidence of 
this change was observed in the PN10 hearts with expression of genes and proteins involved in 
fatty acid oxidation increasing in both mNFD and mHFD hearts.  
 
Considering the changes in glucose metabolism, the mHFD NVCM showed an increased rate 
of glycolysis (49% basal and 22% peak). This increase was supported by an accompanied 
increased expression of GLUT1 and GLUT4 in the mHFD PN1 hearts. Please note, oligomyin 
inhibits ATPase, in doing so restricts ATP production via oxidative phosphorylation pushing 
the cell to produce ATP via glycolysis. While this will increase the ECAR, it does not 
necessarily reflect the maximal glycolytic rate particularly in NVCM which have a high 
glycolytic capacity, where it is possible that the glycolytic capacity of the NVCM exceeds the 
energy requirements of the cell upon the addition of oligomycin. Therefore the maximum 
ECAR obtained post oligomycin treatment is referred to as ‘peak ECAR with ATP synthase 
inhibition’. Interestingly, the mHFD NVCM exhibited an impaired ability to switch between 
the oxidation of palmitate to glucose. This is reflective of the impaired substrate flexibility 
observed in obesity and T2D in which the heart has an impaired ability to switch from fatty 
acid oxidation to glucose oxidation in the presence of insulin [33]. This is likely to be an 
intrinsic adaptation to the mHFD, as the measurements were obtained 3 days post isolation 
from PN1 hearts. While it is not possible to isolate NVCM from PN10 hearts, the normal 
GLUT1 and GLUT4 expression levels observed in mHFD PN10 hearts would suggest that 
glycolysis was no longer increased at PN10. Combined these data suggest that mHFD PN1 
hearts exhibited an increased glycolytic rate and impaired substrare flexibility and PN10 hearts 
an increased fatty acid oxidation.  
 
Considering the role of the AMPK- class IIa HDAC-MEF2 in controlling cardiac metabolism. 
AMPK is known to be activated during times of cardiac metabolic stress, resulting in increased 
energy production by promoting glycolysis through the activatation of phosphofructokinase 2 
and fatty acid oxidation through the phosphorylation of ACC, reducing cardiac malonyl CoA 
and subsequent CPT1 inhibtion. [25]. And as mentioned, we have previously implicated the 
Class IIa HDAC-MEF2 pathway in regulating skeletal muscle fatty acid oxidation. In which 
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we found disruption of the class IIa HDAC corepressor complex through genetic or 
pharmacological strategies increases fatty acid oxidation [16]. The results presented in the 
current paper are consistent with these downstream signalling events of AMPK 
phosphorylation and of the signalling and transcriptional end points of the class IIa HDAC-
MEF2 axis in regulating fatty acid oxidation.  
 
As hypothesised, these alterations in cardiac energy metabolism were accompanied by cardiac 
hypertrophy. With increases in heart weight observed at both PN1 and PN10 in mHFD pups. 
Of note, these increases in heart weight were associated with both body weight and fat mass 
(r2=0.434, p<0.001 and r2=0.400, p<0.05, respectively, data not shown) consistent with the 
previous literature. Furthermore, the increases in heart weight were accompanied by an 
increased expression of the foetal gene program at both PN1 and PN10 (MEF2 regulated 
hypertrophic markers ANP and BNP) indicating the increases in heart weight were a 
pathological response and not a physiological response to the mHFD (as the foetal gene 
program is activated in response to signalling associated with pathological hypertrophy and not 
that of physiological hypertrophy). Interestingly, the expression of the foetal gene program in 
mHFD vs mNFD pups was markedly higher at PN1 than at PN10. This expression pattern was 
reflective of MEF2 protein levels, and suggests that the mHFD had a greater impact on MEF2 
activity during gestation than lactation. While the HDAC-MEF2 axis is a well established 
prohypertrophic pathway, the contribution of AMPK in a hypertrophic response less clear. 
With studies reporting AMPK to both inhibit and promote the development of cardiac 
hypertrophy [36-39]. In the current study, we detected 1.8-3.3 fold increases in AMPK 
phosphorylation in the mHFD hypertophic hearts, this association does not identify a causative 
relationship however does implicate AMPK acitivity in the hypertrophic heart with altered 
cardiac metabolism.  
 
Considering the limitations of the current study. Analysis was restricted to male offspring only. 
Previous literature have reported sex dependent effects in response to mHFD [40, 41]. 
Furthermore, a review summarising the past literature reported male offspring to exhibit a more 
pronounced cardiac phenotype in response to a mHFD [42]. Therefore, limiting our analysis to 
males only may not have only restricted our analysis but possibly added bias in favour of our 
hypothesis.  
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In summary, the current study detected increased cardiac AMPK-class IIa HDAC-MEF2 
signalling, early cardiac hypertrophy, transcriptional reprogramming of cardiac metabolism 
and impaired NVCM substrate flexibility in Sprague Dawley rat offspring exposed to a mHFD. 
These data suggest that the increased cardiovascular risk associated with mHFD may in part 
be mediated by adverse cardiac metabolic reprogramming that occurs early in development. 
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SUPPLEMENTARY TABLES  
 
Supplementary Table 1A. Calculated Nutritional Parameters 
Calculated Nutritional Parameters 
 Normal fat diet High fat diet 
Protein  
Total Fat  
Crude Fibre  
AD Fibre  
Digestible Energy  
Total calculated digestible energy from lipids Total 
calculated digestible energy from protein  
22.6% 
5.3% 
5.4% 
15.4 MJ / kg % 
 
12% 
25.8% 
22.6% 
23.5% 
5.4% 
19 MJ / kg % 
 
43% 
21% 
 
 
 
Supplementary Table 1B. Calculated Fatty Acid Composition 
Calculated Fatty Acid Composition 
 Normal fat diet High fat diet 
Saturated Fats C12:0 or less  
Myristic Acid 14:0 0.30% 
Palmitic Acid 16:0 5.80% 
Stearic Acid 18:0 3.70% 
Other Saturated Fats 0.10% 
Palmitoleic Acid 16:1 0.40% 
Oleic Acid 18:1 7.70% 
Gadoleic Acid 20:1 0.20% 
Linoleic Acid 18:2 n6 4.46% 
a Linolenic Acid 18:3 n3 0.49% 
Total n3 0.52% 
Total n6 4.50% 
Total Mono Unsaturated Fats 8.24% 
Total Poly Unsaturated Fats 5.11% 
Total Saturated Fats 10.03% 
Trace 
0.04% 
0.9% 
0.5% 
0.03% 
0.05% 
1.5% 
0.02% 
1.8% 
0.2% 
0.23% 
1.82% 
1.53% 
2.07% 
1.5% 
Trace 
0.3% 
5.8% 
3.7% 
0.1% 
0.4% 
7.7% 
0.2% 
4.46% 
0.49% 
0.54% 
4.5% 
8.24% 
5.11% 
10.03% 
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SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 1. Summary of diet types and durations. 
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Supplementary Figure 2. Data from damns in the NFD and HFD groups. A. Body weight 
change throughout study. B. Average MJ consumption from start of diet to end of gestiation. 
C. Starting blood glucose. D. Blood glucose at the end of the study. ***p<0.001 vs damns on 
NFD  
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CHAPTER 3 SUMMARY 
 
In summary, our data support our hypothesis and suggest that a maternal high fat diet induces 
similar maladaptive alterations in cardiac energy metabolism in neonates as those observed in 
response to adult obesity and type 2 diabetes. Furthermore, we have implicated a well-
established pro-hypertrophic axis, the Class IIa HDAC:MEF2 axis, in regulating these changes.  
 
Limitations of the study  
1. We did not show a causative relationship between the Class IIa HDAC-MEF2 axis and 
the presence of LVH or alterations in cardiac energy metabolism. We simply showed 
an association between phosphorylation and protein levels of the Class IIa HDAC-
MEF2 axis with the observed alterations.  
2. While we have NVCM data that allows for indications of intrinsic maladaptions of the 
mHFD, we did not have an experimental group that was switched from a HFD after 
gestation to a foster mother consuming a normal fat diet. However, the experiemtnal 
design used for which the mHFD continued throughout lactation is more representative 
of what is obsereved in humans.  
3. We do not have any echocardiography data. We therefore cannot relate the alterations 
observed in the mHFD pups to cardiac function. 
 
Strengths of the study 
1. The HFD consisted of 43.7% fat, a value that is represtative of HFD composition 
observed in human pregnancy.  
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2. Cardiac energy metabolism and hypertrophy were assessed at both PN1 and PN10, 
allowing us to tease out the influences of the mHFD during gestation and continued 
presence during lactation.  
3. NVCM were isolated from experiemtnal animals of each groups, allowing us to assess 
cardiac bioenergetics from physiologically relevant cells.  
 
There is very little data available investigating early changes in cardiac energy metabolism in 
response to maternal high fat diets. This current work fills a knowledge gap and assists in our 
understanding of the mechanisms in which mHFD may increase cardiovascular risk. 
Furthremore, this data supports that maladaptive alterations in cardiac energy metabolism 
occur early in the disease progression. Further justifying the need for a the identification of 
metabolic modulators in the treatment of the obese/T2D heart. While we observed no change 
in phosphorylation of PKD within the activation loop or autophosphorylation site. We  note 
the difficulties in detecting PKD activity ex vivo as discussed in chapter 1. Chapters 4 and 5 
investigate the potential therapeutic target to do this, PKD.  
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CHAPTER 4 
 
 
 
Cardiac Specific Dominant Negative Protein Kinase D 
Expression Protects from High Fat Diet-Induced 
Cardiomyopathy  
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INTRODUCTION CHAPTER 4 
 
In chapter 1 the potential therapeutic target to treat the obese and T2D heart, PKD was 
discussed. As mentioned, we hypothesised that obesity amd T2D may provide a favourable 
environment for PKD activation due to increased DAG-PKC signalling. While we did not 
observe any associated increase in PKD activation with the mHFD effects in Chapter 3. We 
did observe an increased expression and activation of PKD at PN10 compared to that in PN1 
in both diets. Suggesting PKD expression and activity may differ during different 
developmental stages.  
 
In this chapter the role of PKD in regulating cardiac energy metabolism and in the development 
of obesity/T2D cardiomyopathy is further explored. To do this, NVCM were used for in vitro 
experiments in which we investigated PKD activation in conditions realted to obesity and T2D 
and whether PKD regulates cardiomyocyte energy metabolism. In addition, a diet-induced 
obesity model was used in vivo to assess whether cardiac specific DN PKD expression, in a 
novel mouse model, could protect from obesity/T2D induced cardiomyopathy.   
 
Significance: PKD has been implicated in pressure overload cardiomyopathy but the role of 
PKD in obesity/T2D induced cardiomyopathy is relatively unclear. With increasing research 
into the potential of PKD to act as a therapeutic target in pressure overload cardiomyopathy 
and the continued increasing incidence of obesity and T2D, particularly prior to the 
development of hypertension, understanding the role of PKD in these metabolic settings is 
essential.  
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Aims 
7. To determined which factors associated with obesity and T2D activate PKD in vitro. 
8. To investigate the role of PKD in regulating cardiac energy metabolism. 
9. To determine whether a cardiac specific expression of DN PKD can protect from 
obesity/T2D induced cardiomyopathy.   
 
Paper status; to be submitted for peer review. 
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ABSTRACT 
 
Background: An increasing body of evidence supports PKD inhibition as a therapeutic option 
for the treatment of cardiomyopathy. However the majority of the previous research has 
investigated PKD in a setting of pressure overload-induced cardiomyopathy.  There is little 
known about the role of PKD specifically in obesity/T2D cardiomyopathy. In the current paper 
we investigated the influence of Protein kinase D (PKD) in the develpoment of obesity/T2D 
cardiomyopathy.  
 
Methods: Neonatal ventricular cardiomyocytes were used to assess PKD activation in 
conditions related to obesity and T2D and cellular bioenergetics and respiration analysis were 
used in NVCM expressing a constitutively active (CA) PKD construct (expressed via lenti-
virus infection), to determine whether PKD regulates cardiac energy metabolism. Mice 
expressing an inducible, cardiac specific dominant negative (DN) PKD transgene were 
developed. These mice were challenged with a high fat diet (HFD) for 18 weeks, two weeks 
after DN PKD induction at 12 weeks of age,  to determine whether DN PKD could protect 
from obesity/T2D cardiomyopathy.  
 
Results: Angiotensin II, norepinephrine and glucose oxidase activated PKD in vitro. NVCM 
expressing CA PKD exhibited reduced rates of glycolysis and glucose oxidation, and  increased 
fatty acid oxidation vs contriol (GFP) NVCM. Mice fed HFD exhibited an obesity/pre-diabetes 
phenotype, for which cardiac specific DN PKD mice exhibited protection from developing LV 
hypertrophy and systolic dysfunction.  
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Conclusions: Insults associated with obesity and T2D activated PKD in vitro. PKD activation 
induces alterations in cardiac energy metabolism similar to those observed in obesity/T2D, and 
PKD activity is required for the development of obesity-induced cardiomyopathy.  
 
INTRODUCTION 
 
Obesity and T2D cardiomyopathy is characterised by the development of hypertension and 
diastolic dysfunction, independent of hypertension and other cardiac disease. If left untreated, 
this condition may progress to heart failure (likely heart failure with preserved ejection 
fraction). An increasing body of evidence supports PKD inhibition as a therapeutic option for 
the treatment of cardiomyopathy. However the majority of the previous research has 
investigated PKD in a setting of pressure overload-induced cardiomyopathy.  There is little 
known about the role of PKD specifically in obesity/T2D cardiomyopathy. 
 
Considering what is known about PKD in pressure overload cardiomyopathies first, PKD 
protein expresson and activity, as indicated via phosphorylation of the activation loop 
(S744/748) and the autophosphorylation site (S916), have been reported to be increased in 
response to norepinephrine infusion in SpragueDawley rats [1], aortic insufficiency and 
stenosis induced heart failure in New Zealand White rabbits [2], infusion of angiotensin and 
phenylephrine and transthoracic aortic constriction (TAC) in mice [3] and in spontaneously 
hypertensive heart failure (SHHF) rats (which was further exerbated in response to TAC) [1]. 
Furthremore, cardiac specific over expression of PKD1 in mice has been reported to induce 
dilated cardiomyopathy, systolic dysfunction and reactivaiton of the foetal gene program [1]. 
Mice with cardiac-specific PKD1 knockout exhibit protection from myocardial infarction or 
isoproterenol and angiotensin induced cardiac hypertrophy, dysfunction and fibrosis [4]. This 
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protection was reported, in part, to be due to a reduction in PKD-induced Class IIa HDAC-
MEF2 signalling and activation of the feotal gene program. Combined, these data suggest that 
PKD is associated with the development of cardiomyopathy induced via a broad range of 
pressure overload stress stimuli.  
 
In humans, PKD protein expression and activity, as also indicated via phosphorylation status, 
have been reported to be increased in failing myocardium vs non-failing myocardium [2]. 
These increases in PKD activity were accompanied by increased HDAC5 nuclear export, 
suggesting PKD-Class IIa HDAC signalling is increased in human heart failure. It is important 
to note however, as the prevalence of stresses such as hypertension, obesity and T2D within 
these human patient samples are unknown, it is unclear whether pressure overload and/or 
metabolic stress stimuli were associated with these increases in PKD activity in humans. 
Considering cardiac PKD activation in animal models of obesity and T2D, the focus of the 
current paper, PKD activity has been reported to be increased in rats exhibiting T2D 
cardiomyopathy induced via high fat feeding and streptozotocin injection [5]. Outside of this 
in vivo study, there is little known about the activity of PKD in obesity/T2D induced 
cardiomyopathy. 
 
In the current paper, we aimed to increase our understanding of the role of PKD in obesity and 
T2D cardiomyopathy, by investing whether insults associated with obesity and T2D can 
activate PKD in vitro and by determining whether cardiac-specific dominant negative (DN) 
PKD expression can protect from high fat diet (HFD) induced cardiomyopathy in mice.  
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METHODS 
 
The study was carried out in accordance with guidelines of the National Health and Medical 
Research Council (NHMRC) of Australia and was approved by the Deakin University Animal 
Ethics Committee. 
 
Neonatal ventricular cardiomyocyte cell isolation  
NVCM were used in the following in vitro experiments to assess PKD activation in conditions 
related to obesity/T2D and in cardiac energy metabolism. Briefly, PN1 hearts from C57BL6 
mice were collected and immediately transferred to Hanks balanced and salt solution (HBSS, 
Gibco, Life Tech, 14175-095) under sterile conditions. The atria were removed and the 
ventricular tissue were incubated overnight in HBSS/trypsin (Gibco, Invitrogen, 27250-018) 
solution at 4°C. The following day, ventricular tissue was transferred to HBSS/collagenase 
type 2 (Worthington Biochemical Corporation, LS004176) and gently agitated at 37°C with 
the media containing the dissociated cells collected every 10 minutes, four times, remaining at 
37°C. The dissociated cells were then spun down and the pellets were resuspended in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Life Tech, 11885-084), foetal bovine 
serum (FBS, HyClone, In Vitro, 15-010.02) and ampicillin (Sigma, A9393).  The cell 
suspensions contained a mixture of cardiomyocytes and fibroblasts. To separate the cell types, 
the cell suspensions were plated onto 10 cm petri dishes and incubated at 37°C for 45 minutes, 
twice. This is sufficient time for fibroblasts to adhere to the plate, whereas cardiomyocytes 
require >24 hours to adhere. The remaining cell suspensions containing predominantly 
cardiomyocytes were plated onto 12 well plates at a density of 1x106 cells/well for cell 
treatment and protein collection analysis and onto a 24-well XF24 cell culture microplate at a 
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cell density of 1.5x104 cells/well for cellular bioenergetics and respiration analysis. In both 
instances, cells were diluted in DMEM, FBS, ampicillin and 5-bromo-2-deoxyuridin to prevent 
proliferation of any remaining fibroblasts (Thermo Fisher and Scientific, B23151). The NVCM 
were left for 48 hours to recover. Cells were used in experiments if  >80% of cells  exhibited 
visible contraction. 
 
NVCM treatments 
To assess which factors associated with obesity and T2D might activate PKD, NVCM were 
treated with the following insults; glucose, insulin, glucose oxidase, palmitate, angiotensin II, 
norepinephrine, endothelin I and TNF-a. Cells were collected at the following time points after 
insult exposure; 0 mins, 15 mins, 30 mins, 60 mins, six hours, 24 hours and 48 hours, with 
protein collected for western blot analysis. Note that the maximum time possible for chronic 
treatments was 48 hours, due to the lifespan of the NVCM. For those treatments where there 
appeared to be alterations in PKD phosphorylation, additional experiments were performed to 
obtain replicates (n=4-6). 
 
Lentivirus production and infection  
To overexpress CA PKD in NVCM, cells were infected with a lentivirus (LTV) expressing a 
CA PKD construct, which contained the catalytic domain of PKD1 (amino acids 550-918) 
without its regulatory domain, as we have previously described (McGee et al., FASEB J, 2014). 
CA PKD was subcloned into the pLV.ExSi.P/Neo-EF1 plasmid and lentiviral particles were 
packaged in 293T cells and purified by Cyagen Bioscience. As a control, NVCM were also 
infected with a LTV containing a GFP construct. 48 hours post isolation, NVCM media was 
refreshed and wells were “spiked” with thawed LTV solutuion at 40 plaque forming units 
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(PFU) for PKD (CA) and 20 PFU for GFP. Note that initial experiments were perfromed to 
determine the lowest number of LTV particles required to obtain significant expression of CA 
PKD (data not shown). 24 hours post infection, NVCM were washed and media refreshed. 
After an additional 24 hours NVCM were collected for protein analysis or were used for 
cellular bioenergetics experiments.   
 
Bioenergetics and respiration analysis 
Cellular bioenergetics and respiration analysis were performed using the Seahorse XF24 Flux 
Analyzer (Seahorse Bioscience). Two different assays were performed; a glucose oxidation 
assay coupled to a mitochondrial function test and a fatty acid dependency assay. For the 
glucose oxidation assay, cells were washed and incubated in a non-CO2 incubator for 1 hour in 
unbuffered DMEM containing 25 mM of glucose (pH 7.4). Three basal extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR) measurements were performed. 
These measurements were repeated following injection of each of the following compounds; 
oligomycin (ATP synthase inhibitor), FCCP (chemical uncoupler) and rotenone and antimycin 
(complex I and III inhibitors). All compounds were used at a final concentration of 1M. For  
fatty acid dependency, cells were washed and incubated in a non-CO2 incubator for 1 hour in 
DMEM containing glutamax (1mM), sodium pyruvate (1mM), glucose (5mM), palmitate 
(200uM) and carnitine (0.5mM). For the fatty acid dependency assay, three basal extracellular 
acidification rate (ECAR) and oxygen consumption rate (OCR) measurements were performed. 
These measurements were repeated five more times following the injection of 40 µM of 
Etomoxir (CPT1 inhibitor, #E1905), after which a combination of BPTES (Glutaminase 
inhibitor II – glutamine inhibitor, #SML0601) at 3 µM and UK5099 (mitochondrial pyruvate 
transporter – pyruvate inhibitor, #P20160) at 2 µM were injected into the wells and the 
measurements were repeated. For the fatty acid capacity assay the same protocol was followed, 
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however the combination of BPTES and UK5099 were injected first, followed by the Etomoxir 
injection. From this assay, three measurements were obtained, 1. Fuel Dependency, which is 
the reliance on palmitate to maintain baseline respiration. 2. Fuel Capacity, the ability of the 
mitochondria to oxidase fatty acids when glucose and glutamine oxidation is inhibited and 3. 
Fuel Flexibility, which is the difference between fuel capacity and dependency (the ability of 
the NVCM to increase fatty acid oxidation above baseline level). Calculations of respiratory 
parameters of mitochondrial function were performed as previously described [6] and included 
subtraction of non-mitochondrial respiration from all mitochondrial respiration parameters. 
Following completion of the assays, ECAR and OCR were normalized to total protein as 
assessed via standard BCA assay.  
 
Generation of cardiac-specific DN PKD mice. 
To determine whether genetic modification reducing PKD activity can protect from HFD 
induced cardiomyopathy, a novel mouse line was generated. Most research on the role of PKD 
in the heart has focussed on PKD1 and has utilised a floxed PKD1 mouse line generated in Eric 
Olson’s laboratory. A caveat to this model is that compensatory redundancy between PKD 
isoforms has been observed in some experimental settings (Guo et al., JBC, 2011). 
Furthermore, the effect of metabolic insults on the activation of the three PKD isoforms is 
unknown. Therefore, in collaboration with GenOway, we made a novel mouse line that will 
express DN PKD in a tissue-specific and inducible manner. To do this, we utilised a well 
characterised single point mutation (K612Win humans, K618W in mice) in the ATP binding 
domain of PKD1 that inhibits ATP binding and renders the kinase inactive ([7]). This DN PKD 
also acts in a DN manner against PKD2 and 3 ([7, 8]). Mouse K618W PKD1 was subcloned 
into a Rosa26 locus targeting vector that utilises the endogenous Rosa26 promoter coupled to 
a synthetic CAG promoter to drive high levels of transgene expression. Furthermore, a STOP 
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codon flanked by loxP sites was inserted between the CAG promoter and the DN PKD cDNA, 
so that the DN PKD transgene will only express when the loxP sites are excised with Cre 
recombinase. Targeting vector construction was performed by GenOway, followed by 
homologous recombination in C57BL6 ES cells and ES blastocyst injection and generation of 
chimeric animals. The chimeras were crossed with WT female C57BL6 mice. PCR and 
southern blot analysis were used to confirm successful homologous recombination in the 
embryonic stem cells and for the characterisation of the F1 progeny. 
 
Generation of experimental animals.  
To generate mice that express cardiac-specific DN PKD, we utilised a cardiac-specific Cre 
recombinase mouse line whereby the cardiac specific alpha-MHC (α-MHC) promoter drives 
the expression of Cre recombinase that is flanked by modified estrogen receptor (MerCreMer; 
Jackson’s Laboratory). Using this system, Cre recombinase is constitutively expressed, but is 
only transported to the nucleus (where it can influence recombination) when the modified 
estrogen receptor elements bind with tamoxifen. Therefore, crossing DN PKD knock in mice 
with α-MHC mice will allow for cardiac-specific and inducible expression of DN PKD.  8 
week old homozygous α-MHC (+/+) and heterozygous DN PKD (-/+) breeding partners as 
described above were and shipped to the Deakin University Animal House Facility, Geelong, 
Australia. The animals were housed under constant temperature and humidity control with 12 
hour light-dark cycles. To generate aged matched experimental animals (male DN PKD -/+. α 
-MHC -/+ and DN PKD -/-. α -MHC -/+ mice) the two mouse lines were first expanded to 
create additional breeding partners. One male was provided with one or two female breeding 
partners and females were separated upon confirmation of pregnancy. Subsequent pups were 
weaned and genotyped at 21 days of age (genotyping described below). Expansion of the DN 
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PKD -/+ line yielded offspring of three genotypes; 50% DN PKD -/+ (used for future breeding), 
25% DN PKD +/+ and 25% DN PKD (humanely killed via CO2). Expansion of the α-MHC 
+/+ mice yielded offspring all of the same genotype; 100% α-MHC +/+ (all used for future 
breeding). Age matched experimental animals were generated by mating DN PKD -/+ mice 
with α-MHC +/+ mice. This yielded offspring of two genotypes; 50% DN PKD -/+. α-MHC -
/+ (males used for experiments, females humanely killed) and 50% DN PKD -/-. α-MHC -/+ 
(males used for experiments, females humanely killed via CO2) (Supplementary Figure 1).  
 
Genotyping 
For genotyping, DNA was extracted and purified from ear clippings using the Qiagen DNeasy 
Blood & Tissue Kit (#69504).  A 3 primer PCR protocol was then used to amplify the WT and 
recombined allele within the same reaction (Provided by GenOway, Supplementary Table 1). 
This 3 primer PCR yielded bands of two sizes, the WT allele detectable at 727 base pairs (bp) 
and the recombined allele detectable at 270 bp (Supplementary Figure 2A). After confirming 
the 3 primer PCR only amplified two products of the expected sizes, the remaining genotyping 
was then outsourced to the Garvan Institute Molecular Genetics Laboratory, Sydney, Australia. 
Genotyping was performed using the same 3 primer PCR reaction but analysed via High 
Resolution Meltcurve analysis for which 3 melt curves were obtained, for control, DN PKD (-
/+) and DN PKD (+/+) (Supplementary Figure 2B).  
 
Animal experiments  
The animal studies consisted of 4 groups, male control (DN PKD -/-. α-MHC -/+) and DN PKD 
(DN PKD -/+. α-MHC -/+) mice fed either a chow or HFD, (43% of digestible calories as fat; 
Specialty Feeds (South Australia), cat # SF004) (n=12-22/group).  At 12 weeks of age all mice 
were administered a single dose of tamoxifen (40mg/kg). Tamoxifen was first dissolved in 
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100% ethanol to 100mg/mL and sonicated in a water bath for 10 min before being dilute in 
pre-warmed soybean oil to 10mg/mL. Mice were administered a volume in L corresponding 
to 4 x body weight (in g) via subcutaneous injection. This tamoxifen administration procedure 
was used as it has been shown to effective induce Cre recombination without deleterious effects 
on heart structure and function (Lexow et al., Dis Mod. & Mech., 2013). Furthermore, as all 
animal received tamoxifen, we were able to effectively control for this potential insult. Two 
weeks post tamoxifen injection, animals were placed into their diet groups and remained on 
the diets for 18 weeks. We have previously found that 13 weeks of HFD can induce 
impairments in cardiac function in C57BL6 mice (Gaur et al., Diab. Obes. Metab., 2017). Body 
weight was monitored fortnightly, body composition via Echo-MRITM (EchoMRI Corporation 
Pty Ltd, Singapore) was assessed at 0, 2, 4, 8 and 12 weeks into the diet period. An insulin 
tolerance and glucose tolerance tests were performed at 14 and 16 weeks into the diet period. 
For the insulin tolerance test, mice were administered a bolus of insulin (0.75U/kg of lean 
mass) via i.p. injection after a 5 hr fast. Blood glucose was measured via a handheld glucometer 
(Roche Accucheck) at 0, 20, 40, 60, 90 and 120 min after insulin administration from a drop 
of blood obtained from the tail. For the glucose tolerance test, mice were administered a bolus 
of glucose (2mg/g of lean mass) via oral gavage after a 5 hr fast. Blood glucose was measured 
via a handheld glucometer (Roche Accucheck) at 0, 15, 30, 45, 60 and 90 min after glucose 
administration from a drop of blood obtained from the tail. A further 30 L of blood was 
obtained at 0, 15, 30 and 60 min after glucose administration from the tail using a negative 
displacement pipette for the determination of plasma insulin. This blood was collected in 
heparin tubes, before being spun down, the plasma collected and stored at -20oC for later 
analysis. Echocardiography was performed at 17 weeks post diet (protocol below). One week 
later, n=8 mice per group were administered 50mg of [U13C]-glucose (Cambridge Isotopes) 
via oral gavage after a 5 hr fast and were humanely killed via cervical dislocation 60 min later, 
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at which time hearts were immediately snap frozen in liquid nitrogen for later analysis of 
glucose flux through glycolysis and the TCA cycle using gas chromatography-mass 
spectrometery (Kowlaski et al., BBRC, 2015). Another n=4 mice from each of the control and 
DN PKD chow fed groups were administered 2mg/kg of angiotensin II (Sigma) via i.p. 
injection after a 5 hr fast and were humanely killed via cervical dislocation 30 min later, at 
which time hearts were immediately collected snap frozen in liquid nitrogen for later analysis 
of novel PKD substrates in the context of angiotensin II stimulation via phosphoproteomics 
analysis (Hoffman et al., Cell Metab., 2015). Similarly, n=4 per mice per group from the control 
and DN PKD HFD fed groups were humanely killed via cervical dislocation after a 5 hr fast, 
at which time hearts were immediately collected snap frozen in liquid nitrogen for later analysis 
of novel PKD substrates in the context of high fat feeding via phosphoproteomics analysis. The 
remaining mice were humanely killed humanely killed via cervical dislocation after a 5 hr fast, 
at which time hearts were dissected, the aorta and atria were removed, the hearts were blotted 
gently to remove excess blood and weighed. Heart were either snap frozen in liquid nitrogen 
or a midsection of the ventricular tissue (n=6/ group) was taken for histology (see protocol 
below) and the remaining ventricular tissue was then snap frozen in liquid nitrogen and stored 
at -80C for later analysis. 
 
Echocardiography 
Echocardiography was performed at 17 weeks post diet, using a Phillips HD15 diagnostic 
ultrasound system with a 15MHz linear-array transducer. Mice were anesthetised via 1.5% 
isoflurane inhalation and M-Mode measurements were used to assess LV structure (n=10-
12/group). M-mode measurements included; intraventricular septum diameter, during diastole 
(IVSd) and systole (IVSs), left ventricular internal diameter, during diastole (LVIDd) and 
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systole (LVIDs) and left ventricular posterior wall thicknesses, during diastole (LVPWd) and 
systole (LVPWs). Fractional shortening (FS%), ejection fraction (EF%) and estimated LV 
mass were derived from the M-mode measurements. With estimated LV mass determined via 
Troy’s equation [16] where estimated LV mass = 1.05 ([LVIDd + LVPWd + IVSd]3- 
[LVIDd]3).  
 
Histology 
LV mid-sections (n=6/group) were fixed in 10% formalin. They were paraffin embedded and 
sectioned at a thickness of 4μm. Staining consisted of hematoxylin and eosin (H&E) staining 
and was performed at Monash University histology platform, Melbourne, Australia. Stained 
tissue was imaged by light microscopy at 400x magnification and analysed qualitatively with 
Zeiss AxioVision software. 
 
Western blots 
Frozen ventricular tissue (~20mg) that was dedicated for phosphoproteomics analysis 
(n=4/group) was homogenised in ice-cold lysis buffer containing; 50mM Tris pH7.5, 1mM 
EGTA, 1mM EDTA, 1% triton X-100, 10% glycerol, 50mM NaF, 1mM Na3VO4, 5mM 
Na4P2O7, 1mM DTT, protease inhibitor cocktail) and protein content was determined via 
standard BCA method. 30µg of protein were separated by SDS-PAGE and transferred onto 
PVDF membrane using standard protocols. Membranes were blocked in 5% BSA and 
incubated in primary antibody solutions (1:1000) over night. The primary antibodies used 
included; total PKD, pS916 PKD, GFP, total cTn1, pS23/24 cTnI, total HDAC5 (Cell 
Signalling Technology, Danvers, USA), pS259 HDAC, pS133 CREB, total CREB, PKD 
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substrate [17] and α-tubulin (Sigma-Aldrich, St. Louis, USA). ChemiDoc™ XRS+ with Image 
Lab™ software was used to visualise the membranes. 
STATISTICS 
 
All data represented as mean ± SEM unless otherwise stated. All data were analysed via one 
way ANOVA or students t-test where appropriate using SPSS version 23. p<0.05 was 
considered significant. 
 
RESULTS 
 
PKD is activated by insults associated with obesity and type 2 diabetes in NVCM 
Palmitate, glucose oxidase and endothelin-1 increased PKD phosphorylation at S916 at 60 
minutes, 6 hours and 30 minutes post treatment respectively (n=3-6) (Figure 1). All other 
treatments (norepinephrine, insulin, angiotensin II and TNF-α) did show significant changes in 
PKD activation compared to their associated vehicle treatments (Supplementary figure 3).  
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Figure. 1. Metabolic activators of PKD in NVCM. Palmitate treatment for 60 minutes, 
glucose oxidase (GO) treatment for 6 hours and endothelin I (ET-1) treatment for 30 minutes. 
n=3-6, *p<0.05, ***p<0.001 vs vehicle. 
 
NVCM infected with LVT-PKD (CA) exhibited increased PKD expression and activity.  
LTV-PKD (CA) infected NVCM exhibited a >3 fold increased expression of PKD than the 
NVCM infected with the LTV-GFP (p<0.001) (Figure 2A). GFP expression levels were 
undetectable in NVCM infected with the LTV-PKD (CA) (p<0.001) (Figure 2B). To determine 
whether the expression of CA PKD increased PKD signalling, known PKD cardiac targets 
were assessed (Figures 2C-D). HDAC5 phosphorylation at S259/total HDAC5 increased 
(p<0.05) (Figure 2C). cTnI phosphorylation at s22/23/total cTnI levels were unchanged, as was 
CREB phosphorylation at S133/total CREB. Combined, these data suggest that our LTV 
successfully increased PKD expression and activity. We next determined the influence of this 
increased PKD activity on cardiac energy metabolism.  
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Figure 2. Western blot assessment of PKD activity and signalling in NVCM injected 
with LVT-PKD (CA). A. GFP, B. PKD, C. HDAC5, D. Representative blots. n=4, * p<0.05, 
*** p<0.001 vs GFP infected NVCM.  
 
Constitutively active PKD expression increased fatty acid dependency and decreased 
glucose utilisation and substrate flexibility in NVCM 
Considering the glucose oxidation assay first, in which the exogenous substrate provided was 
restricted to glucose, glucose oxidation and glycolysis rates were decreased in NVCM infected 
with LTV-PKD (CA), indicated by reductions in both basal ECAR and OCR respectively 
(Figure 3A-B). Respiration rate due to ATP turnover was also decreased, while maximum OCR 
remained unchanged. In the fatty acid dependency assay, NVCM infected with the LTV-PKD 
(CA) exhibited an increased dependence on palmitate for mitochondrial oxidation, decreased 
capacity to enhance fatty acid oxidation when glucose oxidation was inhibited and a decreased 
substrate flexibility when switching from palmitate to glucose oxidation upon CPT1 inhibition 
(Figure 3C).  
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Figure 3. Bioenergetics and respiration analysis in NVCM infected with LTV-PKD, A. 
Glucose oxidation assay, basal extracellular acidification rate (ECAR) B. Glucose oxidation 
assay, oxygen consumption rate (OCR) C. Fatty acid dependency and substrate flexibility 
assay. n=1 (made up of NVCM isolated from two litters and 10 replicates), *** p<0.001 vs 
LTV-GFP NVCM. 
 
HFD increased body weight, fat mass and plasma insulin levels 
HFD fed mice from both control and DN PKD groups exhibited an increased body weight and 
fat mass compared to chow fed control and DN PKD mice (Figure 4A-B). Lean mass was 
increased in both HFD groups compared to chow (Figure 4C), note that lean mass was already 
increased in DN PKD HFD group vs chow groups at time of tamoxifen injection. Plasma 
glucose and glucose tolerance remained unchanged in response to the HFD (Figure 4D). 
Fasting insulin levels increased in both control and DN PKD HFD groups (Figure 4E). 
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However insulin tolerance remained unchanged (Figure 4F). These data suggest the HFD fed 
mice from both groups exhibited an obesity phenotype with hyperinsulineamia.  
 
 
Figure 4. Obesity/T2D characterisation. A. Body weight (grams), B. Lean mass (grams), C. 
fat mass (grams), D. Plasma glucose during glucose tolerance test, E. Plasma insulin during 
insulin tolerance test and F. Plasma glucose during insulin tolerance test. n=12-15, *p<0.05, 
**p<0.01, *** p<0.001 vs control chow, × p<0.05, ××× p<0.001 vs DN PKD chow.  
 
DN PKD expression increased post tamoxifen injection 
Two weeks post tamoxifen injection, expression of cardiac PKD increased more than 10 fold 
(Supplementary Figure 4). This increase remained 16 weeks post injection (Figure 5G). As 
expected, expression of the DN PKD protein was accompanied by reduced phosphorylation of 
PKD within the activation loop S744/748 (Figure 5A, 5G), but interestingly, also with an 
increased phoshorylation of PKD at it’s autophosphorylation site, S916 (Figure 5B, 5G).  There 
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were no differences in the phosphorylation of the known cardiac PKD targets, HDAC5, CREB 
or cTnI (Figure 5D-G). However there was a markedly reduced expression of PKD consensus 
motifs in DN PKD hearts (figure 5C, 5G).  
 
Figure. 5. Protein expression in control and DN PKD animals fed the HFD. A. S744/748 
PKD/TOTAL, B. S916 PKD/TOTAL, C. PKD consensus motif, D. S254 HDAC5/TOTAL, E. 
S133 CREB/TOTAL, F. S22/23 cTnI/TOTAL, G-H. Representative western blot images. 
n=4/group. *p<0.05, **p<0.01, ***p<0.001 vs control. 
 
Expression of cardiac DN PKD improved systolic function in HFD mice 
Heart weights remained unchanged in response to the HFD in both control and DN PKD groups 
and cardiomyocyte cell size did not differ via qualitative assessment (Supplementary Figures 
5-6). However M-Mode measurements taken during diastole showed that IVSd and LVIDd 
were increased in DN PKD HFD vs DN PKD chow (p<0.05) and LVPWd was increased in 
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control HFD and DN PKD chow vs control chow (p<0.05) (Figure 6A-C). During systole, IVSs 
was decreased in control HFD vs control chow (p<0.05) and increased in control HFD vs 
control chow and in DN PKD HFD vs DN PKD chow (Figure 6C). LVIDs remained unchange 
(Figure 6D). Estimated LV mass was increased in control HFD vs control chow (p<0.05) 
(Figure 6G). EF% and FS% were decreased in control HFD vs control chow (p<0.05) and 
increased in DN PKD HFD vs control HFD (p<0.05) (Figure 6H-I). Therefore, the HFD 
induced mild LV hypertrophy and moderate systolic dysfunction. DN PKD expression was 
able to protect from increases in LVPWd and systolic decline in HFD. However, in DN PKD 
chow animals, increases in IVDs, LVIDd and LVPWd suggest remodelling of the LV in 
response to the trangene expression.  
 
Figure 6. Echocardiography parameters in control and DN PKD mice given a chow or 
HFD. A. Interventricular septum diameter during diastole (IVSd), B. left ventricular internal 
diameter during diastole (LVIDd), C. left ventricular posterior wall diameter during diastole 
(LVPWd), D. Interventricular septum diameter during systole (IVSs), E. left ventricular 
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internal diameter during systole (LVIDs), F. left ventricular posterior wall diameter during 
systole (LVPWs), G. Estimated left ventricular mass (grams),  H. Ejection fraction % (EF %) 
and I. Fractional shortening % (FS %). n=10-12, * p<0.05 vs control same diet, × p<0.05 vs 
DN PKD chow, ǂ p<0.05, ǂ ǂ p<0.01 vs control chow. 
 
DISCUSSION 
 
Obesity and T2D cardiomyopathy is clincially becoming an increasingly accepted and 
diasgnosed condition. Of concern in the field however, is the lack of drugs to specifically target 
the obese and/or T2D heart and associated alterations in cardiac energy metabolism [9]. In this 
study we investigated the role of an emerging potential therapeutic target, PKD, in the 
development of obesity/T2D cardiomyopathy. The major findings from the study are that; 
NVCM expressing PKD (CA) exhibit an increased reliance on fatty acid oxidation and a  
reduced glucose utilisation and metabolic flexibility and that mice expressing a cardiac specific 
DN PKD displayed protection from high fat diet induced cardiomyopathy.  
 
The high fat diet consisted of 43% fat. While this high fat percentage is quite high it still 
comparable to that reported in obese and T2D patients [10, 11]. In addition, many HFD studies 
from North America use a 60% fat diet. The HFD induced an obesity/pre-type 2 diabetic 
phenotype, however did not induce T2D (no increased fasting glucose were observed and 
glucose levels returned to normal within 2 hours during the GTT). While we expected the 45% 
HFD to induce both obesity and glucose intolerance, a similar GTT phenotype in C57BL6 mice 
given a high fat and high sucrose diet has been reported in the past [12]. In regards to the 
cardiac phenotype induced by the HFD in control animals, the HFD induced mild LV 
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hypertrophy and mild systolic dysfunction (diastolic function could not assessed). Expression 
of the DN PKD transgene protected from HFD-induced hypertrophy and systolic dysfunction 
as hypothesised. However, of interest, in the chow DN PKD animals we observed alterations 
in LV geometry that indicate the presence of LV hypertrophy. This suggests that 
downregulation of PKD in a healthy setting (chow diet) may be maladaptive to cardiac 
structure, while downregulation of PKD in an obeseogenic setting (HFD) is protective. 
Possibly due to PKD having a role that is required to regulate normal cardaic energy 
metabolism in a healthy adult heart. With a disregulation of this PKD activity in an obeseogenic 
setting promoting the development of cardiac hypertrohpy and dysfunction.  
One of the most exciting findings from the current paper were the cardiac bioenergetic and 
repiration analsyes performed in NVCM. Expression of CA PKD in these cells induced a 
metabolic profile similar to that observed in the obese and T2D heart, signified by reduced 
utilisation of glucose, increased fatty acid oxidation and impaired substrate flexibility. As we 
did not observe an uncoupling between glycolysis and glucose oxidation, it’s tempting to 
speculate that the decreased glucose utilisation in the NVCM expressing the PKD (CA) may 
be due to a reduction in glucose uptake, possibly through the GLUT4 transporter. However, in 
contrast to this statement, previous studies have reported contraction induced activation of PKD 
to promote GLUT4 translocation and glucose uptake [13] and that contraction induced GLUT4 
translocation and glucose uptake are inhibited in NVCM when the cells were treated with the 
PKD inhibtors staurosporin and calphostin-C [14]. An alternative explanation for the lack of 
uncoupling observed in the NVCM expressing CA PKD may be the lower energy requirments 
for the NVCM compared to those in a working heart, with the NVCM exhibiting no energic 
need to compensate for the reduced glucose oxidation via glycolysis.  
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Some limitations from this in vitro work however include the lack of a DN PKD construct 
being infected into the NVCM. It would have been benefical to observe the effects of DN PKD 
expression under high glucose and high fat conditions. Furthermore, this work relied on the 
lenti-virus for expression of the PKD (CA) construct, whereas an adenovirus is a more suitable 
vector for infection of NVCM. However, despite this limitation we were still able to 
successfully get expression of the infected constructs and observed the downstream signalling 
of putative PKD targets that would be expected, suggesing that the LTV, while not the ideal 
vector, was successful.  
Considering PKD activity in the in vivo study. The DN PKD expressing animals exhibited 
reduced phosphorylation of PKD within the activation loop, as expected. However, the S916 
site exhibited increased phosphorylation. This does not necessarily indicate increased 
phosphorylation of an active form of PKD, as the S916 site could be phosphorylated by any 
kinase that has CaMK consensus motif activity. Furthermore, it is possible that the mutation in 
the DN PKD construct interferes with the function of the pleckstrin homology domain, which 
basally inhibits PKD auto-phosphorylation at the S916 site [15]. It is only after phosphorylation 
of PKD within the activation loop at S744/748 that this pleckstrin homology sites auto-
inhibitory effect is relieved, with a conformational change occurring in the PKD protein 
allowing for auto-phosphorylation of PKD at S916. Despite the potential cause, there were no 
indications that this increased phosphorylation at S916 was associated with increased PKD 
activity. Current work in our laboratory is ongoing to optimise a non-radioactive PKD activity 
assay, where we aim to achieve a direct measurement of PKD activity. This work will assist in 
determining a direct measure of PKD activation in DN PKD expressing mice opposed to the 
indirect measures used in the current study.  
In summary, this work implicates PKD in regulating cardiac energy metabolism and shows that 
cardiac specific DN PKD expression can protect from HFD induced cardiomyopathy in mice. 
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Future work is needed to assess a pharmacological PKD inhibitor in vivo in a setting of 
obesity/T2D cardiomyopathy and to gain a greater understanding of how PKD regulates 
cardiac energy metabolism.   
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SUPPLEMENTARY DATA 
 
 
 
Supplementary Figure 1. Flow Diagram illustrating how experimental animals were 
generated: To generate experimental animals (male DN PKD -/+.a-MHC -/+ mice) two mouse 
lines were crossed; DN PKD -/+ and a-MHC +/+. Before these lines were crossed together, 
each line was first expanded to get enough breeding pairs to generate age matched experimental 
animals A. Expansion of the DN PKD -/+ line yields offspring of three genotypes; 50% DN 
PKD -/+ (used for future breeding), 25% DN PKD +/+ and 25% DN PKD (humanely killed). 
B. Expansion of the a-MHC +/+ yields offspring all of the same genotype; 100% a-MHC +/+ 
(all used for future breeding). C. Age matched experimental animals were generated by mating 
the DN PKD -/+ mice with the a-MHC +/+ mice. This yielded offspring of two genotypes; 50% 
DN PKD -/+. a-MHC -/+ (males used for experiments, females humanely killed) and 50% DN 
PKD -/-. a-MHC -/+ (males used for experiments, females humanely killed). 
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Table 1. 3 primer PCR protocol. 
 
Reaction mix Reaction conditions 
Genomic DNA 30 ng Step Temp. Time Cycles 
Primers  
each 
15 
pmol Denaturing 94°C 120s 1 x 
dNTPs 0.5 mM Denaturing 94°C 30s 
 
Reaction buffer  0.1 Vol Annealing 65°C 30s 35 x 
Expand Long 
Template Polym.  
2.6 U Extension 68°C 300s   
Reaction volume 50.0 µl Completion 68°C 480s 1 x 
 
 
 
Supplementary Figure 2. A. Representative southern blot images from the genotyping 
optimisation. Showing amplification achieved of the WT allele, 727 bp and of the recombined 
allele, 270 bp. B. Example melt curves. Blue, control animals. Red, DN PKD (-/+) and Green, 
DN PKD (+/+). 
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Supplementary Figure 3. Representative western blot images from time course experiments 
in NVCM. Norepinephrine (NE), angiotensin II (Ang II).  
 
 
Supplementary Figure 4. Tamoxifen induced expression of the PKD protein in chow and 
HFD fed animals. n=4, *** p<0.001 vs control. 
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Supplementary figure 5. Heart weight (grams) in control and DN PKD animals fed either 
chow or HFD. 
 
 
Supplementary figure 6. Representative H&E staining of cardiomyocytes. Two hearts shown 
per group. A. control chow. B. DN PKD chow. C. control HFD and D. DN PKD HFD 
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CHAPTER 4 SUMMARY 
 
The data from the current study predominately supported our hypothesis, suggesting PKD is 
involved in regulating cardiac energy metabolism and that a downregulation of PKD can 
provide protection from obesity/T2D cardiomyopathy. However, many unanswered questions 
still remain from the current study that prevent a clear understanding on the role of PKD in 
obesity/T2D cardiomyopathy. In this chapter summary please find additional experiments and 
analysis that highlight the attempts made to further understand the role and mechanism of 
action of PKD in obesity/T2D cardiomyopathy and the challengers that were faced in being 
able to do this. Many of these analyses were not performed in the current thesis because of 
delays in the generation of the new mouse model and the time constraints due to mandatory 
PhD submission deadlines.  
 
Limitations of the study  
4. No measurements of cardiac energy metabolism in DN PKD mice 
5. No echocardiographic assessment of diastolic function 
6. No quantitative assessment of cardiomyocyte histology was performed 
7. No western blot analysis of PKD expression and activity in control and DN PKD chow 
fed animals 
8. No direct analysis of PKD activity was achieved 
 
Strengths of the study 
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4. Expression of the DN PKD protein was cardiac specific and inducible. Allowing the 
mice to age to adulthood without any genetic interference prior to the induction of DN 
PKD gene expression.   
5. The HFD model successfully induced an obesity phenotype with increased body 
weight, body fat and hyperinsulinemia. Representative of the “typical” obese, pre-
diabetic patient.  
6. Cardiac bioenergetics and respiration analysis were performed in a biologically relevant 
in vitro model, NVCM, which successfully expressed a CA PKD construct.  
 
Challenges in detecting PKD activation in vitro and in vivo 
Our DN PKD expressing mice did not show clear decreases in PKD activity. And no clear 
changes in putative PKD targets were observed. It is worth noting the complexity in PKD 
activation that is not fully understood. There is increasing evidence to support spatial temporal 
and transient activation of PKD [16]. As we used whole tissue homogenates and took 
measurements from one time point at the end of the study duration, it’s possible we restricted 
the window in which we could detect altered PKD activity and downstream signalling. 
Experiments performed in vitro in the NVCM highlighted the transient and complex nature of 
PKD activation. For example, a change of media and immediate collection of protein resulted 
in large instant increases in PKD activation, which lasted up to 6 hours post media change 
(Figure 4.1). This activation of PKD post media change represented a challenge in ensuring we 
did not obtain false positives when treating the NVCM. To overcome this, the media were 
refreshed ~8 hours prior to NVCM being treated, with the subsequent treatments added directly 
to the media via “spiking”.  
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Figure 4.1. Representative S916 PKD blots of time course treatment experiments in NVCM, 
with media change occurring at same time of treatment. Note that vehicle were collected at the 
last time point of 24 hours. Angiotensin II (Ang II), endothelin-1 (ET-1), glucose oxidase (GO), 
norepinephrine (NE).  
 
Furthermore, the glucose concentration in the media effected our ability to alter PKD 
phosphorylation status. Time course treatments performed in NVCM cultured under high 
glucose conditions no longer showed the same activation of PKD as that observed under low 
glucose conditions (Figure 4.2). These results suggest that nutrient status may transiently alter 
PKD activation status and that under chronic exposure to high glucose conditions, the basal 
phosphorylation status of PKD may be increased, for which additional insults known to activate 
PKD have no additive effect.  
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Figure 4.2. Representative S744/748 PKD, S916 PKD and PKD total blots of time course 
treatment experiments in NVCM, with cells incubated in media containing high glucose. 
Angiotensin II (Ang II), endothelin-1 (ET-1), glucose oxidase (GO), norepinephrine (NE). 
 
Mode of action of PKD remains unclear 
Evidence supporting PKD acting via HDAC-MEF2 signalling in the development of pressure 
overload cardiomyopathy is quite convincing. As discussed, in our work, we did not detect any 
increased activation of HDAC5 or other known cardiac PKD substrates in response to the HFD 
in vivo. We were only able to observe increased activation of these PKD substrates in vitro in 
NVCM expressing a constitutively active PKD construct. It is therefore unclear, if in vivo, DN 
PKD expression protected from HFD induced cardiomyopathy by attenuating HDAC-MEF2 
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signalling. The substantial decrease in PKD consensus motifs observed however, suggest the 
presence of other cardiac PKD targets that remain unknown. Our attempts to identify a mode 
of action for PKD on other aspects of growth signalling were largely unsucessful. For example, 
please see the mTOR pathway below in which no changes were detected when COS7A cells 
were transfected with CA PKD (Figure 4.3).  
 
To assist in understanding the mode of action of PKD, we are currently performing 
phosphoproteomic analyses of the DN PKD hearts. This work will be important to identify new 
signalling molecules downstream of PKD that may be involved the physiological effects 
observed in the current study.  
 
Figure 4.3. Representative western blots of mTOR signalling proteins in COS7A cells 
transfected with PKD (CA).  
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In Summary, the current chapter has shown that PKD is implicated in regulating cardiac energy 
metabolism and that DN PKD expression can protect from HFD induced cardiomyopathy. 
Suggesting PKD inhibition will provide a beneficial therapeutic target for the treatment of 
obesity and T2D cardiomyopathy. In the final chapter 5, we investigate the effects 
pharmacological PKD inhibition in the obesity/T2D animal mode, the db/db mouse.  
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CHAPTER 5 
 
 
The PKD Inhibitor CID755673 Enhances Cardiac 
Function in Diabetic db/db Mice  
179 
 
CHAPTER 5 INTRODUCTION 
 
In this final chapter we aimed to investigate the effects of a selective PKD inhibitor 
Benzoxoloazepinolone (CID755673), on cardiac structure and function in a mouse model of 
obesity and T2D, the db/db mouse. db/db mice are homozygous for a mutation in their leptin 
receptor. Leptin is a hormone involved in reducing appetite. While db/db mice are still able to 
produce the hormone leptin, without a functional leptin receptor the mice continue to eat, 
develop obesity, T2D and eventually heart failure. Mice that a heterozygous for this mutation, 
db/+, have a function leptin receptor and act as healthy lean controls. Alternatively, as db/db 
mice originate from the C57BL6 background, WT C5BL6 mice are also used as control mice 
in db/db studies. The db/db mice were chosen for the following study as they are an established 
model of obesity and T2D with the onset of obesity occurring by 3-4 weeks of age and T2D by 
4-8 weeks of age. Therefore, by adult age the mice will exhibit both obesity and T2D. In regards 
to the db/db mice as a model of obesity/T2D cardiomyopathy, the onset of diastolic 
dysfunction, systolic dysfunction and LV hypertrophy have been reported at varying ages and 
severities (Table 5.1). Therefore, we first aimed to characterise the presence of obesity and 
T2D in the db/db model prior our intervention.  
 
The PKD inhibitor, CID755673 is not competitive with ATP allowing CID755673 to act as a 
highly selective inhibitor of all three PKD isoforms; PKD1, PKD2, and PKD3 (the ATP-
binding pocket is highly conserved among kinases, inhibitors that compete with ATP therefore 
have reduced specificity) [1]. In the following paper we were the first to assess the use of this 
inhibitor in vivo.  
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Table 5.1. Summary of echocardiography parameters reported in db/db mice 
Ref Model Age 
Body 
weight 
Blood 
glucose 
Diastolic 
dysfunction 
Systolic 
dysfunction 
Hypertrophy 
[2] 
db/+ vs 
db/db 
6 wks 
22 ± 1 vs 
30 ± 1 (g) 
9 ± .6 vs 20 
± 2 (mM) 
21% >  E wave No change Not measured 
12 wks 
28 ± .5 vs 
48 ± 1 (g) 
14 ± 1 vs 53 
± 4 (mM) 
29% > A wave, 
32% <  E/A ratio 
27% > LVIDs, 
26% < FS% 
Not measured 
[3] 
C57BL6 
vs 
db/db 
8 wks 
22 ± 1 vs 
40 ± 2 (g) 
3 ± .5 vs 8 ± 
1 (mM) 
No change No change No change  
12 wks 
26 ± .5 vs 
48 ± 1 (g) 
2 ± .6 vs 8 ± 
1 (mM) 
No change No change  No change 
16 wks 
27 ± 2 vs 
43 ± 2 (g) 
3 ± .3 vs 13 
± 3 (mM) 
No change No change No change 
[4] 
db/+ vs 
db/db 
16 wks 
27 ± 1 vs 
45 ± 2 (g) 
7 ± .5 vs 24 
± 1 (mM) 
< LV passive 
stiffness 
No change  
30% > in 
LVPWd  
[5] 
db/+ vs 
db/db 
2 mths 
31 ± 1 vs 
43 ± 1 (g) 
Not 
measured 
Not measured 
25% < FS%,  
11% >  LVIDs 
No change 
6 mths 
37 ± 2 vs 
62 ± 2 (g) 
Not 
measured 
Not measured 
No change  
 
38% > LVPWd,  
36% > LVM 
[6] 
db/+ vs 
db/db 
5 wks 
16 ± 1 vs 
23 ± 1 (g) 
6 ± 0.5 vs 8 
± 2 (mM) 
No change No change No change  
9 wks 
21 ± .5 vs 
43 ± 1 (g) 
9 ± .4 vs 20 
± 1 (mM) 
No change  No change 
> LVPWd, 
> LVM 
13 wks 
25 ± .7 vs 
44 ± 1 (g) 
6 ± .3 vs 18 
± 3 (mM) 
> LVEDV < EF% 
> LVPWd, 
> LVM 
17 wks 
Not 
measured 
Not 
measured 
> LVEDV < EF% 
> LVPWd, 
> LVM 
22 wks 
23 ± 1 vs 
48 ± 2 (g) 
Not 
measured 
> LVEDV < EF% 
> LVPWd, 
> LVM 
[7] 
C57BL6 
vs 
db/db 
22 wks Increased increased 
< E’:A’ ratio, 
> IVRT, 
> LVEDp 
No change 
> LVM, 
35% > LVPWd 
 
[8] 
db/+ vs 
db/db 
10 wks Increased  Increased  < Em No change 
> LVPWd  
 
[9] 
db/+ vs 
db/db 
10 wks 
25 ± .5 vs 
50 ± 5 (g) 
5 ± .5 vs 29 
± 2 (mM) 
Not measured 
 No change 
 
40% increase 
LVPWd,  
58% > LVM 
 
[10] 
db/+ vs 
db/db 
30 wks 
30 ± 2 vs 
62 ± 4 (g) 
Increased  < E:A ratio No change 
33% > HW/TL 
ratio 
Ejection fraction % (EF%), ejection time (ET), fractional shortening % (FS%), heart weight (HW), 
interventricular relaxation time (IVRT), left ventricular (LV), left ventricular end diastolic pressure 
(LVEDp),  left ventricular internal diameter, during diastole (LVIDd), left ventricular posterior wall 
thicknesses, during diastole (LVPWd), myocardial peak early diastolic velocity (Em), tibia length (TL). 
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Significance: Heart failure kills more men and women than any form of cancer in Australia. 
As current therapies show little effectiveness in treating the obese and/or T2D heart, new 
therapies are urgently needed to treat this high risk population.  
 
Aims 
10. To characterise the presence of obesity/T2D cardiomyopathy in db/db mice. 
11. To investigate the effects of PKD inhibition, via CID755673 treatment on the 
presence of obesity/T2D cardiomyopathy in db/db mice.  
 
Paper status is published, reference; Venardos, K., De Jong, K. A., Elkamie, M., Connor, 
T., & McGee, S. L. (2015). The PKD Inhibitor CID755673 Enhances Cardiac Function in 
Diabetic db/db Mice. PLoS ONE, 10(3).  
182 
 
The PKD Inhibitor CID755673 Enhances Cardiac Function in Diabetic db/db Mice 
 
Kylie Venardos1, Kirstie A. De Jong1, Mansour Elkamie1, Tim Connor1, Sean L. McGee1,2  
 
 
1Metabolic Remodelling Laboratory, Metabolic Research Unit, School of Medicine, Deakin 
University, Waurn Ponds, Australia; 2Program for Metabolism and Inflammation, Baker IDI 
Heart and Diabetes Institute, Melbourne, Australia. 
 
 
Running title: CID755673 administration in diabetic cardiomyopathy 
 
 
 
 
 
  
183 
 
ABSTRACT 
 
The development of diabetic cardiomyopathy is a key contributor to heart failure and mortality 
in obesity and type 2 diabetes (T2D). Current therapeutic interventions for T2D have limited 
impact on the development of diabetic cardiomyopathy. Clearly, new therapies are urgently 
needed. A potential therapeutic target is protein kinase D (PKD), which is activated by 
metabolic insults and implicated in the regulation of cardiac metabolism, contractility and 
hypertrophy. We therefore hypothesised that PKD inhibition would enhance cardiac function 
in T2D mice. We first validated the obese and T2D db/db mouse as a model of early stage 
diabetic cardiomyopathy, which was characterised by both diastolic and systolic dysfunction, 
without overt alterations in left ventricular morphology. These functional characteristics were 
also associated with increased PKD2 phosphorylation in the fed state and a gene expression 
signature characteristic of PKD activation. Acute administration of the PKD inhibitor 
CID755673 to normal mice reduced both PKD1 and 2 phosphorylation in a time and dose-
dependent manner. Chronic CID755673 administration to T2D db/db mice for two weeks 
reduced expression of the gene expression signature of PKD activation, enhanced indices of 
both diastolic and systolic left ventricular function and was associated with reduced heart 
weight. These alterations in cardiac function were independent of changes in glucose 
homeostasis, insulin action and body composition. These findings suggest that PKD inhibition 
could be an effective strategy to enhance heart function in obese and diabetic patients and 
provide an impetus for further mechanistic investigations into the role of PKD in diabetic 
cardiomyopathy.  
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INTRODUCTION 
 
Obesity and type 2 diabetes (T2D) are associated with the development of heart failure, which 
accounts for ~65% of deaths in obese and diabetic patients [11]. Diabetic cardiomyopathy 
describes abnormalities in cardiac metabolism that impair contractile function and induce 
pathological ventricular hypertrophy [12]. The early stages of diabetic cardiomyopathy are 
characterised by impaired cardiac metabolism, which include insulin resistance, reduced 
glucose oxidation and increased lipid oxidation [12].  These metabolic alterations result in an 
energetic deficit that first manifests as diastolic dysfunction, before progressing to systolic 
dysfunction, and later hypertrophy and heart failure [13]. Existing therapeutics for T2D have 
limited impact on preventing the development of diabetic cardiomyopathy and some even 
aggravate the condition [14]. Therefore, new therapies that effectively combat the development 
of diabetic cardiomyopathy are urgently needed. 
 
Protein kinase D (PKD) is activated by metabolic abnormalities, neuroendocrine factors and 
oxidative stress that are associated with obesity and T2D [15]. It is a serine/threonine kinase 
with three known isoforms; PKD1-3 [15]. Previously thought to be a Protein kinase C (PKC) 
isoform termed PKCµ, catalytic domain homology has since distinguished PKD as a member 
of the calcium calmodulin-dependent kinase (CaMK) family [15]. Activation of PKD involves 
binding of diacylglycerol to N-terminal cysteine rich domains that relieves autoinhibition of 
the catalytic domain [16]. Phosphorylation of PKD at a number of sites within the C-terminal 
catalytic domain confers full PKD activation, culminating in serine 916 autophosphorylation 
[17]. Numerous growth factors, neuroendocrine factors and oxidative stress are all potent 
activators of PKD activity [15]. A number of studies have showed that metabolic abnormalities 
associated with obesity and T2D increase PKD activity. Indeed, PKD activation is increased in 
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cardiomycoytes co-treated with the saturated fatty acid palmitate and high glucose [18]. Similar 
data is observed in the hearts of male Wistar rats exhibiting hyperglycemia in response to acute 
(1 day) and chronic (7 day) streptozotocin treatment [18]. In addition, neurohormonal 
signalling associated with obesity/T2D, such as endothelin-1 and norepinephrine, has also been 
shown to activate PKD in vitro [19]. Changes in PKD activity are also dynamic and regulated 
in a spatiotemporal manner [19], meaning that quantification of PKD activity in chronic disease 
states in vivo can be challenging. PKD is known to target a number of substrates in 
cardiomyocytes, including the class IIa histone deacetylases (HDACs) [20] and cardiac 
troponin I (cTnI) [21], to regulate processes such as metabolism [22], contractility [21] and 
hypertrophy [20]. Together, these data suggest that PKD could be an effective target for 
pharmacological modulation in diabetic cardiomyopathy. 
 
A number of small molecule compounds with inhibitory action against PKD have been 
discovered and synthesised. Of these, the benzoxoloazepinolone family of compounds have 
high relative potency and specificity against PKD isoforms. The parent benzoxoloazepinolone, 
termed CID755673, has IC50 values of 180, 280 and 227nM against PKD1-3 respectively, and 
shows ~1000 fold selectivity over closely related PKC kinases [1]. Importantly and unlike 
many other kinase inhibitors, this compound acts independently of the kinase ATP-binding 
domain [1], which potential explains its high degree of specificity. This compound inhibits 
PKD-regulated processes, including class IIa HDAC phosphorylation [1], and has been used 
to inhibit prostate cancer growth and motility [23] and pancreatitis in vivo [24] in a PKD-
dependent manner. The aim of this study was to determine whether the PKD inhibitor 
CID755673 could prevent cardiac dysfunction in T2D db/db mice. Here we report that T2D 
db/db mice are a model of early stage diabetic cardiomyopathy, characterised by both diastolic 
and systolic dysfunction, without overt alterations in left ventricular morphology, which was 
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associated with elevated PKD2 auto phosphorylation in the fed state and a gene expression 
signature characteristic of PKD activation. Administration of the PKD inhibitor CID755673 to 
T2D db/db mice for two weeks enhanced indices of both diastolic and systolic left ventricular 
function and was associated with reduced heart weight. These data suggest that PKD inhibition 
could be an effective strategy to enhance cardiac function in obese and T2D patients.  
 
 
METHODS 
 
Animal experiments  
This study was carried out in strict accordance with animal care guidelines stipulated by the 
National Health and Medical Research Council (NHMRC) of Australia. The project was 
approved by the Deakin University Animal Ethics Committee (Application Number G09-
2012). All efforts were made throughout the study to minimise animal suffering. Male wild 
type C57BL6, C57BL6J T2D db/db and control heterozygous (db/-) mice were obtained from 
the Animal Resource Centre (Perth, Western Australia) and housed under constant temperature 
and humidity with 12 h light-dark cycles, with free access to water and food. Untreated db/- 
and db/db mice underwent cardiac function assessment at 8 weeks of age and were killed two 
days later in the fed or fasted state and the heart and right tibia were collected for later analysis. 
For acute inhibitor studies, C57BL6 mice were administered a single dose of vehicle (5% 
DMSO in PBS, pH 7.4), or the selective PKD inhibitor CID755673 at 1 or 10mg/kg body 
weight. Mice were killed one or four hr later and heart collected for later analysis. For chronic 
inhibitor experiments, 8-week old db/db mice received vehicle or CID755673 at 1 or 10mg/kg 
bodyweight for 16 days, by daily intraperitoneal (i.p.) injection. Body composition by 
EchoMRI and insulin tolerance was assessed after 12 days of treatment. Insulin tolerance in 
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db/db mice was assessed following a 4hr fast by measuring blood glucose obtained from the 
tail prior to, and 20, 40, 60, 90 and 120 min after insulin (3.5U/kg) administration by i.p. 
injection.  Cardiac function was assessed after 14 days of treatment. At least 2 days later, mice 
were killed and 4hr fasted blood glucose, the heart and right tibia were collected for later 
analysis.  
 
Echocardiography  
Echocardiography was performed on mice (n=7-8/group) under isoflurane inhalation 
anaesthesia using a Phillips HD15 diagnostic ultrasound system with 15MHz linear-array 
transducer. Intraventricular septum and left ventricular (LV) posterior wall thicknesses and LV 
chamber dimensions during both diastole and systole were assessed in M-mode. Doppler 
imaging provided indices of LV filling, aortic flow and ejection times. Fractional shortening 
(FS) and ejection fraction, were derived from the M-mode measurements. LV mass was 
estimated using M-mode data according to the equation by Troy [25], where estimated LV 
mass = 1.05 ([LVIDD + LVPWD + IVSD]3- [LVIDD]3), where LVIDD is LV internal diameter 
at diastole, LVPWD is LV posterior wall thickness at diastole and IVSD is intraventricular 
septum thickness at diastole. 
 
Tibia length measurement  
Hind legs were covered with 1M NaOH and incubated at 37°C for 5 hours to digest skin, fat 
and muscle. The tubes were gently agitated every 30 minutes to help aid digestion. After 
digestion, the kneecap was carefully removed with forceps, and the tibia collected, rinsed, and 
then dried on paper towel briefly. Tibia length (TL) was then measured using a vernier calliper 
and used to normalise heart weights. 
 
188 
 
Histology  
Hearts (n=3) were rinsed with cold PBS, trimmed and the mid-sections fixed in 10% formalin. 
Fixed hearts were paraffin embedded, sectioned (4μm thick) then stained with haematoxylin 
and eosin (H&E). Stained tissue was imaged by light microscopy at 400x magnification and 
analysed with Zeiss AxioVision software. The size of approximately two hundred cells per LV 
were measured from 4-6 different fields to assess cardiomyocyte size. 
 
Western blotting  
Heart ventricles (n=3/group for acute inhibitor studies and n=7-8/group for all other analyses) 
were homogenised in ice-cold lysis buffer (50mM Tris pH7.5, 1mM EDTA, 1mM EGTA, 10% 
glycerol, 1% triton X-100, 50mM NaF, 5mM Na4P2O7, 1mM Na3VO4, 1mM DTT, protease 
inhibitor cocktail) and protein content was determined using the BCA method. 30µg of protein 
was separated by SDS-PAGE and transferred onto PVDF membrane using standard protocols. 
Blocked membranes were exposed to primary antibodies towards total PKD, pS916 PKD, total 
cTn1, pS23/24 cTnI, total HDAC5 (Cell Signalling Technology, Danvers, USA), pS498 
HDAC [26] and α-tubulin (Sigma-Aldrich, St. Louis, USA). Membranes were visualised using 
the ChemiDoc™ XRS+ with Image Lab™ software. 
 
Real time RT-PCR  
Heart ventricles (n=7-8/group) were homogenised in trizol and RNA was isolated using 
RNeasy columns (Qiagen, Doncaster, Australia). RNA was reverse transcribed using 
Superscript III chemistry (Life Technologies, Mulgrave, Australia) and cDNA was quantified 
using Oligreen (Life Technologies, Mulgrave, Australia). Real time RT-PCR was performed 
using primers specific for Cox7a, PPARα, CPT-1b, PGC-1α, PDK4, GLUT4 and β-actin 
(sequences available upon request). Gene expression was quantified using the 2ΔCT method 
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and normalisation to β-actin expression, which was not different between groups (Figures S1 
and 2).  
 
Statistical analyses  
All data were analysed using unpaired t-tests or one-way analysis of variance with Tukey’s 
post-hoc, using GraphPad Prism version 6.0 (Graph-Pad Software Inc., San Diego, USA) and 
p < 0.05 was considered statistically significant. All data are reported as mean + standard error 
of the mean (SEM). 
 
RESULTS 
 
db/db mice displayed impaired cardiac function  
The db/db mouse model of T2D is a validated model of diabetic cardiomyopathy [27], however 
the exact phenotype and stage of disease at a given age can be dependent on strain background 
and other colony specific factors [28]. We therefore evaluated disease progression in 8-week 
old db/db C57BL6J mice through cardiac morphology and function assessment by 
echocardiography. Compared with control db/- mice, db/db mice had increased body weight 
and fasting blood glucose (Figure 1A), consistent with their T2D phenotype. There was no 
difference in heart rate, or gross heart weight between db/- and db/db mice (Figure 1A). 
Normalised heart weight to body weight and tibia length were different in db/db mice, due to 
increased body weight and reduced tibia length in these mice (Figure 1A). Echocardiographic 
assessment of heart structure and function by M-mode and Doppler imaging (Figure 1B) 
showed that LV structural dimensions were similar, except that db/db mice had thicker 
intraventricular septum at diastole and thinner LV posterior wall at systole (Figure 1C). 
Diastolic dysfunction was evident in db/db mice, characterised by a reduced E:A ratio (Figure 
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1D) and increased deceleration time (Figure 1E). No histological evidence of fibrosis was 
observed (data not shown). An increased ejection time (Figure 1F), reduced ejection fraction 
(Figure 1G) and decreased fractional shortening (Figure 1H) also indicated systolic dysfunction 
in these mice. These data validate the 8-week old db/db mouse as a model of developing 
cardiomyopathy characterised by diastolic and systolic dysfunction, but not pathological 
hypertrophy. 
 
 
 
Figure 1: Cardiac dysfunction in db/db mice. (A) Physiological and cardiac morphological 
measures; (B) Representative M-mode and Doppler images; (C) LV Structural dimensions; (D) 
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E:A ratio; (E) Deceleration time; (F) Ejection time; (G) Ejection fraction, and; (H) Fractional 
shortening in db/- and db/db mice. Data represented are mean ± SEM, n=7-8/group. * Denotes 
significantly different from db/- mice (p<0.05). IVS – intraventricular septum thickness; LVID 
– left ventricular internal diameter; LVPW – left ventricular posterior wall thickness.  
 
db/db mice have increased PKD2 autophosphorylation in the fed state and display a gene 
expression signature consistent with cardiac PKD activation 
We next assessed ventricular PKD activation in these mice. As PKD activation is sensitive to 
nutrient availability [18], this was done in mice in the fed and fasted state. No difference was 
found in autophosphorylation of full length PKD1 at S916 (Figure 2A and B), which is 
indicative of PKD activity [29], but we did observe an increase in full length PKD2 
autophosphorylation at S916 in feb db/db mice (Figure 2A and C). However, no differences in 
the phosphorylation of target motifs within the PKD substrates cTn1 and HDAC5 were 
detected (Figures 2D, E and F). As PKD activity is regulated in a spatiotemporal and dynamic 
manner [19], measurement of static PKD autophosphorylation and PKD substrate 
phosphorylation might not be indicative PKD activation patterns in vivo. We therefore 
examined a gene expression signature indicative of chronic PKD activation in myocytes [22] 
as a more persistent measure of PKD activation. The expression of 4 out of 6 PKD-dependent 
genes was elevated in fasted db/db mice (Figure 2G and S1). These data suggest that the 
diastolic and systolic dysfunction observed in db/db mice is associated with increased PKD2 
activity in the fed state and a gene expression signature consistent with elevated PKD 
activation. 
192 
 
 
Figure 2: Assessment of PKD activation in db/db mice. (A) Representative western blots; 
(B) S916 PKD1 phosphorylation; (C) S916 PKD2 phosphorylation; (D) Representative 
western blots; (E) S23/24 cTn1 phosphorylation; (F) S498 HDAC5 phosphorylation in db/- 
and db/db mice in the fed or 4 hr fasted state, and; (G) Heat map of a PKD- dependent gene 
expression signature in 4 hr fasted db/db mice. Expression values are relative to db/- mice. Data 
represented are mean ± SEM, n=7-8/group.  
 
The PKD inhibitor CID755673 reduces PKD activation in a time and dose-dependent 
manner in C57BL6 mice 
 To determine whether CID755673 reduces PKD activity in the heart, wild type C57BL6 mice 
were administered vehicle (5% DMSO in PBS) or CID755673 at 1 or 10mg/kg body weight, 
and were killed 1 and 4 hr after drug administration. One hr after administration, CID755673 
reduced PKD1 S916 autophosphorylation at both 1 and 10mg/kg (Figure 3A and B), while 
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there was no effect on PKD2 (Figure 3A and C). Four hr after administration, CID755673 had 
no effect on PKD1 S916 autophosphorylation (Figure 3D and E), while the 10mg/kg dose 
reduced PKD2 S916 autophosphorylation (Figure 3D and F). These data show that .i.p. 
administered CID755673 reduced PKD activity in a time and dose-dependent manner.  
 
 
Figure 3: Acute CID755673 administration reduces PKD activity in a time and dose-
dependent manner. (A) Representative western blots; (B) S916 PKD1 phosphorylation; (C) 
S916 PKD2 phosphorylation in the ventricles of wild type C57BL6 mice 1 hr after drug 
administration. (D) Representative western blots; (E) S916 PKD1 phosphorylation; (F) S916 
PKD2 phosphorylation in the ventricles of wild type C57BL6 mice 4 hr after drug 
administration. Data represented are mean ± SEM, n=3/group. * Denotes significantly different 
from vehicle-treated mice (p<0.05). 
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The PKD inhibitor CID755673 enhanced left ventricular function in db/db mice  
db/db mice were administered vehicle or CID755673 at 1 or 10mg/kg body weight by daily i.p. 
injection for two weeks. CID755673 had no effect on body weight or fasting blood glucose, 
but did induce a dose-dependent decrease in gross heart weight and heart weight when 
normalised to tibia length (Figure 4A). CID755673 administered at 10mg/kg increased heart 
rate when compared with vehicle (Figure 4A). Echocardiographic assessment of heart structure 
and function by M-mode and Doppler imaging (Figure 4B) showed that CID755673 
administration at 10mg/kg reduced LV posterior wall (LVPW) thickness at diastole when 
compared with both vehicle and 1mg/kg CID755673 administration regimens (Figure 4C). 
CID755673 administered at both doses reduced LV internal diameter (LVID) at systole. No 
other differences in LV morphology at either diastole or systole were observed with 
CID755673 administration. However, CID755673 administration at 10mg/kg enhanced both 
diastolic function, signified by an increased E:A ratio (Figure 4D) and reduced deceleration 
time (Figure 4E), and systolic function, demonstrated by decreased ejection time (Figure 4F). 
Dose-dependent increases in indices of systolic function, such as ejection fraction (Figure 4G) 
and fractional shortening (Figure 4H) were also observed. Together, these data show that the 
PKD inhibitor CID755673 enhanced both diastolic and systolic cardiac function in db/db mice, 
which was associated with a reduction in gross heart weight and reduced LVID at systole.  
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Figure 4: The PKD inhibitor CID755673 enhances cardiac function in db/db mice. (A) 
Physiological and cardiac morphological measures; (B) Representative M-mode and Doppler 
images; (C) LV Structural dimensions; (D) E:A ratio; (E) Deceleration time; (F) Ejection time; 
(G) Ejection fraction, and; (H) Fractional shortening in db/db mice treated with vehicle, 1mg/kg 
or 10mg/kg CID755673. Data represented are mean ± SEM, n=7-8. † Denotes significantly 
different from vehicle mice (p<0.05). # Denotes significantly different from 1mg/kg 
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CID755673-treated mice. Veh – vehicle; IVS – intraventricular septum thickness; LVID – left 
ventricular internal diameter; LVPW – left ventricular posterior wall thickness.  
 
CID755673 administration was associated with an altered PKD-dependent gene 
expression signature, consistent with PKD inhibition 
We next assessed PKD-dependent signalling in the ventricles of vehicle and CID755673-
treated mice that had undergone a 4hr fast (Figure 4A). We first assessed whether CID755673 
administration altered our PKD-dependent gene expression signature. The expression of 4 
PKD-dependent genes was reduced by CID755673 administration across both doses, 
suggestive of PKD inhibition, while the remaining 2 genes were markedly increased (Figure 
5A and S2). No differences in S23/S24 cTn1 (Figure 5B and C) and S498 HDAC5 (Figure 5B 
and D) phosphorylation was observed with CID755673 administration. However, we did 
observe a significant increase in the expression of the KCNH2 gene (Figure 5E), which encodes 
a potassium voltage-gated channel involved in cardiomyocytes electrical function that is 
thought to be suppressed by PKD in obesity [30]. Together, these data suggest some 
impairment in downstream PKD signalling in CID755673 treated db/db mice. 
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Figure 5: Assessment of PKD activation in CID755673-treated db/db mice. (A) Heat map 
of a PKD- dependent gene expression signature; (B) Representative western blots; (C) S23/24 
cTn1 phosphorylation; (D) S498 HDAC5 phosphorylation; (E) KCNH2 gene expression in 
vehicle, 1mg/kg and 10mg/kg CID755673-treated db/db mice. Expression values are relative 
to db/- mice. Data represented are mean ± SEM, n=7-8/group. * Denotes significantly different 
from vehicle-treated mice (p<0.05). 
 
CID755673-mediated reduction in heart size was not specific for the LV 
We further assessed the cardiac remodelling that contributing to the reduced heart size and 
enhanced cardiac function observed following CID755673 administration. To examine the 
specific effects on heart morphology, we examined LV cell size by histology (Figure 6A).  
CID755673 administration at 10mg/kg reduced LV cell size (Figure 6A), and calculated LV 
mass from M-mode echocardiography was reduced at both drug doses (Figure 6B). However 
calculated LV mass was not different when normalised to total heart weight (Figure 6C), 
suggesting that the reduction in heart weight was consistent across all chambers of the heart. 
These alterations could not be ascribed to changes in body composition or insulin tolerance 
(Figure S3), suggesting that gross alterations in systemic metabolism were not involved. 
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Together, these data show that the PKD inhibitor CID755673 enhanced cardiac systolic and 
diastolic function in diabetic cardiomyopathy in association with reduced heart size, but with 
only minor alterations in LV internal structural dimensions.  
 
 
 
Figure 6: The CID755673-mediated reduction in heart size is not specific for the LV. (A) 
Representative cell size images and quantification; (B) Estimated gross LV mass, and; (C) LV 
mass normalised to heart weight in db/db mice treated with vehicle, 1mg/kg or 10mg/kg 
CID755673. Data represented are mean ± SEM, n=3-8/group. † Denotes significantly different 
from vehicle mice (p<0.05). 
 
DISCUSSION 
 
Cardiovascular disease and heart failure are major comorbidities for T2D, accounting for ~65% 
of deaths due to T2D [11]. Clearly new therapeutic strategies are needed to attenuate the 
incidence of cardiovascular disease mortality in obese and T2D patients, which would be most 
effectively targeted in the early stages of diabetic cardiomyopathy development. Here we 
showed that the obese and T2D db/db mouse on a C57BL6J background at 8 weeks of age 
represents a model of developing diabetic cardiomyopathy characterised by systolic and 
diastolic dysfunction, in the absence of compensatory pathological hypertrophy. Therefore, this 
mouse model is useful for the study of developing diabetic cardiomyopathy and for 
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experimental drug studies aimed at preventing the disease in its early stages. We observed 
increased PKD2 activation in the fed state in these db/db mice and components of a gene 
expression signature of PKD activation were elevated. Administration of the PKD inhibitor 
CID755673 to db/db mice for 2-weeks improved both systolic and diastolic cardiac function, 
and was associated with a reduction in gross heart size. Together, these data suggest that 
compounds with inhibitory activity towards PKD could be effective in enhancing cardiac 
function in diabetic cardiomyopathy, when administered in the early stages of the disease.  
 
The finding that PKD2 autophosphorylation was increased in db/db mice in the fed state 
provides further evidence that PKD isoforms are sensitive to alterations in substrate 
availability. The finding that PKD2 activation was not different between control and db/db 
mice after 4 hr of fasting is consistent with other observations showing that PKD activation is 
dynamic [31] and can be regulated in a spatiotemporal manner [19]. It is possible that static 
measures of PKD activity in whole ventricle lysates are not spatiotemporally sensitive enough 
to accurately assess PKD activity in vivo. Therefore, we assessed a gene expression signature 
of PKD activation, which we previously identified in myocytes following constitutively active 
PKD expression [22], as a more stable measure of PKD activation in these hearts.  Although 
consisting primarily of metabolic genes, we observed that 4 of 6 genes of the expression 
signature were elevated in diabetic db/db mice when compared with control mice. It should be 
noted that the 2 remaining genes, PDK4 and GLUT4, were substantially increased in response 
to CID755673. However, it is possible that these genes were up-regulated by secondary 
mechanisms related to alterations in glucose flux following the cardiac remodelling by 
CID755673. Clearly further research will be required to more clearly define PKD activation 
patterns in the development of diabetic cardiomyopathy in vivo, including any time course of 
activation and the putative factors contributing to any increases in PKD activity. An intriguing 
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finding from this study was that despite measures of PKD activation and the profound effects 
of CID755673 on cardiac function in db/db mice, we did not observe any alterations in the 
phosphorylation of two putative downstream PKD targets in these same mice. cTn1 and 
HDAC5 are both phosphorylated by PKD and are thought to regulate contractility and 
hypertrophy and metabolism responses, respectively. However, the effect of CID755673 on 
the cardiomyopathy observed in db/db mice could be due to the regulation of other, including 
as yet unidentified, PKD targets.  
 
The underlying mechanisms by which CID755673 enhanced both diastolic and systolic 
function are unknown. However, in the context of developing diabetic cardiomyopathy, PKD 
is known to regulate both cardiac metabolism and contractility. Indeed, loss of PKD1 through 
either siRNA or through genetic knockout is associated with a loss of GLUT4 translocation 
and glucose uptake [32]. This is consistent with our own data in myocytes showing that 
constitutive PKD activation enhances glucose oxidation [22]. However, as the development of 
diabetic cardiomyopathy is associated with a shift from glucose to lipid metabolism, this would 
suggest that PKD inhibition would be unlikely to result in restoration of glucose metabolism 
that in turn prevents or reverses the diabetic cardiomyopathy phenotype. However, PKD has 
also been linked to increased fatty acid uptake under insulin resistant conditions [33], 
suggesting that impairment in PKD activity could contribute to cardiac lipotoxicity in insulin 
resistance. An alternative mechanism by which CID755673 had its effects on diastolic and 
systolic function could be through modulation of cardiac contractility. Indeed, heart rate was 
increased in CID755673-treated animals, possibly indicating that contractile processes and/or 
calcium handling were improved. While we did not see any difference in cTn1 phosphorylation 
in any of our analyses, we did observe an increase in the expression of the KCNH2 gene, which 
encodes the Kv11.1 voltage-gated potassium channel that is required for normal cardiac 
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electrical conduction. PKD has been found to suppress this gene in obesity [30] and could be 
one mechanism by which PKD inhibition enhanced both diastolic and systolic function. 
 
Treatment of db/db mice with CID755673 resulted in a dose dependent reduction in gross heart 
size. Although this was associated with a reduction in LV cell size and estimated LV mass, the 
reduction in mass was not specific for the LV as there was no change in LV mass when 
normalised to heart weight. This is consist with our initial characterisation of the db/db model 
that showed no pathological hypertrophy and suggests that a fundamental process controlling 
cardiomyocyte size was affected by CID755673 treatment. Indeed, a recent report suggests that 
PKD3 can directly phosphorylate and activate S6K1, in an mTOR-independent manner, which 
contributes to breast cancer cell growth [34]. Whether this mechanism explains the whole heart 
phenotype observed in the present study is unclear, however it should be noted that the 
reduction in heart size was not associated with deleterious effects on heart function but instead 
improvements in cardiac function. This could suggest that the reduction in heart weight in 
CID755673-treated mice was related to decompensation due to enhanced function.  Indeed, the 
reduction in heart size and enhancement in cardiac function is remarkably similar to that 
observed with loss of phospholamban in disease states [35].  
 
In conclusion, here we showed that the 8 week old db/db mouse is a model of developing 
diabetic cardiomyopathy characterised by diastolic and systolic dysfunction, but not 
pathological hypertrophy, and PKD2 activation in the fed state. Diastolic and systolic 
dysfunction was enhanced following 2-weeks of treatment with the CID755673 PKD inhibitor 
and was associated with a reduction in gross heart weight. Current first line treatments for T2D 
are typically focussed on controlling blood glucose levels, and have varying effects on diabetic 
cardiomyopathy [14, 36, 37]. The remaining high prevalence of heart failure in obesity and 
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T2D suggests that additional therapeutic interventions are required. The proof-of-principle 
findings in the present study suggest that small molecules that have inhibitory activity towards 
PKD could be promising therapeutics to reduce heart disease in obese and diabetic patients. In 
addition to genetic gain and loss of function studies to determine the exact role of PKD in 
diabetic cardiomyopathy, further toxicity and efficacy testing of other PKD inhibitors and long 
term drug studies are warranted and could support a role for PKD inhibition as a therapeutic 
treatment option for developing diabetic cardiomyopathy.  
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CHAPTER 5 SUMMARY 
 
In summary our data supported our hypothesis and met the aims of the study. With the PKD 
inhibitor reducing heart size and restoring diastolic and systolic function in the db/db mouse. 
As the inhibitor had no effect of blood glucose or body weight, these improvements appeared 
to be independent of T2D and obesity.   
 
Limitations of the study  
 
1. CID755673 was not used in db/+ lean litter mates. 
2. PKD activity was only assessed via phosphorylation status.  
3. The systemic effects of PKD inhibition were not assessed. For example the effect of 
PKD inhibition on insulin secretion.  
 
Strengths of the study 
 
1. Obesity and T2D cardiomyopathy was characterised in the db/db model. 
2. The intervention was applied at adult age, post the development of obesity and T2D. 
Therefore we were able to assess whether the PKD inhibitor improved obesity and T2D 
cardiomyopathy. 
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CONCLUSION 
 
 
This thesis has addressed some of the main limitations surrounding the detection and treatment 
of obesity and T2D cardiomyopathy (Figure 1). One of the greatest obstacles in the field has 
been the lack of data that clearly shows LV structure and function in normotensive obese and/or 
T2D patients. Previous work have often considered obesity and T2D as one disease state and/or 
hypertension as a common co-morbidity in these metabolic settings. This has resulted in a 
failed understanding of the extent, if any, obesity and T2D have on their own and in 
combination in the development of LV remodelling and diastolic dysfunction. Considering 
these past limitations it is not surprising that so much controversy and uncertainty has remained 
in the field. Furthermore, as cardiovascular risk is predominately assessed via monitoring the 
secondary development of hypertension in obesity and T2D it is reasonable to expect that the 
majority of research has focused on identifying therapeutic options that are targeted towards 
treating hypertension and not obesity and T2D induced alterations in cardiac energy 
metabolism. This point highlights the second and third major obstacles of the field, the lack of 
understanding how obesity and T2D increase cardiovascular risk independent of hypertension 
and how these metabolic diseases alter cardiac energy metabolism in the heart. Previous 
research have been successful in detecting increased incidence of cardiovascular risk in obese 
and/or T2D patients and in characterising the alterations in substrate preferences and substrate 
use in the obese and/or T2D heart (as discussed in this thesis). However the mechanisms 
surrounding this increased risk and dysregulations in cardiac energy metabolism remain 
complex and unclear.  
The thesis has addressed these three main obstacles in the field as summarised below;  
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1. By characterising cardiac structure and function in clearly separated normotensive obese 
and/or T2D patients we were able to tease out the influences of these conditions alone and in 
combination in the development of LV remodelling and dysfunction. We identified significant 
alterations in LV structure and function in normotensive metabolically non-healthy obese, 
normotensive T2D and normotensive obese and T2D patients similar to those observed in 
corresponding hypertensive groups. We identified two easily accessible clinical parameters; 
fasting blood glucose and pulse pressure that can be applied to assist in identifying which 
normotensive patients may exhibit the most risk for the observed alterations in LV structure 
and function. Therefore increasing the application potential of this study. Furthermore, the 
identification for specific grades of diastolic dysfunction to associate with LV geometric 
patterns and for RWT vs LVPWd to provide a more sensitive measure to detect alterations in 
LV geometry highlight the diagnostic benefit of applying LV geometry assessment in 
normotensive obese and/or T2D patients. While the study consisted of relatively small sample 
groups, the confirmation that the participants exhibited normal association with age and 
diastolic decline and between age and indices of LVH provided added confidence in the 
relevance of these findings to the wider population.  The significance of this work in the field 
is that the normotensive obese and/or T2D participants assessed would normally be deemed 
low risk with no further action required. Our results suggest that current practices in monitoring 
the development of hypertension in these patients are inadequate to assess risk. And the 
additional use of transthoracic echocardiography is justified to rule out the presence of LV 
remodelling and dysfunction.  
 
2. We were able to increase understanding of how obesity and T2D increase cardiovascular 
risk by assessing early alterations in cardiac energy metabolism in response to a mHFD and by 
assessing cardiac energy metabolism and structure/function in two separate adult mouse 
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models of obesity and T2D, the db/db mouse and diet induced obese mouse model (discussed 
in point 3). The mHFD model allowed us to investigate whether early re-programming events 
occur in the heart that may predispose to risk later in life. As obesity is often “inherited” this 
study design is relevant to the obesogenic foetal environments we are observing today. Some 
of the most interesting findings from this study were the NVCM bioenergetics and respiration 
analysis, in which we identified NVCM from pups exposed to the mHFD to exhibit an 
increased reliance on fatty acids for oxidative metabolism, decreased glucose utilisation and 
impaired metabolic flexibility. This work was supported in RNA and protein analysis and 
suggested that the mHFD induced maladaptive alterations in cardiac energy metabolism that 
are similar to what is observed in adult obesity and T2D. While PKD expression was 
unchanged in the PN1 and PN10 hearts exposed to the mHFD vs mNFD we were able to detect 
increases in Class IIa HDAC-MEF2 activity. A prohypertrophic pathway in which PKD is 
known to signal via in response to pressure overload stress, however in this case we observed 
an associated increased activity of the Class IIa HDAC kinase, AMPK. Interestingly, while 
there was no maternal diet effect, PKD expression was higher at PN10 compared to that at 
PN1. Suggesting, PKD expression and activity may differ at developmental stages. There are 
some limitations of this study that need to be considered when interpreting the results. We did 
not cross-foster the mHFD pups post birth, to assist in separating prenatal and postnatal 
influences. Cellular bioenergetics and respiration analysis were restricted to PN1 hearts and all 
analyses were restricted to male offspring. We do not have any functional echocardiographic 
data in the offspring and we do know if the reprogramming events persisted into adulthood. 
And we have not shown a causative relationship, but rather an association, between AMPK-
HDAC-MEF2 signalling with the presence of cardiac hypertrophy and increased fatty acid 
oxidation. Overall, this work did not implicate PKD activity in early alterations in cardiac 
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energy metabolism and hypertrophy, however this work suggests that a mHFD may predispose 
to cardiovascular disease later in life by reprogramming cardiac energy metabolism.   
 
3. And finally, this thesis investigated a potential therapeutic target, PKD, in the development 
of obesity/T2D cardiomyopathy. In vitro studies identified PKD activation to induce alterations 
in cardiac energy metabolism similar to those observed in the adult obese/T2D heart. And in 
vivo studies identified that inhibition of PKD protects from obesity/T2D cardiomyopathy. As 
part of this work, we successfully developed a novel mouse model that expressed a cardiac 
specific DN PKD. When challenged with a HFD, these mice exhibited protection from the 
development of cardiac hypertrophy and systolic dysfunction. Considering our second animal 
model, we detected significant alterations in LV structure and function in the db/db mice 
compared to that in their lean littermates. With the db/db mice exhibiting severe hypertrophy 
and diastolic and systolic dysfunction (compared to the mild phenotype induced via HFD in 
the DN PKD mice). These alterations in the db/db mice were accompanied by increased PKD 
activity during the fed state. Three weeks of PKD inhibition via i.p injection of the PKD 
inhibitor CID755673, reduced heart size and restored cardiac function (both diastolic and 
systolic function) in these animals. To the best of our knowledge we were the first study to use 
CID755673 in vivo and to show that pharmacological PKD inhibition in a mouse model of 
obesity/T2D was beneficial to the heart.  Considering the systemic effects of PKD inhibition, 
CID755673 treatment in the db/db mice did not improve systemic insulin resistance. body fat 
composition or fasting glucose. Therefore, in a setting of obesity and T2D, PKD inhibition 
would need to be accompanied by life style modification and/or an insulin sentisising drug, 
such as metformin. In saying that, we are still a long way off in the field from seeing early 
detection and treatment of obesity/T2D cardiomyopathy via PKD inhibition. Future work is 
needed to work with clinicians to improve cardiovascular risk assessment in normotensive 
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obese and/or T2D patients. Which ultimately will allow for the earlier identification of 
alterations in cardiac structure and function. However before this can happen, larger scale 
studies that asses in detail cardiac structure and function in normotensive obese and/or T2D 
patients, as we have in Chapter 2, are required. In particular, a larger scale studies which have 
recruited different ethnicities and broader age groups. And further investigation is required to 
understand how PKD regulates cardiac energy metabolism and how inhibition of PKD 
provided protection from obesity and T2D induced cardiomyopathy before it can be considered 
as a valid therapeutic target.  
 
 
Figure 1. Summary of signalling and end points in hypertrophy and cardiac energy 
metabolism that were investigated in the thesis. For which this thesis implicated PKD in 
regulating cardiac hypertrophy and alterations in cardiac energy metabolism.   
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LIST OF ABBREVIATIONS 
 
 
  
1H-MRS 1H-Magnetic Resonance Spectroscopy 
AC Adenylyl cylase 
AMPK AMP-activated protein kinase
Ang-II Angiotensin-II 
ANP Atrial natriuretic peptide 
ASE American Society of Echocardiography
BMI body mass index
BNP Brain natriuretic peptide 
BP blood pressure
BSA body surface area
BW body weight
CA constitutively active
CAD Coronary artery disease
CaMK Calcium calmodulin-dependent kinase 
CH concentric hypertrophy
CI Cardiac ischemia
CRD Cysteine rich domain 
CRD concentric remodelling
cTnI Cardiac troponin I 
DAG Diacylglycerol
DD diastolic dysfunction
DT deceleration times 
EF% Ejection fraction %
EFS Electrofield stimulated
EH eccentric hypertrophy
ET-1 Endothelin-1
Fas Fatty acids
FS % Fractional shortening %
G proteinsHeterotrimeric guanine-nucleotide regulatory proteins 
GPCRs G protein coupled receptors 
HATs Histone acetylases 
HDACs Histone deactylases 
HDL-C high density lipoprotein cholesterol
HF Heart failure
HFD High fat diet 
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HW/TL Heart weight/tibia length 
IP3 Inositol 1,4,5-P3 
ISO Isoprotereol
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LIST OF ABBREVIATIONS 
 
 
  
IVSd interventricular septum dimension
LDL-C low density lipoprotein cholesterol
LPA Lisophosphatidic acid 
LPL Lipoprotein lipase
LTV Lenti-virus
LV Left ventricle
LV left ventricle
LVH left ventricular hypertrophy
LVIDd left ventricular internal diastolic dimension 
LVIDs left ventricular internal systolic dimension 
LVMI left ventricular mass index
LVPWd left ventricular posterior wall diameter during diastole
LVPWs left ventricular posterior wall diameter during systole
MEF2 Myocyte enhancer factor-2 
MI Myocardial infarction 
MVO2 Myocardial oxygen consumption 
NE Norepinephrine
NVCM Neonate ventricular cardiomyocytes
PE Phorbol esters 
PH Pleckstrin homology 
PKA cAMP dependent protein kinase 
PKC Protein kinase C
PKD Protein kinase D
PKD1 cKO PKD1 knockout in cardiomyocytes 
PLC Phospholipase C 
RWT relative wall thickness
SHR Spontaneously hypertensive rat 
STZ Streptozotocin
T2D Type 2 diabetes
T2D type 2 diabetes
TG Triglyceride
VLDP Very low density lipoproteins 
αARs α-adrenergic receptors 
βARs β-adrenergic receptors 
β-MHC β-myosin heavy chain 
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Brief summary: In this paper we review the cardiac energy metabolic changes that occur in 
heart failure.  An emphasis is made on distinguishing the differences in cardiac energy 
metabolism between heart failure with preserved ejection fraction (HFpEF) and heart failure 
with reduced ejection fraction (HFrEF) and in clarifying the common misconceptions 
surrounding the fate of fatty acids and glucose in the failing heart. 
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Abstract 
 
Alterations in cardiac energy metabolism contribute to the severity of heart failure.  However, 
the energy metabolic changes that occur in heart failure are complex, and are dependent not 
only on the severity and type of heart failure present, but also on the co-existence of common 
co-morbidities such as obesity and type 2 diabetes.   In this paper we review the cardiac energy 
metabolic changes that occur in heart failure.  An emphasis is made on distinguishing the 
differences in cardiac energy metabolism between heart failure with preserved ejection fraction 
(HFpEF) and heart failure with reduced ejection fraction (HFrEF) and in clarifying the common 
misconceptions surrounding the fate of fatty acids and glucose in the failing heart.   The major 
key points from this paper are as follows; 1) Mitochondrial oxidative capacity is reduced in 
HFpEF and HFrEF, 2) Fatty acid oxidation is increased in HFpEF and reduced in HFrEF 
(however oxidative metabolism of fatty acids in HFrEF still exceeds that of glucose), 3) 
Glucose oxidation is decreased in HFpEF and HFrEF, 4) There is an uncoupling between 
glucose uptake and oxidation in HFpEF and HFrEF, resulting in an increased rate of glycolysis, 
5) Ketone body oxidation is increased in HFrEF, which may further reduce fatty acid and 
glucose oxidation, and finally 6) Branched chain amino acid oxidation is impaired in HFrEF. 
The understanding of these changes in cardiac energy metabolism in heart failure are essential 
to allow the development of metabolic modulators in the treatment of heart failure.  
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Introduction  
 
Heart failure is a debilitating disease that is a major killer of both men and women [1].  It places 
a huge economic burden on western society, and also has a substantial impact on quality of 
life, with millions of individuals having significant disabilities associated with heart failure [2].   
Heart failure presents primarily as two major types, heart failure with reduced ejection fraction 
(HFrEF) and heart failure with preserved ejection fraction (HFpEF). Both types of heart failure 
and their associated co-morbidities and mortalities have been reported at a comparable 
prevalence [3-5]. The criteria to diagnose HFrEF is clearly defined, characterised by the 
presence of systolic dysfunction with an ejection fraction <45-50%, with or without the 
accompanying presence of diastolic dysfunction. The criteria to diagnose HFpEF is less clear, 
although it is generally accepted to be characterised by the presence of diastolic dysfunction 
and elevated LV filling pressure, without LV dilation and with preserved systolic function or 
mild systolic dysfunction (ejection fraction >50%) [6].  
 
Current therapies to treat heart failure act primarily by reducing neurohormonal signalling or 
by improving hemodynamics. However, despite some successes, these treatments lack 
effectiveness in completely preventing mortalities associated with heart failure, with death 
rates at 20% and 50%, one and five years post diagnosis respectively [2]. Furthermore, while 
existing therapeutics were initially developed to treat HFrEF, the increasing incidence of 
HFpEF and lack of HFpEF specific drugs has pushed their application into both forms of heart 
failure. However, studies report little effectiveness of these traditional heart failure drugs in 
improving HFpEF [7-9]. We are therefore in need of new therapeutic options to treat both 
forms of heart failure.   
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An increasing body of evidence supports targeting alterations in cardiac metabolism in the 
treatment of heart failure. While myocardial oxygen transport may not be limiting in heart 
failure, myocardial oxygen consumption (MVO2) is very high in the heart.   As a result, the 
failing heart can exhibit an energy deficit (containing 30-40% less ATP than a healthy heart) 
due to altered energy substrate availability and impaired mitochondrial oxidative metabolism 
[10, 11].  It is also generally accepted that one of the reasons that existing inotropes fail in the 
treatment of heart failure is that they increase oxygen consumption, making hearts less efficient 
[12].  In contrast, increasing the efficiency of oxygen utilization can increase cardiac function.  
An example of this is the use of calcium-sensitizing agents that can increase myocardial 
contractility without concomitant increases in oxygen consumption [12].  Another approach to 
increase cardiac efficiency that will be discussed in this review is to switch myocardial energy 
substrate preference to a more efficient energy substrate.  However, the identification of 
potential metabolic modulators to treat heart failure is reliant on our understanding of the 
changes occurring in cardiac energy metabolism in the failing heart.  These changes are 
complex and are dependent not only on the severity and type of heart failure present, but also 
on the co-existence of common co-morbidities such as hypertension, obesity and type 2 
diabetes. In experimental studies, this complexity is further exacerbated by differences in 
substrate preference between animal strains [13, 14] and the methods used to induce heart 
failure [15]. This review will discuss the current knowledge of the energy metabolic changes 
that occur in heart failure, with a particular emphasis on distinguishing the differences between 
HFrEF and HFpEF and in clarifying the common misconceptions surrounding the fate of fatty 
acids and glucose in heart failure.  
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Energy metabolism in the normal heart 
 
The heart is constantly beating, from an early stage of embryonic development throughout our 
entire life time. This beating requires a large and constant supple of energy. The healthy adult 
heart is able to obtain this energy by metabolising a number of different energy substrates, and 
can adapt its energy substrate use depending on energy substrate availability. Typically, the 
heart obtains about 40% of its energy needs from the metabolism of glucose, lactate, ketones, 
and amino acids, with the remaining 60% originating from the metabolism of fatty acids. These 
energy substrates are used to produce energy in the form of adenosine triphosphate (ATP) and 
must be acquired continuously from the blood due to a low ability for the heart to store energy 
substrates intracellularly. The majority of ATP produced in the healthy adult heart (~95%) is a 
result of mitochondrial oxidative metabolism, ~70-90% of which is derived from fatty acid 
oxidation and the remaining from the metabolism of glucose, lactate, ketone bodies and amino 
acids (in particular, branched chain amino acids, BCAA). The remaining ~5% of ATP is 
produced from glycolysis. Below is a description of normal cardiac metabolism of these 
substrates, to assist the reader in understanding the changes in cardiac energy metabolism in 
heart failure. 
 
Fatty acid metabolism: Fatty acids circulate in the blood either as fatty acids bound to albumin, 
or as part of triacylglycerols (TGs) contained in chylomicrons and very low density lipoproteins 
(VLDL) (Figure 1a). These TGs need to be cleaved by lipoprotein lipase at the sarcolemma to 
allow their uptake into the cardiomyocyte [16]. Once cleaved, fatty acid uptake is then 
facilitated by two mechanisms; fatty acid transporters (CD36, fatty acid transport protein-1 and 
cytoplasmic fatty acid binding protein) and/or via passive diffusion [17]. Once inside the cell, 
fatty acids are esterified forming fatty acyl-CoA. Fatty acyl CoA molecules are converted to 
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acyl-L-carnitine moieties by carnitine palmitoyltransferase 1 (CPT-1) [18] and transported into 
the mitochondria where they are converted back to fatty acyl CoA and undergo β-oxidation, 
producing acetyl CoA that can be used in the TCA cycle and flavin adenine dinucleotide 
(FADH2) and nicotinamide adenine dinucleotide (NADH) which can enter the electron 
transport chain (ETC) to generate ATP.  The TCA cycle also produces NADH and FADH2 that 
feeds into the electron transport chain, which in the presence of oxygen results in the conversion 
of ADP to ATP (Figure 1a).  
 
Fatty acid oxidation can be regulated in multiple ways, including via: 1) fatty acid supply to 
the heart, 2) malonyl CoA induced CPT-1 inhibition [19] (malonyl CoA is produced via acetyl 
CoA carboxylase [20] and degraded by malonyl CoA decarboxylase (MCD)), 3) the ratios of 
FAD/FADH2 and NAD
+/NADH (which can influence enzymatic activity of acyl-CoA 
dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase, respectively), 4) the acetyl CoA/CoA 
ratio which can influence the activity of 3-ketoacyl-CoA thiolase, 5) post-translational 
acetylation of fatty acid oxidative enzymes, and 6) transcriptional  regulation of fatty acid 
oxidative enzyme expression (Figure 1a). This tight regulation of fatty acid oxidation is 
required to maintain the hearts ability to switch between available substrates. Metabolic 
flexibility is vital in the heart due in part, due to differences in substrate efficiency.  
 
Fatty acids produce the greatest ATP yield per 2 carbon out of all cardiac substrates, however 
they also have the highest oxygen requirement to produce this ATP. For the generation of ATP 
from a typical fatty acid, palmitate, the heart consumes 23 molecules of O2 per fatty acid 
molecule with an ATP yield of 105, P/O ratio 2.33, making fatty acids the least efficient (ATP 
produced/O2 consumed) of the myocardial energy substrates. Fatty acid efficiency is further 
reduced due to the requirement of the hydrolysis of two Pi molecules from ATP for the 
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esterification of fatty acids to fatty acyl CoA. In addition, the cytoplasmic cycling of fatty acids 
between fatty acyl CoA and TG and back to fatty acids also requires 2 Pi molecules, a process 
further decreasing fatty acid efficiency (Figure 1a).  
 
Glucose metabolism: Glucose is taken up by the cardiomyocyte via GLUT1 and GLUT4 
transporters, with GLUT4 being primarily responsible for the insulin-dependent uptake of 
glucose (Figure 1b). Once glucose is transported into the cell it is phosphorylated by 
hexokinase, generating glucose 6-phosphate (G6P). G6P can then be utilised in multiple 
pathways, which include the generation of pyruvate via glycolysis, the synthesis of glycogen, 
or being shuttled into the hexosamine biosynthetic or pentose phosphate pathways.  The 
pyruvate generated from glycolysis can either be converted to lactate or be transported into the 
mitochondria via the mitochondrial pyruvate carrier (MPC) and converted to acetyl-CoA by 
pyruvate dehydrogenase (PDH).  This acetyl CoA is then further metabolized in the TCA cycle. 
PDH is activated via dephosphorylation by PDH phosphatase and inhibited by PDH kinase 
(PDK), the latter of which is activated by increased acetyl CoA/CoA and NADH/NAD+ ratios.  
Alternatively, pyruvate can be carboxylated to oxaloacetate or malate by pyruvate carboxylase 
or malic enzyme respectively, replenishing the TCA cycle intermediates (a process called 
anaplerosis) (Figure 1b).  
 
When considering the amount of O2 consumed to produce ATP, glucose is the most efficient 
of the energy substrates, consuming 6 molecules of O2 per glucose molecule with an ATP yield 
of 31, P/O ratio of 2.58. Unlike fatty acid oxidation (which as mentioned consumes two Pi 
molecules in the initial cytoplasmic esterification of the fatty acids) glucose metabolism 
produces two Pi molecules in the cytoplasm during the glycolytic conversion of glucose to 
pyruvate. In the instance that glucose-6-phosphate is converted to glycogen, one high energy 
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phosphate molecule is required (UTP to UDP). However the release of glucose from glycogen 
and eventual conversation back to glucose-6-phosphate does not require any high energy 
phosphate. There is, therefore, the net loss of one high energy phosphate in the cytoplasmic 
cycling of glucose-6-P to glycogen and back to glucose-6-P (Figure 1b). 
 
Ketone body metabolism: Ketone bodies are produced in the liver from acetyl CoA 
(predominately sourced from fatty acid oxidation). β-hydroxybutyrate (βOHB) is the 
predominant ketone body oxidised in the heart. Its uptake is facilitated by SLC16A1 after 
which it is transported into the mitochondria for oxidation (Figure 1c).  β-hydroxybutyrate 
dehydrogenase 1 (BDH1) catalyses the oxidation of βOHB to acetoacetate (AcAc).  AcAc is 
then activated by the CoA transferase succinyl-CoA:3 oxoacid-CoA transferase (SCOT) to 
acetoacetyl CoA (AcAc CoA). AcAc CoA then undergoes a thiolysis reaction from which 
acetyl CoA is produced, that then enters the TCA cycle (Figure 1c).  
 
Ketones are readily metabolized by the heart, but their contribution to overall energy 
production is normally lower than that of fatty acids and glucose, primarily due to a low 
concentration of ketones to which the heart is exposed. When considering oxygen consumption 
for ATP production, ketones are more efficient than fatty acids, but less energy efficient than 
glucose. With βHOB having a P/O ratio of 2.5.  This is of particular importance due to the fact 
that ketone body oxidation occurs at the expense of both fatty acid and glucose oxidation [21-
24]. In vitro studies in primary rat cardiomyocytes show that AcAc can reduce fatty acid 
oxidation by 30% [25] and incubation with βOHB can reduce insulin stimulated glucose 
oxidation by up to 50%.  Interestingly, 6 hours post removal of βOHB, insulin stimulated 
glucose uptake remains inhibited in the cardiomyocytes, suggesting elevated ketone bodies 
may have a lasting effect on the inhibition of glucose oxidation in fed states [26].  
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Branched chain amino acid (BCAA) metabolism: BCAAs (leucine, isoleucine, and valine) 
are essential amino acids acquired from the diet that can be fully metabolised within the heart.  
The first step of BCAA metabolism in the heart involves their transamination to their 
corresponding branched chain α-keto-acid (BCKA) by the mitochondrial branched chain 
amino-transaminase (BCATm) (Figure 1d) [27].  This step is reversible and involves the 
transfer of the α-amino group to α-ketoglutarate producing glutamate.  The second step in 
BCAA metabolism involves the oxidative decarboxylation of the BCKAs by the mitochondrial 
branched chain α-keto acid dehydrogenase (BCKDH).  BCKDH activity is regulated by 
phosphorylation with BCKDH by a BCKDH kinase (BDK), which inhibits activity, and 
dephosphorylation by PPC2m, which activates BCKDH.  The products of BCKDH either 
eventually provide acetyl CoA for the TCA cycle or succinyl CoA for anaplerosis (Figure 1d).   
 
While BCAA are traditionally associated with health benefits such as increased muscle mass 
and improved post exercise recovery and glucose homeostasis [28, 29], an increasing body of 
evidence has linked BCAA with the development of insulin resistance. Cross sectional studies 
have identified strong correlations between plasma and insulin resistance in obese and T2D 
patients [30-32] and retrospective studies have reported increased plasma BCAA levels to be 
predictive of the future development of insulin resistance [33]. Two main mechanisms have 
been proposed for BCAA induced insulin resistance: 1) Persistent mTOR signalling (in 
particular via leucine), leading to an uncoupling between insulin signalling and the insulin 
receptor and 2) Impaired BCAA metabolism, resulting in accumulation of BCAA metabolites 
that exert toxic effects.  
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Figure 1:  Overview of energy metabolism in the normal heart.  
A) Glucose Metabolism: Glucose is transported into the cell via glucose transporter 1 or 4 
(GLUT1, GLUT4), it then undergoes glycolysis in which glucose is converted to glucose 6-
phosphate (G6P) by hexokinase and eventually to pyruvate. Pyruvate is transported into the 
mitochondria via a mitochondrial pyruvate carrier (MPC) and is converted to acetyl CoA by 
pyruvate dehydrogenase (PDH). Alternatively pyruvate is converted to lactate by lactate 
dehydrogenase,which can then be transported out of the cell via a monocarboxylate transporter 
(MCT). B) Fatty acid metabolism: Myocardial fatty acids originate either from fatty acids 
bound to albumin in the blood or from triacylglycerol (TG) contained in chylomicrons and very 
low density lipoproteins (VLDL). CD36 and FA transport protein-1 (FATP-1) facilitate fatty 
acid uptake. Inside the cell FAs are esterified forming fatty acyl-CoA, after which they are 
either converted to TG or the acyl group is transferred to carnitine via the carnitine 
palmitoyltransferase (CPT-1) and transported into the mitochondria where CPT-2 converts it 
back to fatty acyl CoA which can then undergo β-oxidation producing acetyl CoA. CPT-1 is 
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inhibited by malonyl CoA produced via acetyl CoA carboxylase (ACC) and degraded by 
malonyl CoA decarboxylase (MCD). 5' AMP-activated protein kinase (AMPK) is an inhibitor 
of ACC. C) ß-hydroxybutyrate (βOHB) metabolism: β-hydroxybutyrate (βOHB) is produced 
in the liver from acetyl-CoA. It is transported into the cell via SLC16A1 where βOHB 
dehydrogenase 1 (BDH1) catalyses the oxidation of βOHB to acetoacetate (AcAc). AcAc is 
then activated by succinyl-CoA:3 oxoacid-CoA transferase (SCOT) to acetoacetyl-CoA 
(AcAc-CoA) which undergoes a thiolysis reaction producing acetyl-CoA.  D) Branched chain 
amino acid metabolism: The branched chain amino acids (BCAA) leucine, valine and 
isoleucine are transported into the cell and undergo transamination to the branched chain α-
keto-acids (BCKA); α-ketoiscocaproic acid, α-ketoisvaleric acid and 2-keto-3-methylvaleric 
acid respectively by the mitochondrial branched chain amino-transaminase (BCATm). BCKAs 
undergo oxidative decarboxylation by the mitochondrial branched chain α-keto acid 
dehydrogenase (BCKD) producing isovaleryl-CoA, isobutyryl CoA and alpha-methylbutyryl-
CoA respectively. BCKD activity is inhibited by BCKDH kinase (BDK) and activated by 
protein phosphatase (PP2Cm). BDK activity is regulated by α-ketoiscocaproic acid. It is at the 
point of decarboxylation in which the catabolic pathways diverge. α-ketoiscocaproic acid is 
further metabolised to acetoacetate and acetyl-CoA, α-ketoisvaleric to methylmalonyl CoA and 
2-Keto-3-methylvaleric acid to acetyl CoA and methylmalonyl CoA. Methylmalonyl CoA can 
be converted to succinyl CoA by methylmalonyl CoA mutase (MUT) (which can then be 
incorporated into the TCA cycle or the ETC). The acetyl CoA produced fatty acid β-oxidation, 
glucose oxidation, βOHB oxidation and BCAA oxidation enter the tricarboxylic acid (TCA) 
cycle, producing and flavin adenine dinucleotide (FADH2) and nicotinamide adenine 
dinucleotide (NADH) which can then enter the electron transport chain (ETC), consuming 
oxygen (O2) to generate adenosine triphosphate (ATP).  
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Mitochondrial oxidative metabolism is impaired in heart failure 
 
Mitochondrial dysfunction in heart failure:  As mentioned, the majority of ATP produced in 
a healthy heart is the result of oxidative metabolism. The failing heart is said to undergo a 
reversal back to a foetal state with an increased glucose utilisation and glycolytic metabolism. 
The advantage being a lower O2 consumption rate. However, this hypothesised advantage is 
reliant on the assumption that the capacity for mitochondrial oxidation in the failing heart is 
maintained. However the failing heart can have 30-40% less ATP content than a healthy heart 
[15, 16], which is likely due to the presence of a reduced mitochondrial oxidative capacity in 
heart failure. Impaired mitochondrial function in the failing heart can occur due to a number of 
reasons, including: 1) decreased transcriptional regulation of mitochondrial biogenesis and 
fatty acid oxidation [34, 35], 2) increased reactive oxygen species (ROS) production, 3) 
impairments in mitofission, 4) sustained mitophagy and 5) increased autophagic cell death of 
cardiomyocytes [36, 37].  Combined these factors contribute to the presence of glycolytic 
compensation and uncoupling between glucose oxidation and glycolysis in heart failure. 
 
Decreased transcriptional regulation of mitochondrial biogenesis and fatty acid oxidation: 
Compromised mitochondrial biogenesis can contribute to impaired mitochondrial function.  An 
important transcriptional regulator of mitochondrial biogenesis is PPARγ coactivator-
1α (PGC1). PGC1 can activate the expression of nuclear respiratory factor-1 NRF-1 and 
NFR2, whose target genes are involved in mitochondrial replication, maintenance and 
components of the electron transport chain [38]. In heart failure, PGC1 is down-regulated, 
resulting in a decreased mitochondrial biogenesis [5].  Also down-regulated in heart failure is 
the transcriptional factor PPARα, which is the predominant isoform regulating fatty acid 
oxidation in the heart [34]. This results in a decreased expression of many genes involved in 
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fatty acid uptake and oxidation, particularly in the setting of HFrEF [43].  However, 
complicating this issue is that PPAR can be activated in some forms of HFpEF, particularly 
HFpEF associated with diabetes and obesity, resulting in an up-regulation of fatty acid 
oxidation [22,39].  
 
Increased reactive oxygen species (ROS) production: ROS, such as superoxide and hydrogen 
peroxide, are produced predominately in the mitochondria and are indicators of mitochondrial 
stress and dysfunction [39]. Increases in ROS have been observed in the failing human heart 
and in animal models of heart failure [40-43]. Furthermore, circulating ROS levels have been 
shown to predict cardiovascular outcomes in patients [44]. Mechanistic studies suggest that 
ROS increase lipid peroxidation, damage mitochondrial DNA, deplete antioxidants and reduce 
mitochondrial ATP production [39, 44].  In animal studies the use of exogenous antioxidants 
to mitigate these effects of ROS have been reported to reduce cardiomyocyte damage, improve 
cardiac function and prevent the progression of heart failure [39].  
 
Sustained mitophagy, and increased autophagy of cardiomyocytes: Mitochondrial fission and 
mitophagy are closely linked. With mitochondrial fission facilitating the segregation of 
components of the mitochondria that are dysfunctional into an organelle that can undergo 
mitophagy (degradation). Mice with cardiomyocyte specific deletions of proteins involved in 
mitofission (preventing the assembly of these organelles) develop heart failure, exhibiting an 
accumulation of defective mitochondria and an increased mitophagy of the entire mitochondria 
instead of mitophagy restricted to organelles containing the dysfunctional mitochondrial 
components. [36, 37]. Mitophagy is increased in the heart in response to pressure overload 
stresses, possibly in an attempt to prevent mitochondrial damage and maintain ATP production 
[37]. However, sustained mitophagy, as seen in heart failure, causes excessive mitochondrial 
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clearance, reducing the number of mitochondria in the heart. Furthermore, in states in which 
mitophagy is impaired, dysfunctional mitochondria cannot be adequately degraded and as such 
they continue to cause damage, eventually promoting autophagy of the cardiomyocyte [37, 45].  
 
Combined these factors promote the overall reduction in mitochondrial oxidative capacity and 
therefore ATP production in heart failure. This includes a decrease in the mitochondrial ATP 
production from all carbon substrates requiring mitochondrial oxidative metabolism (fatty 
acids, glucose, lactate, ketones, and amino acids) [10, 46]. However, as will be discussed, the 
degree by which the mitochondrial oxidation of these different energy substrates decreases 
differs, which is also dependent on whether heart failure is manifested as HFpEF or HFrEF. 
 
Glycolytic compensation and uncoupling between glucose oxidation and glycolysis in heart 
failure:  In an attempt to compensate for the decreases in mitochondrial oxidative metabolism 
and ATP production in heart failure glycolytic rates increase, since glycolysis is an alternate 
source of ATP production independent of mitochondrial oxidative metabolism (Figure 2a).   In 
heart failure there is an increase in glucose uptake, GLUT1 expression (transporter of glucose 
with a predominant glycolytic fate), activity of phosphofructokinase 1 (PFK-1, the first enzyme 
involved in glycolysis), and glycolytic flux [47, 48].  However, this increase in glycolysis is 
insufficient to completely compensate for the energy deficit in heart failure or to restore cardiac 
function. This is in part due to glycolysis producing only two ATP molecules per glucose 
molecule, compared to 31 ATP molecules that would have been produced if glucose was 
terminally oxidised. Furthermore, this increase in glycolysis is uncoupled to the oxidation of 
pyruvate and lactate and is accompanied by an accumulation of H+ in the cytoplasm, which 
may eventually lead to Ca2+ accumulation. Therapeutic interventions, or the use of inducible 
cardiac specific mutations that result in an increased glucose oxidation in a setting of heart 
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failure, have resulted in improved and in some cases restored cardiac structure and function. 
For example, in leptin resistant obese/T2D mice exposed to myocardial infarction, restoration 
of glucose oxidation achieved by treatment with a STAT3 activator attenuated myocardial 
infarction induced reductions in ejection fraction and increases in end diastolic and systolic 
volumes [49].  In mice exposed to coronary artery ligation knockout of malonyl CoA 
decarboxylase improved coupling between glycolysis and glucose oxidation, decreased H+ 
production and improved total LV work (of note this was despite an increased hypertrophic 
response in these mice) [50].  These studies highlight the detrimental impact this uncoupling 
between glycolysis and glucose oxidation has in the development of heart failure. 
 
Changes in cardiac energy metabolism in heart failure with reduced ejection fraction and 
in heart failure with preserved ejection fraction 
 
When considering the changes in cardiac energy metabolism in HFrEF and HFpEF it’s 
important to consider the difficulties in comparing these two disease states and experimental 
methods used to induce them. Animal models of HF were initially developed to study HFrEF, 
experimentally induced via surgical procedures such as transthoracic aortic constriction (TAC), 
abdominal aortic constriction (AC), myocardial infarction (MI) and rapid ventricular pacing or 
via administration of hormones that increase nuerohormonal signalling such as angiotensin II 
(Ang II) and norepinephrine or with the use of transgenic animals that develop HF such as 
models of spontaneous hypertension or impaired cardiac metabolism [15]. Animal models of 
HFpEF are more limited than those available to study HFrEF. Often involving the use of 
volume and pressure overload models that were insufficient to induce a reduction in EF % or 
models specific to diastolic dysfunction, allowing a phenotype closely linked to that of HFpEF 
(diastolic dysfunction, increased stiffness LVPWd, increased LVED pressure and normal 
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systolic function). Experimental methods to induce diastolic dysfunction include; aortic 
banding, systemic hypertension, obesity and T2D [51].  
 
Changes in cardiac energy metabolism in heart failure with reduced ejection fraction: The 
energy metabolic changes occurring in HFrEF are generally accepted to include reductions in 
fatty acid oxidation and glucose oxidation, and increases in glycolysis (Figures 2a-b and Table 
1) and increases in ketone body oxidation and impaired BCAA metabolism (Figures 2c-d and 
Table 1).  
 
 
 
Figure 2: Changes in energy metabolism in heart failure.  
A) Alterations in fatty acid metabolism, B) Alterations in glucose metabolism, C) Alterations 
in Beta-hydroxybutyrate (βOHB) metabolism and D) Alterations in branched chain amino acid 
(BCAA) metabolism. An arrow facing up indicates an increase and down indicates a decrease. 
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Blue symbols represent changes seen in heart failure with preserved ejection fraction and red 
symbols represent changes seen in heart failure with reduced ejection fraction.  
Abbreviations: Glucose transporter 1 and 4 (GLUT1, GLUT4), glucose 6-phosphate (G6P), 
mitochondrial pyruvate carrier (MPC), pyruvate dehydrogenase (PDH), monocarboxylate 
transporter (MCT). Very low density lipoproteins (VLDL), FA transport protein-1 (FATP-1, 
triacylglaycerol (TG), carnitine palmitoyltransferase (CPT-1), acetyl CoA carboxylase (ACC), 
malonyl CoA decarboxylase (MCD), 5' AMP-activated protein kinase (AMPK), tricarboxylic 
acid (TCA) cycle, flavin adenine dinucleotide (FADH2), nicotinamide adenine dinucleotide 
(NADH), electron transport chain (ETC), adenosine triphosphate (ATP).  β-hydroxybutyrate 
(βOHβ), monocarboxylate transporter 1 (SLC16A1), β-hydroxybutyrate dehydrogenase 1 
(BDH1), acetoacetate (AcAc), succinyl-CoA:3 oxoacid-CoA transferase (SCOT), acetoacetyl-
CoA (AcAc-CoA), Branched chain α-keto-acids (BCKA), branched chain amino-transaminase 
(BCAT), mitochondrial branched chain α-keto acid dehydrogenase (BCKD), mitochondrial-
target 2C-type ser/thr protein phosphatase (PP2Cm). 
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Table 1. Summary of Changes in Cardiac Metabolism in Heart Failure 
 
 
CHANGES IN CARDIAC METABOLISM IN HEART FAILURE 
HFpEF HFrEF 
FATTY ACID 
OXIDATION 
Increased in humans, measured 
in vivo [86, 87] 
Reduced in humans in vivo [55, 
56, 86] and in mice [21] and rats 
[60] measured via ex vivo 
perfusion. 
GLUCOSE OXIDATION 
Reduced in mice, measured via 
ex vivo perfusion [103, 104] 
Reduced in human measured in 
vivo [113] and in mice [65, 66] 
and rats [67] measured via ex 
vivo perfusion 
GLYCOLYSIS 
Unchanged [111] or increased 
[114] in rats, measured via ex 
vivo perfusion.  
Increased in humans measured 
via ex vivo biochemical analysis 
[115] and in rats measured ex 
vivo [67]. 
COUPLING BETWEEN 
GLUCOSE OXIDATON 
AND GLYCOLYSIS 
Unchanged in mice [103] or 
reduced in rats [114]. 
Reduced in humans measured 
via ex vivo biochemical analysis 
[47] and in mice measured ex 
vivo [50]. 
KETONE BODY 
OXIDATION 
Unknown, insufficient data 
Increased in humans [62, 116] 
and in mice measured via ex vivo 
biochemical analysis [21].  
BCAA METBAOLISM Unknown, insufficient data 
Impaired in humans [79] and 
mice [79, 84], measured via ex 
vivo biochemical analysis. 
Heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction 
(HFpEF), branched chain amino acid (BCAA). 
 
Fatty acid metabolism in HFrEF: The rate of myocardial fatty acid oxidation decreases with 
the progression of HFrEF. In studies assessing 13C palmitate uptake and clearance during the 
stage of compensated hypertrophy (normal systolic function) no differences in fatty acid uptake 
or oxidation were observed in either human patients, Dahl salt sensitive rats fed a high salt diet, 
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spontaneously hypertensive rats, or Wister rats 8 weeks post myocardial infarction [52-54].  
However, as the severity of HFrEF progresses (EF < 50%) decreases in fatty acid oxidation 
have been detected in human patients with idiopathic dilated cardiomyopathy (IDCM) [55-57], 
as well as in Dahl salt sensitive rats fed a high salt diet, spontaneously hypertensive rats, Wister 
rats 20 weeks and 6 months post myocardial infarction and in canine models of cardiac pacing 
studies [53, 54, 58-60]. This decrease in fatty acid oxidation, however, is not always a 
consistent finding. Other studies have observed no differences in fatty acid uptake in patients 
with IDCM, or an actual increase in fatty acid uptake in patients with congestive heart failure 
[61, 62]. These inconsistencies in fatty acid utilisation are likely attributable to the differences 
in disease severity and presence of co-morbidities in patients with ejection fractions ranging 
from 16-48% and body mass indexes ranging from 23-38 in the above studies. 
 
In those studies that did observe decreases in fatty acid oxidation, a parallel decrease in the 
expression and/or activity of genes and enzymes involved in transcriptional regulation of fatty 
acid oxidation (PPARα, retinoid X receptor α (a cofactor of PPAR and PGC1α, and estrogen 
related receptors (ERRα and ERRγ)) were observed, as well as a number of enzymes involved 
in fatty acid oxidation, including CPT-1, MCAD, CD36 and FATP1 [53, 54, 58-60, 63, 64].  
These expressional changes are consistent with a reduction in fatty acid oxidation in heart 
failure.  However, although fatty acid oxidation is reduced in HFrEF, fatty acids still account 
for a greater proportion of mitochondrial oxidative capacity than glucose. 
 
Glucose metabolism in HFrEF:  While glucose metabolism is commonly reported to be 
increased in HFrEF, this is not always accompanied by an increase in glucose oxidation but 
rather a decrease in glucose oxidation and an increase in glycolysis. Increases in glucose 
utilisation (uptake) have been reported in patients with IDCM (88-98%) [55-57], in canine 
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models of cardiac pacing (~ 150%) [59] and in Dahl salt sensitive rats fed a high salt diet 
(240%) [54]. Glycolysis and glucose oxidation rates were not assessed in these above studies, 
however GLUT1 expression is increased in the Dahl salt sensitive rats suggesting an increased 
capacity for glucose uptake that may have a predominant glycolytic fate [53, 58].  Furthermore, 
human heart tissue obtained from HFrEF patients shows reduced expression of MCT1, PDH 
and of pyruvate/alanine aminotransferases, suggesting reduced transport and metabolism of 
pyruvate. In addition, GLUT1, GLUT4 and PFK are also reduced in failing hearts, suggesting 
impaired glucose uptake and metabolism [63]. In animal studies that have been able to assess 
glucose oxidation, decreases have been observed in mice 3 weeks post abdominal aortic 
constriction, 5-6 weeks post TAC in mice, in rats with volume overload induced heart failure 
[65-67], and in pacing-induced heart failure in pigs [68]. In contrast, a study conducted 10 
weeks post TAC in mice observed increases in both glycolysis and glucose oxidation rates [69], 
while a study in pacing-induced heart failure in dogs also showed an increased glucose 
oxidation [41].  
 
Ketone body oxidation in HFrEF: The concentration of ketone bodies circulating in the body 
increase during fasting [70, 71].  Interestingly, in patients with congestive heart failure (CHF) 
this increase in response to fasting has been shown to be further exacerbated. With CHF 
patients exhibiting a greater increased in plasma ketone body levels during a 20 hour fast 
compared to control patients that persisted post intravenous administration of glucose at the 
end of the fasting period [72].  
 
Very few studies have assessed changes in myocardial ketone body oxidation in heart failure, 
despite numerous studies observing increased plasma levels of ketone bodies in patients with 
heart failure and that fact that ketone bodies have the ability to undergo oxidation at the expense 
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of fatty acids and glucose [21]. One study quantifying substrate utilization in arterio-venous 
blood samples reported an increased ketone body oxidation of ~100% in patients with HFrEF 
[62]. It should be noted however, this difference was not significant and was restricted to a 
sample of nine heart failure patients and ten healthy patients [62]. In experimental animals, 
TAC induced LVH in mice (but not systolic dysfunction) is associated with increased 
expression of the enzymes involved in ketone oxidation, as well as well as an increased βOHB 
oxidation [21]. The addition of myocardial infarction in these mice to push the progression of 
LVH to HFrEF, results in further increases in oxidation of βOHB, which is accompanied by 
decreased expression of genes involved in fatty acid oxidation and reduced presence of TCA 
cycle intermediates (with the exception of succinate). In addition, a prolonged 24 hour fast in 
these mice results in an increased expression of SLC16A1, which is involved in ketone uptake 
in the heart, suggesting that TAC + myocardial infarction induced HFrEF is associated with an 
increased capacity for myocardial ketone body uptake and that ketone body oxidation in HFrEF 
may impair myocardial fatty acid oxidation and anaplerosis [21]. In addition, mice expressing 
a cardiomyocyte specific knockout of SCOT (preventing them from terminally oxidising 
βOHB), show increased fatty acid oxidation [73].  Interestingly, these animals are also more 
susceptible to TAC induced increases in LV mass [73]. These data support the concept of 
increased ketone body oxidation in heart failure and subsequent inhibitory on fatty acid 
oxidation.  However, whether this increased ketone metabolism is adaptive or maladaptive in 
heart failure has yet to be established. It is important to consider the efficiency of the substrate 
and whether ketone body metabolism occurs at the expense of the oxidation of fatty acids or 
glucose. In regards to efficiency, ketone bodies do indeed produce more energy per 2 carbons 
than glucose. However when considering the P/O ratio, ketone bodies are less efficient than 
glucose. While an increased ketone body metabolism at the expense of fatty acids may appear 
a desirable shift in substrate preference in the failing heart, we also need to take into account 
236 
 
that this may also occur at the expense of glucose oxidation, to which ketone bodies are less 
efficient in regards to their P/O ratio.  Unfortunately in these above in vivo studies glucose 
oxidation and glycolysis rates have not been assessed.  
 
Branched chain amino acid oxidation in HFrEF: Increases in plasma BCAA levels have 
been detected in heart failure patients and have been identified as early predictors of the future 
development of cardiovascular disease [74-78]. Circulating and cardiac BCAA levels also 
increase post myocardial infarction [76]. These increases in BCAA levels may be due to an 
impaired BCAA oxidation in heart failure [79-81]. The accumulation of BCAA’s in heart 
failure may activate cardiac mTOR signalling, thereby promoting cardiac hypertrophy [82, 83].   
This is supported by studies showing that stimulation of BCAA oxidation or inhibition of 
mTOR (with rapamycin) can improve heart function [71, 76], while BCAA supplementation 
further increases mTOR signalling and worsens cardiac dysfunction [84].  
 
The protein phosphatase PPC2m is important in BCAA oxidation, as it increases 
phosphorylation and inhibition of BCKDH, a key enzyme involved in BCAA oxidation. In 
mice deficient for PPC2m, myocardial BCAA and BCKA levels are elevated. These mice 
develop HFrEF, suggesting that decreased BCAA metabolism can cause systolic dysfunction 
[79]. This same study also reported defects in BCAA metabolism in human heart failure tissue 
and in mice with TAC induced heart failure [79]. The consequences of accumulation of BCKA 
were further investigated in vitro, with the authors proposing that products of BCAA oxidation 
inhibit complex I and increase superoxide production resulting in an impaired mitochondrial 
function [79]. 
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Changes in cardiac energy metabolism in heart failure with preserved ejection fraction: 
Studies assessing cardiac metabolism in HFpEF are more limited than those in HFrEF, due to 
the lack of appropriate experimental models to study HFpEF.   Studies of HFpEF have included 
volume and pressure overload models that were insufficient to induce a reduction in %EF, or 
models specific to diastolic dysfunction, such as aortic banding and models of obesity and T2D, 
allowing a phenotype closely linked to that of HFpEF (increased stiffness LVPWd, increased 
LVED pressure and normal systolic function) [51]. With the use of obesity and T2D as model 
of HFpEF, it is not surprising that HFpEF is generally accompanied by increased fatty acid 
oxidation and reduced glucose oxidation with either an increase or no change in glycolysis 
(Figures 2a-b and Table 1). Data regarding ketone bodies and BCAA in metabolism in HFpEF 
is however very limited, while availability of ketones and BCAA may be increase (Figures 2c-
d and Table 1), it is unclear of the role these substrates have in the HFpEF. 
 
Fatty acid oxidation in HFpEF: Increases in plasma concentrations of fatty acids have been 
associated with increased risk of the development of HFpEF [85]. With myocardial fatty acid 
oxidation increasing in response to conditions such as type 2 diabetes (T2D), obesity and 
insulin resistance. Obese women with LVH and reduced cardiac efficiency show an increased 
myocardial fatty acid uptake and oxidation, with the severity of their insulin resistance 
correlating with the higher rates of fatty acid oxidation [86].  In addition, type 2 diabetic men 
with T2D cardiomyopathy also exhibit increased fatty acid uptake and oxidation [87].  These 
finding are consistent with animal models of obesity and T2D, such as diet induced obese 
(DIO), db/db and ob/ob mice.   In these animals, the heart switches to a predominant reliance 
on fatty acid oxidation, while exhibiting LVH [88], diastolic dysfunction [89, 90] and in severe 
cases, systolic dysfunction [91-93]. Furthermore, transgenic mice exhibiting increased fatty 
acid uptake [94, 95] or oxidation [96, 97] also develop of LVH and diastolic dysfunction. 
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Interestingly, transgenic models in which fatty acid oxidation is inhibited exhibit an enhanced 
response to pressure overload induced heart failure [98]. These data suggest that disturbances 
in fatty acid oxidation, resulting in increased fatty acid oxidation, may promote the 
development of heart failure. 
 
Glucose metabolism in HFpEF: Increases in plasma glucose levels have been correlated with 
the severity of heart failure and have been suggested to be a predictor of the future development 
of heart failure [99, 100]. Rodent models of T2D and insulin resistance (in which plasma 
glucose levels are increased and myocardial insulin resistance develops) exhibit LVH, diastolic 
dysfunction and systolic dysfunction and show increased susceptibility to pressure and volume 
overload induced heart failure [101, 102].  
 
Similar to HFrEF, glucose oxidation rates are also decreased in HFpEF [103, 104].  Decreases 
in myocardial glucose oxidation are very prominent in obese and diabetic mice that develop 
HFpEF [105-107].   This decrease in glucose oxidation in HFpEF is not restricted to models of 
insulin resistance or T2D. Angiotensin II induced HFpEF in mice, results in a decreased 
glucose oxidation (45%) that was accompanied by increased PDK4 expression and reduced 
PDH activity [103]. This finding is consistent with another study observing the same decreases 
in glucose oxidation in angiotensin II treatment mice, an effect that was blunted in response to 
PDK4 deletion [104].  Of note, angiotensin 1-7 treatment has also been shown to be ameliorate 
diastolic dysfunction in diabetic db/db mice [108]. In mice subjected to HFpEF due to an aortic 
artery constriction, a decrease in myocardial glucose oxidation precedes the development of 
diastolic dysfunction [65], which further supports the impact that a reduction in glucose 
oxidation has in the development of heart failure [104].   Furthermore, transgenic mice with a 
mutation preventing the oxidation of pyruvate also develop LVH, diastolic dysfunction [109] 
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and systolic dysfunction [110].  These data suggest that decreases in glucose oxidation promote 
HFpEF and that glucose oxidation is required for normal cardiac metabolism and to cope with 
heart failure promoting stresses. In contrast to these findings another study which induced 
HFpEF in Wister rats via aortic artery restriction, detected increases in both glucose oxidation 
and glycolysis (25%). These alterations were accompanied by a reduction in SERCA2a mRNA, 
with the authors speculating that altered calcium handling may have contributed to the 
increased rate of glycolysis [111].  
 
Ketone body and branched chain oxidation in HFpEF: Data regarding the changes in ketone 
body and branched chain amino acid oxidation in HFpEF is presently lacking. While plasma 
concentration of ketone bodies and BCAA are increased in insulin resistance and T2D, two 
disease states with high risk for HFpEF, it unclear if these increases associate with increased 
myocardial uptake and oxidation [70, 71].  Serum metabolite analysis detected higher levels of 
AcAc and β-OHB in patients with HFpEF than in patients with HFrEF, suggesting an increased 
reliance on ketone bodies as an energy source in HFrEF compared to that in HFpEF [112]. 
However, a role for ketone bodies in the development of HFpEF cannot be ruled out on this 
data alone. Future work is therefore required to elucidate the roles/if any ketone bodies and 
BCAA have in the development of HFpEF.  
 
Summary 
 
The metabolic changes occurring in heart failure are complex. HFpEF is generally 
accompanied by decreases in myocardial glucose oxidation and increases in glycolysis and 
fatty acid oxidation.   The effects of HFpEF on ketone bodies and BCAA oxidation remains 
unclear.  In contrast, HFrEF is generally accompanied by reductions in myocardial fatty acid 
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oxidation, glucose oxidation and BCAA oxidation, with increases in glycolysis and ketone 
body oxidation.  A common metabolic defect seen in HFpEF and HFrEF is a decrease in 
myocardial glucose oxidation, which has been associated with a decreased cardiac efficiency 
and function.  As a result, strategies that increase glucose oxidation may be have therapeutic 
potential in treating heart failure, regardless of whether it is HFpEF or HFrEF.  
 
This paper discusses cardiac energy metabolism in HFrEF and HFpEF. To gain an 
understanding of the effects of treatments used in heart failure on cardiac energy metabolism 
we direct the reader to another paper published in this special edition release entitled 
“Metabolic adaptors in heart failure. Past, present and future”.  
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